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Abstract 
 
Identification of Cellular Host Factors That Associate With LINE-1 ORF1p 
and the Effect of the Zinc Finger Antiviral Protein ZAP on LINE-1 
Retrotransposition 
 
By 
 
John B. Moldovan 
 
Chair: John V. Moran 
 Long INterspersed Element-1 (LINE-1 or L1) is the only active 
autonomous retrotransposon in the human genome. The human genome 
contains over 500,000 L1 sequences, which account for approximately 17% of 
human DNA. L1 sequences mobilize throughout the human genome by a copy-
and-paste mechanism known as retrotransposition. Most genomic L1 sequences 
are incapable of mobility (i.e., retrotransposition) because they are either 5'-
truncated, internally rearranged, and/or mutated; however, it is estimated that 
each human cell contains at least 80-100 intact L1 sequences that are 
retrotransposition capable.  
 L1 retrotransposition is inherently mutagenic and on occasion can disrupt 
gene expression leading to diseases such as hemophilia A and cancer. Due to 
the mutagenic potential of L1 retrotransposition, it thus stands to reason that the 
host cell has evolved mechanisms to protect the cell from unabated 
retrotransposition. In this thesis I identified cellular host factors that associate 
with the first L1 open reading frame protein, ORF1p. I demonstrate that the zinc 
finger antiviral protein ZAP associates with L1 ORF1p and inhibits human L1 and 
Alu retrotransposition as well as the retrotransposition of LINE elements from 
mice and zebrafish. Molecular genetic, biochemical, and fluorescence 
microscopy data suggest that ZAP interacts with L1 RNA and reduces the 
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expression of full-length L1 RNA and the L1-encoded proteins, thereby providing 
mechanistic insight into how ZAP may restrict retrotransposition.  
 In addition to ZAP, I show that the ORF1p-associated cellular host factors 
MOV10, hnRNPL, and PAR-4  also inhibit L1 retrotransposition. Mechanistic data 
suggest that ZAP, MOV10, hnRNPL, and PAR-4 restrict L1 retrotransposition by 
distinct mechanisms, suggesting that each of these cellular host factors may 
target different post-transcriptional steps in the L1 retrotransposition cycle.  
 Importantly, ZAP and MOV10 were first characterized as antiviral proteins 
due to their ability to suppress retroviral activity. Notably, several other host cell 
antiviral factors such as APOBEC3 proteins, TREX1, SAMHD1 and RNase L 
have recently been demonstrated to inhibit L1 retrotransposition. Thus, these 
data suggest that ZAP, MOV10 and perhaps other ORF1p-associated cellular 
host factors initially may have evolved to combat L1 and other endogenous 
retrotransposons and subsequently were co-opted as viral restriction factors. 
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Chapter 1 
 
Introduction 
 
Thesis Overview 
 The focus of my thesis addresses the question, what host cell proteins are 
involved in L1 retrotransposition? My thesis research began with a short study of 
the L1 retrotransposition mechanism in which I studied how mutations in the L1 
ORF1p protein affect the function of L1 ribonucleoprotein particles (RNPs), an 
important L1 retrotransposition intermediate. The study of L1 RNPs then 
prompted me to question whether other cellular proteins might associate with L1 
RNPs and modulate L1 retrotransposition activity. The following chapters will 
present the major results of my thesis research in the following order. Chapter 1 
is an introductory chapter that provides background information on the 
mechanism of L1 retrotransposition, how L1 retrotransposition impacts the 
human genome, and what host cell processes are known to regulate L1 
retrotransposition. Chapter 2 presents experiments that examine the role of 
ORF1p in L1 retrotransposition and how mutations in ORF1p affect the function 
of L1 RNPs. Chapter 3 describes the bulk of my thesis research where I used co-
immunoprecipitation experiments in conjunction with tandem mass spectrometry 
to identify host cell proteins that associate with L1 RNPs, and then showed that 
some of these proteins may inhibit L1 retrotransposition. These experiments led 
to the discovery that the zinc-finger antiviral protein (ZAP) restricts human L1 and 
Alu retrotransposition. Chapter 4 extends findings from Chapter 3 and presents 
experiments that show that the RNA helicase MOV10, an additional L1 RNP-
interacting protein identified in Chapter 3, also restricts L1 retrotransposition. In 
the final Chapter (Chapter 5), I discuss the significance of these findings, and 
focus on remaining questions and possible future directions.  
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Introduction to Transposable Elements 
 Transposable elements, sometimes referred to as “jumping genes,” are 
DNA sequences that can move from one DNA site to another within genomic 
DNA. Transposable elements were first discovered in maize during the 1940's by 
Barbara McClintock. She demonstrated that transposable elements could move 
to different chromosomal locations and cause heritable mutations that were 
linked to color variegation (Figure 1.1) (McClintock 1950, McClintock 1951). 
 Since their initial discovery, we have learned that transposable elements 
inhabit the genomes of virtually all organisms from each of the four kingdoms of 
life. Despite the ubiquity of transposable elements, why they exist and what 
function they might serve are puzzling and difficult questions to answer. Indeed, 
for many decades following their discovery transposable elements were 
considered a type of "junk DNA" (Ohno 1972), mainly because they do not 
appear to serve an obvious biological function for the organisms which they 
inhabit. Transposable elements also have been characterized as "selfish DNA" 
with their only purpose thought to be to spread more copies of themselves 
throughout an organisms’ genome (Doolittle and Sapienza 1980, Orgel and Crick 
1980). Regardless of whether one thinks of transposable elements as pieces of 
"junk" or as inherently "selfish" entities, research within the last twenty years has 
revealed that transposable elements make a significant impact on the genomes 
and phenotypes of their hosts (Cordaux and Batzer 2009, Beck et al. 2011, 
Richardson et al. 2015). Whether transposable elements have an ultimate 
function or purpose may never be known, but it is clear that they are more than 
just junk. The continued study of transposable elements will provide insights into 
how they influence their host genomes, which will ultimately contribute to a more 
unified and comprehensive understanding of the basic biological processes that 
govern the function of single cells and entire organisms. 
 This introductory chapter will provide a brief overview of transposable 
elements in the human genome and then focus on the biology of the human long 
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interspersed nuclear element-1 (LINE-1 or L1), the only self-autonomous 
transposable element currently active in the human genome. 
 
Transposable Elements in the Human Genome 
 The initial sequencing of the human genome revealed that nearly 50% of 
human DNA is composed of transposable elements (Lander et al. 2001) and 
more recent studies suggest that as much as 66%-69% of the human genome 
could be composed of transposable elements and other repetitive DNA 
sequences (de Koning et al. 2011). Transposable elements can be grouped into 
two main classes based on whether they mobilize via a DNA intermediate (DNA 
transposons) or an RNA intermediate (retrotransposons). The human genome 
contains a variety both DNA transposons and retrotransposons (Figure 1.2), 
which will be discussed below.  
DNA transposons  
 DNA transposons comprise roughly 3% of the human genome. DNA 
transposons mobilize (i.e., transpose) via a DNA intermediate by a cut-and-paste 
mechanism termed transposition. A classical DNA transposon typically consists 
of a pair of variable length terminal inverted repeat (TIR) sequences that 
surround a transposon-encoded enzyme called transposase (Figure 1.3A), which 
mediates the transposition reaction. During DNA transposition, transposase 
recognizes the TIR sequences on either end of the DNA transposon and 
catalyzes the excision and subsequent insertion of the DNA transposon from one 
place in DNA to another (Craig et al. 2002).  
 DNA transposons are not thought to be active in the human genome, and 
likely have been extinct (i.e., not capable of transposition) in mammals for at 
least 37 million years  (Lander et al. 2001, Pace and Feschotte 2007). Despite 
these facts, recent evidence suggests that a small group of DNA transposons 
may be active in certain bat species (Ray et al. 2007, Mitra et al. 2013). Although 
DNA transposons may not be currently active in humans, they appear to have left 
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an indelible mark on the human genome as several human proteins are thought 
to have evolved from DNA transposons including the RAG1 and RAG2 V(D)J 
recombinase enzymes, which function during B and T cell development 
(Thompson 1995, Lander et al. 2001, Kapitonov and Jurka 2005).  
Retrotransposons 
 Retrotransposons are the most numerous class of transposable elements 
in the human genome (~42% of the genome) (Figure 1.2) (Lander et al. 2001). 
Retrotransposons mobilize via an RNA intermediate by a replicative copy-and-
paste mechanism termed retrotransposition (Boeke et al. 1985, Craig et al. 2002, 
Beauregard et al. 2008, Cordaux and Batzer 2009). Retrotransposons typically 
encode a reverse transcriptase (RT) enzyme, which is required to mediate 
retrotransposition. During retrotransposition, an RNA copy of the retrotransposon 
is reverse transcribed by the retrotransposon-encoded RT to generate a 
retrotransposon cDNA copy, which is inserted into a new genomic location. The 
process of retrotransposition typically results in a net increase of +1 in 
retrotransposon copy number. In principle, the number of retrotransposon copies 
can increase over successive generations to comprise a significant portion of 
genomic DNA in some organisms, such as humans. All retrotransposons can be 
further subdivided into two main groups: long terminal repeat (LTR) 
retrotransposons (Figure 1.3B) and non-LTR retrotransposons (Figures 1.3C-D). 
 LTR retrotransposons: LTR retrotransposons are related to retroviruses in 
structure and function. Human LTR retrotransposons (also known as human 
endogenous retroviruses or HERVs) (Figure 1.3B) comprise ~8% of the human 
genome (Lander et al. 2001). Similar to retroviruses, LTR retrotransposons are 
flanked by a set of LTR sequences, which are direct repeat sequences that 
encode regulatory elements important for LTR retrotransposon function (Craig et 
al. 2002, Beauregard et al. 2008). LTR retrotransposons typically encode reverse 
transcriptase and structural genes analogous to retroviral pol and gag genes 
respectively. The LTR retrotransposition mechanism is also similar to retrovirus 
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replication; however, LTR retrotransposons lack a functional envelope (env) 
gene, which relegates them to an intracellular existence. 
 Human endogenous retroviruses are not thought to be currently active in 
humans (i.e., not retrotransposition-competent) (Lander et al. 2001). With that 
being stated, certain evidence suggests that elevated HERV RNA and protein 
expression may be associated with certain human diseases including cancer and 
diabetes (Conrad et al. 1997, Galli et al. 2005, Bannert and Kurth 2006). 
Although evidence of a retrotransposition competent HERVs has not yet been 
reported, the existence of human and chimpanzee specific endogenous retroviral 
insertions suggests the possibility that endogenous retroviruses have been active 
since the divergence of the human and chimpanzee lineages (Medstrand and 
Mager 1998, Yohn et al. 2005).  
 Non-LTR retrotransposons: As their name suggests, non-LTR 
retrotransposons do not encode LTR sequences. Non-LTR retrotransposons 
comprise about 35% of human DNA and are the only active group of 
transposable elements in the human genome (Lander et al. 2001). Examples of 
human non-LTR retrotransposons include long interspersed nuclear element-1 
(LINE-1 or L1) (Figure 1.3C) and Alu elements (also known as short interspersed 
nuclear elements (SINEs)) (Figure 1.3D). In general, non-LTR retrotransposons 
may encode one or two open reading frames and end in poly-adenosine rich 
sequences; thus, they tend to resemble cellular mRNAs in sequence 
arrangement (Richardson et al. 2015). Non-LTR retrotransposons also typically 
encode a RT enzyme that is similar to LTR retrotransposon and retroviral RT; 
however, non-LTR retrotransposon RT is often augmented by an additional 
endonuclease (EN) enzymatic activity which is important for the non-LTR 
retrotransposition mechanism (Xiong and Eickbush 1990, Feng et al. 1996, Yang 
et al. 1999).   
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Human L1 Elements 
 L1 is the only active autonomous transposable element in humans. 
Approximately 516,000 L1 sequences litter the human genome accounting for 
~17% of human DNA. Most L1 sequences are incapable of retrotransposition as 
they are either 5'-truncated, internally rearranged, or extensively mutated (Lander 
et al. 2001). It is currently estimated, however, that each diploid human genome 
contains 80 to 100 intact L1 sequences that are capable of retrotransposition 
(Sassaman et al. 1997, Brouha et al. 2003). 
Overview of L1 Structure  
 A full-length active human L1 is approximately 6 kb in length and consists 
of a 5' UTR that promotes L1 transcription (Swergold 1990), two open reading 
frames (ORFs) that are separated by a 63 bp intergenic spacer, and a short 3' 
UTR that ends in a variable length poly-adenosine tract (Scott et al. 1987, 
Dombroski et al. 1991) (Figure 1.3C). L1 ORF1 encodes an ~40 kDa nucleic acid 
binding protein (ORF1p) (Martin 1991, Martin and Branciforte 1993, Hohjoh and 
Singer 1996, Hohjoh and Singer 1997) that also exhibits nucleic acid chaperone 
activity (Martin and Bushman 2001, Khazina and Weichenrieder 2009, Khazina 
et al. 2011, Callahan et al. 2012). L1 ORF2 encodes ORF2p, which contains 
endonuclease (EN) (Feng et al. 1996, Cost et al. 2001) and reverse transcriptase 
(RT) activities (Mathias et al. 1991, Dombroski et al. 1994). Both L1 proteins are 
required for L1 retrotransposition (Moran et al. 1996).  
L1 5' UTR 
 The L1 5' UTR contains internal RNA polymerase II promoter activity that 
directs transcription of the L1 in the 5' to 3' direction at or near the first L1 
nucleotide (Swergold 1990, Becker et al. 1993, Athanikar et al. 2004). The L1 5' 
UTR also exhibits antisense (3' to 5' with respect to the L1) promoter activity, the 
function of which has not yet been defined, but in principle could direct the 
transcription of genes adjacent to the L1 5' UTR (Speek 2001, Macia et al. 2011). 
Within the 5' UTR are several transcription factor-binding sites including one Yin 
Yang 1 (YY1)-binding site (Becker et al. 1993, Athanikar et al. 2004), two SRY-
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related (SOX)-binding sites (Tchenio et al. 2000), and a Runx3-binding site 
(Yang et al. 2003). Experiments in cultured cells have shown that deletions or 
mutations of these binding sites reduce L1 transcription and/or L1 
retrotransposition efficiency (Becker et al. 1993, Tchenio et al. 2000, Yang et al. 
2003, Athanikar et al. 2004). Notably, mutations in the YY1-binding site results in 
a loss of L1 transcription fidelity suggesting that YY1 directs transcription to begin 
at the L1 +1 nucleotide (Athanikar et al. 2004). 
L1 ORF1 
 The first L1 ORF encodes ORF1p, an ~40 kDa nucleic acid binding protein 
(Martin 1991, Holmes et al. 1992, Hohjoh and Singer 1996, Hohjoh and Singer 
1997) with demonstrated nucleic acid chaperone activity (Martin and Bushman 
2001). Three ORF1p domains have been identified that are important for ORF1p 
function. The amino terminal ORF1p domain consists of a coiled-coil domain 
marked by a putative leucine zipper motif (Holmes et al. 1992, Hohjoh and Singer 
1996). Evidence suggests that the coiled-coil domain mediates the formation of 
an ORF1p trimer, which is the basic ORF1p functional unit (Martin et al. 2003, 
Basame et al. 2006, Khazina and Weichenrieder 2009). Numerous studies have 
demonstrated that mutations in the coiled-coil domain are incompatible with 
retrotransposition, and impair the ability of ORF1p to form proper trimers and to 
localize properly to L1 RNPs (Moran et al. 1996, Basame et al. 2006, Khazina 
and Weichenrieder 2009, Doucet et al. 2010, Khazina et al. 2011) 
 Early studies using mouse and human cultured cells showed that ORF1p 
binds to L1 RNA to form ribonucleoprotein particles (RNPs) (Martin 1991, Martin 
and Branciforte 1993, Hohjoh and Singer 1996, Hohjoh and Singer 1997). 
Genetic and biochemical analysis has demonstrated that the central domain of 
ORF1p, consists of an RNA recognition motif (RRM) that interacts with the 
ORF1p carboxyl terminal domain (CTD) to mediate nucleic acid binding 
(Januszyk et al. 2007, Khazina and Weichenrieder 2009, Khazina et al. 2011). 
Critically, mutation of either the RRM or CTD disrupts ORF1p nucleic acid 
binding activity, prevents proper L1 RNP formation, and renders L1 unable to 
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retrotranspose (Moran et al. 1996, Martin et al. 2000, Kulpa and Moran 2005, 
Martin et al. 2005, Goodier et al. 2007, Khazina and Weichenrieder 2009, Doucet 
et al. 2010, Khazina et al. 2011).  
 In addition to nucleic acid binding, ORF1p exhibits nucleic acid chaperone 
activity that facilitates the dissociation of mismatched DNA duplexes and/or the 
re-annealing of complimentary DNA strands in vitro (Martin and Bushman 2001, 
Martin et al. 2005, Khazina and Weichenrieder 2009, Callahan et al. 2012). 
Certain genetic and biochemical data suggest that ORF1p nucleic acid 
chaperone activity is required for L1 retrotransposition; specifically that ORF1p 
nucleic acid chaperone activity may be important for the integration of L1 into 
genomic DNA (Martin and Bushman 2001, Martin et al. 2005, Martin et al. 2008). 
Data from the study of other non-LTR retrotransposons, however, suggests that 
ORF1p is not needed for retrotransposition. For example, the zebrafish LINE 
(Zfl2-1), which like human L1 also encodes an ORF1p protein with chaperone 
activity, does not strictly require ORF1p for retrotransposition (Kajikawa et al. 
2012, Nakamura et al. 2012). Additionally, other non-LTR retrotransposons such 
as Alu elements do not strictly require ORF1p to retrotranspose (Dewannieux et 
al. 2003), although it has been proposed the ORF1p may enhance Alu activity 
(Wallace et al. 2008). It is evident that the development of in vitro systems that 
are able to test specific steps in the retrotransposition pathway (i.e., TPRT 
integration step) would provide a better test for what ORF1p functions are 
necessary for retrotransposition.  
L1 ORF2 
 The second L1 ORF encodes an ~150 kDa protein, ORF2p (Ergun et al., 
2004; Doucet et al., 2010; Goodier et al., 2010). ORF2p exhibits endonuclease 
(EN) (Feng et al., 1996) and reverse transcriptase (RT) (Dombroski et al., 1994; 
Mathias et al., 1991) activities, which are required for L1 retrotransposition 
(Moran et al. 1996). The amino terminal portion of ORF2p encodes 
apurinic/apyrimidinic (AP) endonuclease domain (Feng et al. 1996). ORF2p EN 
preferentially cleaves single stranded DNA at an AT-rich consensus sequence: 5' 
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TTTT/A 3' where the "/" indicates the cleavage site (Feng et al. 1996). Mutations 
to catalytic residues within the EN domain impair the ability for ORF2p to cleave 
DNA and renders L1 unable to retrotranspose. 
 ORF2p RT activity resides within a domain located immediately 
downstream of the EN domain. The ORF2p RT domain is similar to RT domains 
from group II introns, retroviruses, telomerase and other endogenous 
retrotransposons (Hattori et al. 1986, Xiong and Eickbush 1990, Eickbush 1997, 
Malik et al. 1999). Early experiments using ORF2 fusion proteins expressed in 
yeast first demonstrated that ORF2 exhibited RT activity (Mathias et al. 1991, 
Dombroski et al. 1994). Subsequent studies were able to purify recombinant 
ORF2p from insect cells and to demonstrate that recombinant ORF2p exhibited 
RNA-dependent and DNA-dependent DNA polymerase activities (Piskareva et al. 
2003). Notably, ORF2 RT is highly processive and lacks a detectable RNase H 
activity; traits which distinguish it from retroviral RTs (Piskareva et al. 2003, 
Piskareva and Schmatchenko 2006). Later studies went on to show that ORF2p 
RT activity co-purified with L1 RNPs and that L1 RNP-associated ORF2p RT 
activity could use the L1 RNA, and to a lesser extent other cellular RNAs, as a 
template for reverse transcription (Kulpa and Moran 2006, Doucet et al. 2010). 
 The carboxyl portion of ORF2p is rich in cysteine amino acid residues and 
is thought to encode a potential zinc-knuckle structure (Fanning and Singer 
1987). The function of the cysteine-rich (C-rich) domain is unknown; however, 
mutations in this region negatively impact L1 retrotransposition, suggesting that it 
is important for ORF2p function (Moran et al. 1996). Notably, mutations in the C-
rich domain also negatively impact ORF2 RT activity and localization of ORF2p 
to L1 RNPs (Clements and Singer 1998, Doucet et al. 2010). Evidence from a 
recent study using a purified peptide from the carboxyl portion of ORF2p 
suggests that the ORF2p carboxyl-terminus may be involved in RNA binding 
(Piskareva et al. 2013). Clearly, the development of in vitro assays to test C-rich 
domain function and/or structural analyses similar to those characterizing the 
ORF2p EN domain (Weichenrieder et al. 2004, Repanas et al. 2007) will help 
further elucidate the function of the C-rich domain in retrotransposition.  
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L1 3' UTR 
 The L1 3' UTR is ~200 bp length and is located between the stop codon of 
ORF2 and the variable length poly adenosine region at the 3' end of the element 
(Grimaldi et al. 1984, Scott et al. 1987, Dombroski et al. 1991). The 3' UTR varies 
significantly between L1s from different mammals except for a highly conserved 
G-rich polypurine tract that is predicted to form a stable secondary structure 
(Howell and Usdin 1997). The L1 3' UTR also contains a relatively weak 
polyadenylation signal that is often bypassed in favor of a stronger 
polyadenylation signal in flanking DNA (Holmes et al. 1994, Moran et al. 1996, 
Moran et al. 1999). Notably, the L1 3' UTR is not strictly required for 
retrotransposition as cell culture experiments have demonstrated that  the native 
L1 polyadenylation signal can be efficiently bypassed and that mutant L1 
elements with deletions in the 3' UTR encompassing the G-rich tract 
retrotranspose at efficiencies similar to wild-type L1 elements (Moran et al. 1996, 
Moran et al. 1999).  
 
The L1 Retrotransposition Pathway 
Overview 
 The L1 retrotransposition cycle (Figure 1.4) involves the transcription of a 
genomic L1 element, which produces a bicistronic L1 mRNA that is then 
translated in the cytoplasm by an unconventional cap-dependent mechanism 
(Leibold et al. 1990, McMillan and Singer 1993, Alisch et al. 2006, Dmitriev et al. 
2007). Following translation, ORF1p and ORF2p preferentially bind to their 
encoding L1 mRNA (a phenomenon termed cis-preference (Esnault et al., 2000; 
Wei et al., 2001)) to form a L1 ribonucleoprotein particle (RNP), which is an 
important L1 retrotransposition intermediate (Doucet et al., 2010; Hohjoh and 
Singer, 1996; Kulpa and Moran, 2005, 2006; Martin, 1991). The L1 RNP is 
thought to gain entry to the nucleus by a process that does not strictly require cell 
division (Kubo et al., 2006), although L1 retrotransposition seems to be 
enhanced in dividing cells (Shi et al., 2007; Xie et al., 2013). Once components 
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of the L1 RNP have entered the nucleus, the L1 RNA is reverse transcribed and 
is integrated into genomic DNA by a concerted process termed target-site primed 
reverse transcription (TPRT) (Cost et al., 2002; Feng et al., 1996; Luan et al., 
1993). Some of these steps will be discussed in further detail below. 
Trans-mobilization of non-autonomous elements 
 The L1-encoded proteins can work in trans to promote the 
retrotransposition of non-autonomous non-LTR retrotransposons such as Alu 
elements (Figure 1.3D) (Dewannieux et al. 2003) and SINE-R/VNTR/Alu (SVA) 
elements (Ostertag et al. 2003, Hancks et al. 2011, Raiz et al. 2012). Alu 
elements are ~300 bp sequences derived from 7SL RNA and are present in over 
one million copies in the genome (~11% of human DNA) (Deininger et al. 1981, 
Ullu and Tschudi 1984, Sinnett et al. 1991, Chu et al. 1995, Lander et al. 2001). 
SVA (SINE-R/VNTR/Alu) elements are composite sequences derived from 
retrotransposon (SINE-R), variable length tandem repeat (VNTR), and Alu 
sequences, and are present in ~2,700 copies in the human genome (Ostertag et 
al. 2003, Wang et al. 2005). Alu and SVA elements are considered non-
autonomous because they do not encode the proteins necessary to promote their 
own retrotransposition and must therefore parasitize the L1-encoded proteins in 
order to retrotranspose. 
 In addition to Alu and SVA elements, a number of other cellular RNAs also 
can be retrotransposed by the L1-encoded proteins. These RNA sequences 
include uracil-rich small nuclear RNAs (e.g., U6 snRNA (Buzdin et al. 2002, 
Gilbert et al. 2005, Garcia-Perez et al. 2007)), small nucleolar RNAs (e.g., U3 
snoRNA (Weber 2006)), and messenger RNAs (Figure 1.3E) (Esnault et al. 
2000, Wei et al. 2001). Taking into account all known RNA species that are 
mobilized in trans by the L1 machinery, the process of L1 retrotransposition  has 
generated nearly 1 billion base pairs of human DNA (Lander et al. 2001). 
L1 Translation 
 The bicistronic nature of the L1 mRNA sets it apart from other eukaryotic 
mRNAs, which typically encode a single ORF, and leads to the question of how 
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the L1 RNA is efficiently translated. Early studies demonstrated that L1 ORF1p 
was expressed in certain cancer derived human and mouse cell lines and/or cells 
transfected with L1 cDNA, which provided the initial evidence that L1 RNA was 
translated (Leibold et al. 1990, Holmes et al. 1992, McMillan and Singer 1993). In 
contrast to the relative ease in detecting ORF1p, L1 ORF2p was much more 
difficult to detect. The only evidence that supported the translation of ORF2 was 
provided by 1) indirect biochemical evidence derived from in vitro assays that 
measured ORF2p RT activity or 2) from genetic cell culture-based 
retrotransposition assays (Mathias et al. 1991, McMillan and Singer 1993, Moran 
et al. 1996). 
 Despite the inability to directly detect ORF2p, genetic and biochemical 
analyses demonstrated that human L1 mRNA was likely translated in a cap-
dependent manner that involved an unconventional termination/re-initiation 
mechanism (Alisch et al. 2006, Dmitriev et al. 2007). This model of human L1 
translation postulates that after reaching the termination codon of ORF1, a 
ribosome continues to scan beyond the end of ORF1 and then re-initiates 
translation at the first ORF2 methionine (AUG) codon (Alisch et al. 2006). 
Another model of L1 translation based on studies of mouse L1 elements 
proposes that mouse L1 translation is dependent on an internal ribosome entry 
site (IRES) located upstream of both ORFs (Li et al. 2006). Studies of human L1 
translation, however, suggest this is likely not the case for human L1 as the 
entire ORF1 sequence can be deleted or replaced by green fluorescence protein 
(GFP) without affecting ORF2 translation (Alisch et al. 2006). Recent 
development of epitope tagging strategies (Goodier et al. 2004, Doucet et al. 
2010) to aid in the purification and detection of L1 proteins should prove useful in 
future studies aimed at determining how L1 is translated.  
The L1 RNP  
 The L1 RNP minimally is composed of L1 RNA, ORF1p, and ORF2p and 
is a necessary L1 retrotransposition intermediate. Early studies first suggested 
that L1 RNA and ORF1p formed an RNP by demonstrating that L1 ORF1p and 
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L1 RNA expressed in mouse F9 cells (embryonal carcinoma cells) co-sediment 
together in sucrose gradients (Martin 1991, Martin and Branciforte 1993). 
Subsequent studies using cultured human cell lines showed that human ORF1p 
binds to human L1 RNA to form RNPs (Hohjoh and Singer 1996, Hohjoh and 
Singer 1997, Hohjoh and Singer 1997) and that L1 RNP formation was 
necessary for L1 retrotransposition (Kulpa and Moran 2005).  
 It remained unknown for some time, however, whether L1 ORF2p was 
also part of the L1 RNP due to an inability to detect ORF2p using standard 
biochemical methods  (Goodier et al. 2004). Eventually, an in vitro assay 
designed to detect L1 ORF2 RT activity (L1 element amplification protocol or 
LEAP) (Kulpa and Moran 2006) was used to show that ORF2p RT activity co-
purified with L1 RNA and ORF1p in cells transfected with engineered L1 
expression plasmids. Subsequent studies using epitope tagged engineered L1 
plasmids were able to demonstrate a direct physical interactions between ORF2p 
and L1 RNA and ORF1p, thus augmenting previous studies that used enzymatic 
assays to infer the presence of ORF2p in L1 RNPs (Doucet et al. 2010, Goodier 
et al. 2010). Despite these findings, the stoichiometry of L1 RNA and L1-encoded 
proteins within an L1 RNP and whether or not other host cell proteins are 
required for L1 RNP function remains unknown. Notably, a recent study has 
demonstrated that different types of L1 RNPs may exist, suggesting that the 
composition of L1 RNPs may change during the L1 retrotransposition cycle 
(Taylor et al. 2013). Indeed, the development of an in vitro cell-free system that 
uses purified L1 RNA and proteins could be useful in determining the 
composition and biochemical properties of functional L1 RNPs. 
TPRT 
 The reverse transcription of L1 RNA and subsequent integration of L1 into 
genomic DNA occurs at the genomic DNA target site by a process termed target 
site primed reverse transcription (TPRT), which was initially characterized for the 
R2Bm non-LTR retrotransposon from the silkworm moth (Luan et al. 1993). In 
the case of L1, once components of the L1 RNP enter the nucleus, the ORF2 EN 
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is thought to generate a single-strand endonucleolytic nick in a single strand of 
genomic DNA at a thymidine rich consensus sequence (e.g., 5’-TTTT/A, 5’-
TCTT/A, 5’-TTTA/A, etc. where the '/' indicates the cut site) (Cost and Boeke, 
1998; Feng et al., 1996; Morrish et al., 2002). This cleavage event exposes a 
free 3’ hydroxyl group, which can then be used by the ORF2p RT as a primer to 
initiate  antisense (-) strand L1 cDNA synthesis using the L1 mRNA as a 
template for the reverse transcription reaction (Cost and Boeke, 1998; Feng et 
al., 1996). Following L1 (-) cDNA synthesis, the top strand of DNA must then be 
cleaved and the L1 cDNA must be copied to complete integration. How these last 
steps of TPRT occur are not fully understood, but it is thought these steps may 
involve ORF2 EN/RT and/or host proteins involved in DNA repair  (Morrish et al., 
2002; Suzuki et al., 2009; Taylor et al., 2013). The TPRT process typically results 
in the generation of variable length target site duplications that flank new L1 
insertions, but can also result in other target site alterations including target site 
deletions (Gilbert et al. 2002, Symer et al. 2002, Gilbert et al. 2005, Richardson 
et al. 2015).  
 
The Impact Of L1 Retrotransposition On The Human Genome 
Discovery of an active human L1 
 It was the discovery that L1 retrotransposition caused hemophilia A that 
alerted researches that L1 was active in the human genome (Kazazian et al. 
1988). In 1988, researchers from the Kazazian lab conducted a screen to detect 
abnormalities in the coagulation factor VIII (F8) gene of a cohort of 240 male 
patients stricken with hemophilia A. The screen revealed L1 insertions into exon 
14 of the F8 gene in 2 out of the 240 patients. Biochemical testing revealed that 
the F8 gene was not functional in either of the affected patients suggesting that 
the L1 insertions had inactivated the F8 gene. Critically, genetic testing revealed 
that the F8 gene was normal (i.e., did not contain an L1 insertion) in the parents 
of the affected individuals. This suggested that the L1 had retrotransposed into 
the F8 genes of the affected patients either the parental germline or during 
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development (Kazazian et al. 1988). In two subsequent studies, a full-length L1 
element (L1.2)  (Dombroski et al. 1991) that likely produced one of the disease-
causing F8 gene insertions was cloned and then demonstrated to actively 
retrotranspose in cultured human cells (Moran et al. 1996). Together, these 
landmark studies confirmed that L1 was active in humans and that L1 
retrotransposition could have a profound impact on the human genome. 
L1 and human disease 
 L1 retrotransposition is responsible for at least 96 single-gene genetic 
diseases in humans (Hancks and Kazazian 2012). Insertional mutagenesis 
caused by the insertion of L1, Alu or SVA (Figures 1.5A and 1.5D) sequences 
into genes can cause mutations (e.g., nonsense mutations, frame-shift 
mutations) that can disrupt normal gene expression and lead to disease. L1-
mediated insertional mutagenesis has been documented in numerous human 
disease cases including hemophilia A (Kazazian et al. 1988), Duchene muscular 
dystrophy (Yajima et al. 1999), and cancer (Miki et al. 1992). Indeed, the 
suppression of gene expression by transposable element insertions is what lead 
to the initial discovery of transposable elements by Barbara McClintock 
(McClintock 1950, McClintock 1984) and the discovery that L1 was active in the 
human genome (Kazazian et al. 1988). Notably, L1-mediated insertional 
mutagenesis is also responsible for disease phenotypes in other animals. For 
example, mutations resulting from L1 retrotransposition are responsible for 
several mutant mouse strains including the spastic mouse (Mulhardt et al. 1994), 
med (motor endplate disease) mouse (Burgess et al. 1995, Kohrman et al. 1996) 
and black-eyed white mouse (Yajima et al. 1999). L1 retrotransposition is also 
associated with diseases in dogs including hemophilia B and narcolepsy (Lin et 
al. 1999, Brooks et al. 2003). 
 Genomic DNA deletions: L1 retrotransposition can sometimes result in 
alterations of genomic DNA at the L1 insertion site (Gilbert et al. 2002, Symer et 
al. 2002, Gilbert et al. 2005, Han et al. 2008). For example, studies using human 
cultured cells have demonstrated that L1 retrotransposition can sometimes result 
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in genomic target-site deletions ranging from 193 bp to ∼3.1 kb (Figure 1.5B) 
(Gilbert et al. 2002, Gilbert et al. 2005). Notably, L1-mediated deletions are 
associated with cases of human disease. For example, an L1 retrotransposition 
event was associated with a large interstitial deletion of ~46 kb in the PDHX gene 
of a patient diagnosed with pyruvate dehydrogenase complex  deficiency (Mine 
et al. 2007). To date, L1 and Alu retrotransposition mediated deletions are 
associated with 12/96 (~13%) of L1 retrotransposition-associated human disease 
cases (Chen et al. 2005, Hancks and Kazazian 2012).  
 Modulation of gene expression: L1 elements encode a number of active 
splice acceptor/donor sites as well as several polyadenylation signals that could 
cause the missplicing and/or premature polyadenylation of cellular genes that 
contain L1 insertions (Figure 1.5D)  (Perepelitsa-Belancio and Deininger 2003, 
Han et al. 2004, Belancio et al. 2006). Analysis of several human disease cases 
has revealed that L1 insertions may interfere with the normal processing of 
cellular RNAs. For example, in a patient diagnosed with choroideremia, an L1 
insertion into the choroideremia (CHM) gene was associated with an exon-
skipping event that deleted exon 6 from the CHM mRNA (van den Hurk et al. 
2003). Alu and SVA insertions also have been associated with diseases involving 
defects in normal RNA processing. For example, an Alu insertion was associated 
with the skipping of exon 22 of the BRCA2 tumor suppressor gene in a patient 
with breast cancer (Miki et al. 1996) and an SVA insertion into the 3' UTR of the 
fukutin gene was associated with the truncation of the fukutin mRNA in a patient 
with Fukuyama muscular dystrophy (FCMD) (Taniguchi-Ikeda et al. 2011).  
 Post-insertion genomic rearrangements: Due to the widely dispersed 
number of L1 and Alu repeats throughout the genome, unequal crossing over 
(i.e., non-allelic homologous recombination (NAHR)) between these sequences 
can sometimes occur, which can result in chromosomal DNA deletions, 
duplications and/or inversions (Figure 1.5F) (Fitch et al. 1991, Gilbert et al. 2002, 
Gilbert et al. 2005, Han et al. 2008, Lee et al. 2008). NHAR between L1 and Alu 
repeats have been documented in several human disease cases including Alport 
syndrome, Perlman syndrome, and a case of glycogen storage disease that was 
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associated with a 7574 bp deletion within the patient's phosphorylase kinase beta 
(PHKB) gene caused by an unequal cross-over event between non-allelic L1s 
(Burwinkel and Kilimann 1998, Segal et al. 1999, Hancks and Kazazian 2012, 
Higashimoto et al. 2013).  
L1 and human genome evolution 
 As discussed up to this point, L1 retrotransposition can cause mutations 
that cause diseases; clearly a negative impact on the human genome. If 
however, a new L1 insertion does not result in a life-threatening disease, the 
insertion may become a permanent feature of the human genome. This is 
evident from the large number of L1 and Alu sequences extant in the genome. 
What then, if any, is the significance of the increasing accumulation of new L1 
retrotransposition-mediated sequence insertions (e.g., L1, Alu, SVA, etc.) on the 
human genome?  
 Active L1 retrotransposition in human genomes is a mechanism that 
generates genomic sequence diversity in the human population. Indeed, it is 
currently estimated that a new L1 retrotransposition event occurs once in every 
20 to 200 live human births while the current Alu retrotransposition rate is 
estimated to occur 1 out of every 20 births (Cordaux and Batzer 2009). Recent 
comparative analyses between the human genome reference sequence (HGR) 
and individual genomes representing distinct human populations have revealed 
the existence of rare active L1 alleles in the human population that are not 
present in the HGR, which suggests that the number and diversity of active L1s 
present in the human population are likely underrepresented by the HGR (Beck 
et al. 2010, Ewing and Kazazian 2010). Notably, recent studies have uncovered 
compelling new evidence that L1 retrotransposition also occurs in adult somatic 
tissues including the human brain, which suggests that L1 retrotransposition 
contributes to somatic variation within an individual (Coufal et al. 2009, Baillie et 
al. 2011, Upton et al. 2015). Thus, L1 retrotransposition generates intra- and 
inter-individual diversity in the human population.   
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 L1-mediated insertions into coding regions could introduce novel 
regulatory elements that could potentially modulate normal gene expression 
(Cordaux and Batzer 2009). Analysis of transposable elements sequences in the 
human genome has revealed that approximately 4% of protein coding genes may 
contain transposable element insertions with L1 and Alu insertions accounting for 
nearly 70% of those insertions (Gibbs et al. 2004). L1 insertions into gene coding 
regions could provide novel transcription factor binding sites, splice sites and/or 
polyadenylation signals, which could directly affect gene expression. 
Experiments done in cultured human cells suggest that L1 insertions within 
protein coding genes can attenuate gene expression, which may involve 
premature polyadenylation and/or other transcriptional elongation defects 
(Perepelitsa-Belancio and Deininger 2003, Han et al. 2004). Additional studies 
suggest that L1 and Alu sequences could introduce alternative splice sites into 
coding regions that may affect the way cellular mRNAs are processed (Belancio 
et al. 2006, Belancio et al. 2008). Finally, recent large-scale sequence analyses 
of the human and mouse transcriptomes have revealed that retrotransposon 
sequence insertions at the 5' end of protein-coding genes can function as 
alternate promoters and that retrotransposon insertions into the 3' UTRs of 
protein coding genes are associated with decreases in gene expression 
(Faulkner et al. 2009).  
 L1 retrotransposition and genomic structural variation: Illegitimate 
recombination events  between L1 and Alu repeats have made a significant 
impact on human genome structure. Combined analyses of the human genome 
suggest that ectopic recombination between Alu sequences may have played a 
significant role in the expansion of segmental duplications in the human genome, 
which account for ~4-5% of genomic DNA (Fitch et al. 1991, Bailey et al. 2003, 
Han et al. 2008, Lee et al. 2008). A potential significant biological outcome of 
segmental duplications is that these events could result in the duplication of 
cellular genes (Bailey et al. 2002, Long et al. 2003). Notably, ectopic 
recombination between repeat sequences are postulated to have given rise to 
human fetal globin genes (Shen et al. 1981). Additionally, unequal crossing over 
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between L1 sequences is thought to be responsible for the duplication of the γ-
globin gene in the primate lineage (Fitch et al. 1991), and may have been 
responsible for the Abp gene duplication in the mouse (Janousek et al. 2013).  
 L1 and Alu-mediated deletions and inversions also have changed the 
genomic DNA landscape. Recent comparative genomic analyses between the 
human and chimpanzee have uncovered at least 73 L1 recombination-
associated deletions and 492 Alu recombination-associated deletions that are 
unique to the human genome (Han et al. 2005, Sen et al. 2006, Han et al. 2008). 
Additional sequence comparisons between the human and chimpanzee 
genomes have revealed that L1 and Alu sequences are associated with 112 out 
of 252 identified chromosomal inversions between humans and chimpanzee (Lee 
et al. 2008). Notably, 27 L1 and/or Alu associated inversions are human-specific 
and 22 are chimpanzee-specific  (Lee et al. 2008). Thus, illegitimate 
recombination events between L1 and Alu are responsible for genomic structural 
changes that may have contributed to differences between the human and 
chimpanzee genomes. 
 Retrotransposition of other cellular RNAs: L1 retrotransposition generates 
additional genomic sequence diversity through the retrotransposition of other 
cellular RNAs such as mRNA (Esnault et al. 2000, Wei et al. 2001) and non-
coding RNAs (e.g., U6 snRNA, U3 snoRNA, Y RNA) (Buzdin et al. 2002, 
Perreault et al. 2005, Weber 2006). The retrotransposition of mRNA, for 
example, can give rise to processed pseudogenes, which are typically defined as 
non-functional intronless copies of functional genes. Comprehensive sequencing 
analysis has revealed that the human genome contains approximately 8,000 
processed pseudogenes, which originate from about 2,500 different functional 
genes (Zhang et al. 2003, Pei et al. 2012). Even though processed pseudogenes 
by definition are not functional, some processed pseudogenes are expressed 
perhaps through the recruitment of adjacent promoters or as part of other 
transcripts (Strichman-Almashanu et al. 2003, Vinckenbosch et al. 2006, Pink et 
al. 2011, Pei et al. 2012).  
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 Remarkably, the retrotransposition of cellular RNAs may have given rise 
to functional genes. For example, the human phosphoglycerate kinase 2 (PGK2) 
gene is a testis specific intronless gene on chromosome 6 that likely resulted 
from the retrotransposition of an mRNA that originated from the PGK1 gene 
located on the X chromosome (McCarrey and Thomas 1987, McCarrey 1990). 
Notably, a number of retrotransposed mammalian testis-specific genes have 
been identified (Bradley et al. 2004, Marques et al. 2005). A recent analysis of 
the canine genome has revealed that a retrotransposed copy of the fibroblast 
growth factor 4 gene  (fgf4) is associated with chondrodysplasia (also known as 
short-limbed or disproportional dwarfism) in over 20 domesticated dog breeds 
(Parker et al. 2009).  
 L1 transductions: A L1 transduction involves the retrotransposition of 
genomic DNA sequences from either the 5' and 3' ends of genomic L1 (Figure 
1.5C). The retrotransposition of genomic DNA from the L1 3' end (known as an 
L1 3' transduction) can occur if L1 transcription continues past the 3' end of an L1 
into the adjoining genomic DNA. This produces a chimeric RNA transcript 
consisting of the L1 element and genomic DNA sequences from the 3' end of the 
L1. The subsequent retrotransposition of this chimeric L1/3' genomic DNA 
transcript would result in the transduction of the 3' flanking genomic DNA 
sequence to a new location in the genome (Holmes et al. 1994, Moran et al. 
1996).  
 L1-mediated 3' transductions have been detected in human disease cases 
(Miki et al. 1992, Holmes et al. 1994). For example, a L1 3' transduction was 
discovered in the dystrophin (DMD) gene of a patient that was diagnosed with 
Duchene muscular dystrophy (Holmes et al. 1994). In this case, the L1 3' 
transduction consisted of 1,400 bp of L1 sequence, followed by a 37 bp poly-
adenosine tract, and an additional 489 bp of non-L1 sequence that was followed 
by another poly-adenosine tract. The unique 489 bp sequence was mapped back 
to an identical genomic DNA sequence on chromosome 1, which resided 
immediately downstream of a full-length genomic L1 element (LRE2). Thus, the 
3' transduced DNA sequence facilitated the identification of the active progenitor 
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element (LRE2) that produced the DMD disease insertion. The subsequent use 
of cell culture based L1 retrotransposition assays demonstrated that L1 
retrotransposition could give rise to 3' transductions in cultured human cells 
(Moran et al. 1996). Notably, recent analyses of the human genome sequence 
have revealed that L1-mediated 3' transductions are responsible for 
approximately 0.6-1.0% of the human genome (Goodier et al. 2000, Pickeral et 
al. 2000) and the use of L1-mediated 3' transduction genomic DNA "tags" have 
enabled researchers to identify highly active L1 subfamilies and explore the 
dynamics of L1 lineage evolution (Brouha et al. 2002, van den Hurk et al. 2007, 
Beck et al. 2010, Macfarlane et al. 2013). 
 In addition to 3' transductions, genomic DNA at the 5' end of an L1 can be 
retrotransposed (known as an L1 5' transduction) if for example, L1 transcription 
were to initiate upstream of the L1 5' end. Indeed, analysis of the human genome 
and direct sequencing of L1 insertions derived from engineered human L1 
retrotransposition insertions in cultured cells have confirmed that L1 5' 
transductions can occur in vivo and in culture cells (Lander et al. 2001, Wei et al. 
2001, Symer et al. 2002). Notably, only two L1 5' transductions have been 
identified in the HGR, suggesting that L1 5' transductions do not occur at the 
same frequency as L1 3' transductions. This could be due to that fact that the 
majority of genomic L1 insertions are 5' truncated. Notably, a somatic L1 5' 
transduction was recently detected in the human brain (Evrony et al. 2012), and 
approximately 8% of SVA elements in the human genome are associated with 5' 
transductions (Damert et al. 2009, Hancks et al. 2009, Hancks et al. 2011). L1 5' 
transductions also have been detected in other animals. For example, an L1-
mediated 5' transduction is associated with an inactivating mutation in the NR2E3 
gene in the retinal degeneration 7 (rd7) mouse, (Symer et al. 2002, Chen et al. 
2006).  
 L1-mediated exon shuffling: The concept of exon shuffling arose from the 
recognition that genes were split into coding (i.e., exons) and non-coding (i.e., 
introns) regions and suggests that exons from different genes can be brought 
together by recombination events to generate sequences that encode novel 
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proteins (Sambrook 1977, Gilbert 1978). Experiments carried out in cultured 
human cells first demonstrated that L1-mediated transduction could in principle 
mediate exon shuffling. In these experiments, researchers demonstrated that a 
synthetic exon could be transduced into a cellular gene via L1-mediated 3' 
transduction and that the synthetic exon could then be expressed as a fusion 
product with that gene (Moran et al. 1999). Notably, three AMAC gene 
duplications are thought to have resulted from SVA-mediated 3' transductions 
(Rozmahel et al. 1997, Xing et al. 2006) and recent high-throughput sequencing 
of human cancer genomes has revealed that nearly one quarter of cancer 
associated L1 insertions contain 3' transductions, which occasionally involve 
entire exons and/or gene regulatory elements (Tubio et al. 2014).  
 The evolution of new genes via retrotransposition: Recent studies also 
have revealed that L1 retrotransposition may have played a role in the evolution 
of genes involved in HIV-1 resistance in distantly related primate species. In owl 
monkeys for example, a TRIM5-cyclophillin A fusion protein (TRIMCyp) that 
confers resistance to HIV-I was determined to have resulted from the 
retrotransposition of cyclophilin A (CypA) mRNA into exon 7 of the TRIM5 gene 
(Nisole et al. 2004, Sayah et al. 2004). In macaques, a similar TRIMCyp fusion 
protein was also discovered. Unlike the owl monkey TRIMCyp fusion, the 
macaque TRIMCyp fusion resulted from retrotransposition of CypA mRNA into 
the 3' UTR of the TRIM5 gene (Brennan et al. 2008, Virgen et al. 2008, Wilson et 
al. 2008). Thus, the L1 retrotransposition may have contributed to convergent 
evolutionary processes in separate branches of the primate lineage. 
 
Where And When Does L1 Jump?  
 L1 must retrotranspose in the germline or in cells that contribute directly to 
the germline to ensure its continued existence. Indeed many studies have 
provided evidence that L1 retrotransposition does occur in the germline as well 
as in somatic cells during embryogenesis. Recent studies now suggest that L1 
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retrotransposition also occurs in certain adult somatic tissues including cells of 
the mammalian nervous system. 
Germline retrotransposition 
 Early studies provided evidence suggesting that L1 retrotransposition 
occurs in the germline by demonstrating that L1 proteins and L1 RNA are 
expressed in cell lines derived from mouse reproductive tissues (Branciforte and 
Martin 1994, Trelogan and Martin 1995, Soper et al. 2008). Subsequent studies 
showed that L1 proteins are expressed in the reproductive tissues of human 
males (Ergun et al. 2004) and that L1 RNA is expressed in human oocytes 
(Georgiou et al. 2009). Cultured human oocytes have also been demonstrated to 
support the retrotransposition of engineered human L1 elements (Georgiou et al. 
2009). The analysis of human diseases further suggests that L1 
retrotransposition may take place in the human germline. For example, a case of 
chronic granulomatous disease (CGD) was thought to have been caused by a 
mutagenic L1 insertion into the CYBB gene during maternal meiosis I or possibly  
during early development (Brouha et al. 2002). 
 Due to the fact that it is difficult to track L1 retrotransposition events in live 
humans, transgenic animal models have been developed to facilitate the study of 
L1 retrotransposition in vivo.  (Ostertag et al. 2002, An et al. 2006, Kano et al. 
2009, O'Donnell et al. 2013). L1-transgenic animals carry an engineered L1 
transgene that is typically marked with retrotransposition indicator cassette that 
expresses a fluorescent marker protein (i.e., EGFP), which conveniently allows 
retrotransposition events to be tracked using EGFP fluorescence or by 
biochemical methods (e.g., Southern blotting, PCR, etc.) using oligonucleotide 
probes specific to the retrotransposition indicator cassette (Ostertag et al. 2002). 
Indeed, experiments using L1 transgenic mice have been used demonstrated 
that engineered L1 transgenes retrotranspose in the germline of male mice 
(Ostertag et al. 2002). 
L1 retrotransposition during development 
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 L1 retrotransposition also can occur in somatic cells during embryonic 
development. For example, cell culture studies have demonstrated that certain 
human embryonic stem cell lines (hESC), human and mouse embryonic 
carcinoma (EC) derived cell lines, as well as mouse post-implantation embryos 
express endogenous L1 RNA and proteins (Skowronski and Singer 1985, 
Skowronski et al. 1988, Martin 1991, Trelogan and Martin 1995, Garcia-Perez et 
al. 2007, Garcia-Perez et al. 2010). Additionally, studies using cell culture based 
retrotransposition assays have demonstrated that hESCs and human embryonic 
carcinoma derived cell lines support high levels of L1 retrotransposition from 
transfected engineered human L1 constructs (Garcia-Perez et al. 2007, Garcia-
Perez et al. 2010).  
 The study of human disease cases has also provided evidence that L1 
retrotransposition can occur during development. For example, an embryonic L1 
retrotransposition event is thought to be responsible for a case of X-linked 
choroideremia (van den Hurk et al. 2003, van den Hurk et al. 2007). In this 
particular case, a male patient diagnosed with X-linked choroideremia carried a 
mutagenic L1 insertion within the choroideremia (CHM) gene that caused 
aberrant splicing of the CHM mRNA (van den Hurk et al. 2003, van den Hurk et 
al. 2007). PCR analysis of the affected patient's family members revealed that 
the mother was a somatic and germline mosaic for the mutated L1 CHM allele 
that found in the patient, thus the original mutagenic CHM L1 insertion must have 
occurred in the mother during her development. 
 Studies using transgenic rodents have also demonstrated that L1 
retrotransposes during development (Prak et al. 2003, Muotri et al. 2005, Kano et 
al. 2009). In a recent study by Kano and colleagues (Kano et al. 2009), a 
comparison between genomic DNA isolated from L1 transgenic mouse sperm 
and from pooled pre-implantation embryos revealed that L1 transgene insertions 
occurred more frequently in pre-implantation embryos. This result suggested that 
L1 retrotransposition may take place more frequently during embryogenesis than 
was previously thought. Notably, it was also observed that L1 transgene RNA 
produced in germline cells could be delivered to the zygote upon fertilization and 
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subsequently inserted into genomic DNA during embryonic development (Kano 
et al. 2009). Thus, L1 transcription that takes place in the germline may generate 
L1 RNA that can be retrotransposed in the developing embryo.  
Somatic L1 retrotransposition in the brain 
 Recent evidence suggests that somatic L1 retrotransposition may 
influence nervous system development. Some of the initial evidence that L1 
retrotransposition occurs in the nervous system was provided by a study that 
examined L1 expression in the brains of rodents (Muotri et al. 2005). The 
researchers in this study demonstrated that neural progenitor cells (NPCs) 
isolated from the rat hippocampus expressed elevated levels endogenous L1 
RNA compared to other cells from the same region of the brain (Muotri et al. 
2005).  Further analyses revealed that rat NPCs were also able to support the 
retrotransposition of engineered human L1 elements. In addition to data derived 
from rat NPCs, the researchers in this study demonstrated that engineered L1 
transgene retrotransposition events could be detected in the brains of L1 
transgenic mice suggesting the somatic L1 retrotransposition occurs in the 
mammalian brain (Muotri et al. 2005). In a following study that examined L1 
retrotransposition in the human brain, researchers showed that human NPCs 
express elevated levels of endogenous L1 RNA and that human NPCs can 
support the retrotransposition of engineered human L1 elements (Coufal et al. 
2009). Quantitative PCR analysis demonstrated that genomic DNA isolated from 
the brains of adult human cadavers contained higher L1 copy numbers then 
genomic DNA isolated from heart and liver tissues (Coufal et al. 2009), 
suggesting that somatic retrotransposition occurs in the human brain.  
 A recent study using single neuron sequencing has estimated that there 
could be as many as 13.7 somatic L1 insertions per hippocampal neuron in the 
human brain (Upton et al. 2015). This estimate is in contrast to another study that 
also used single cell sequencing, which provided an estimate of <0.1 insertion 
per cortical neuron (Evrony et al. 2012) and a study that used quantitative L1 
PCR estimated that there could be as many as 80 somatic L1 insertions per brain 
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cell (Coufal et al. 2009). Despite these differences, these studies help to confirm 
that L1 is active the human brain; advances in sequencing technologies will no 
doubt improve the accuracy of future estimates of somatic L1 insertions in the 
brain. Notably, studies have shown that some somatic L1 insertions in the human 
brain map to genes with potential neurobiological functions (Baillie et al. 2011) 
and a recent study has used somatic L1 retrotransposition events to track cell 
lineages in the frontal cortex providing insight into the temporal and spatial 
patterns of mosaicism in the human brain (Evrony et al. 2015). In addition to data 
obtained from studies of the mammalian brain, a recent study in flies has 
detected elevated transposon activity in the brains of mutant flies, and has 
identified over 200 de novo brain specific transposon insertions, some of which 
occur into genes involved neuronal functions such as memory (Li et al. 2013, 
Perrat et al. 2013). These combined data suggest that genomic heterogeneity 
due to transposon activity may be a conserved feature of the central nervous 
system. Notwithstanding, the extent of L1 retrotransposition activity and whether 
L1 retrotransposition affects the development and/or function of the nervous 
system will need to be carefully addressed in future studies.  
L1 and cancer 
 Evidence also suggests that spontaneous somatic L1 insertions may be a 
feature of certain types of cancer. For example, early studies identified tumor 
specific L1 insertions into the APC gene of a patient diagnosed with colon cancer 
(Miki et al. 1992) and into the myc gene of a patient diagnosed with breast 
cancer (Morse et al. 1988). Recently, several labs have used high-throughput 
sequencing strategies to detect somatic L1 insertions in tumor tissues. 
Sequencing data from these studies have demonstrated that somatic L1 and Alu 
insertions are associated with several types of cancers including lung, colon, 
liver, prostate, ovary, and breast cancers (Iskow et al. 2010, Lee et al. 2012, 
Solyom et al. 2012, Shukla et al. 2013, Helman et al. 2014, Tubio et al. 2014). 
Notably, some tumor-specific L1 insertions have been detected within protein 
coding genes that are commonly mutated in cancer including genes that may 
function as tumor suppressors (Miki et al. 1992, Lee et al. 2012, Shukla et al. 
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2013, Helman et al. 2014). Despite these findings, whether L1 mediated 
insertions are driving tumor formation or merely benign passenger mutations 
remains to be determined. 
 
The Host Response To L1 Retrotransposition 
 As discussed in the previous sections, L1 retrotransposition can 
destabilize genomic DNA through a variety of different mechanisms (e.g., 
insertional mutagenesis, shuffling genomic sequences, NHAR, etc.). Thus, it 
stands to reason that the cells may have adapted ways to control unabated L1 
activity in order to preserve genomic DNA integrity. Some of the mechanisms 
that are thought to regulate L1 retrotransposition (Figure 1.6) will be detailed in 
this final section. 
DNA methylation 
 The methylation of cytosine nucleotides in genomic DNA is a conserved 
gene silencing mechanism that can be found in many different organisms 
including plants, animals, and bacteria (Goll and Bestor 2005). In certain plant 
and animal species the majority of cytosine methylation is associated with 
transposable element sequences, which is thought to control their expression 
(Yoder et al. 1997, Martienssen 1998, Bestor 2003, Goll and Bestor 2005). 
Notably, DNA methylation is thought to function exclusively in the silencing of 
transposable elements in the fungus species, Neurospora crassa (Selker et al. 
2003). Early L1 studies demonstrated a positive correlation between 
hypomethylation of the L1 promoter and the increased expression of L1 proteins 
in human cancer-derived cell lines (Bratthauer and Fanning 1993, Thayer et al. 
1993, Alves et al. 1996), and that the methylation of CpG dinucleotides within the 
human L1 promoter  represses L1 transcription (Hata and Sakaki 1997). More 
recent studies have shown that hypomethylation of L1 promoters is correlated 
with increase L1 expression in the human brain, and in select human induced 
pluripotent stem cells and hESC cell lines (Coufal et al. 2009, Wissing et al. 
2012). Finally, L1 hypomethylation, increased L1 expression, and increased 
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retrotransposition activity have been detected in tumors from certain forms of 
human cancers (Suter et al. 2004, Iskow et al. 2010, Tubio et al. 2014).  
 During mammalian development, genomic DNA is successively de-
methylated and re-methylated once in the early embryo and then once again in 
primordial germ cells. Once established in the early embryo, genomic DNA 
methylation patterns are thought to persist throughout development in adulthood. 
Notably, defects in establishing methylation of genomic DNA during development 
are linked to  increased expression of L1 and other transposable elements and 
abnormal phenotypes in mutant mice. For example, loss of function mutations in 
DNA methyltransferase-1 (Dnmt1), a DNA methyltransferase responsible for 
maintaining DNA methylation during development, results in a dramatic increase 
in IAP LTR retrotransposon expression in mutant mouse embryos as well as 
embryonic lethality (Walsh et al. 1998). Similar phenotypes are observed in 
mutant mice with loss of function mutations in Dnmt3L, a gene that is necessary 
for establishing de novo methylation of genomic DNA in the germline. Dnmt3L 
mutant male mice exhibit a catastrophic defect in spermatogenesis that is 
accompanied by a loss of L1 and IAP element methylation and increased L1 and 
IAP element expression in germline tissue (Bourc'his and Bestor 2004). Notably, 
a recent study suggests that derepression of L1 sequences during epigenetic 
reprogramming of the embryonic germline may be linked to oocyte attrition in 
female mice (Malki et al. 2014). Despite these data, whether the derepression of 
L1 and other transposable element sequences plays a direct causative role in 
development defects will require further study. 
Other mechanisms that silence L1 expression 
 In addition to DNA methylation, the modification of histone proteins (e.g., 
acetylation, methylation) also may help regulate L1 expression. For example, one 
study using cultured human embryonic carcinoma cell lines suggests that histone 
deacetylase enzymes may act to maintain epigenetic silencing of newly 
integrated L1 insertions (Garcia-Perez et al. 2010).  Histone modifications have 
also been suggested to regulate L1 expression in developing mouse embryos 
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and in germline cells (Di Giacomo et al. 2013, Fadloun et al. 2013, Pezic et al. 
2014).  
 A number of cellular proteins that recognize epigenetic modifications in 
genomic DNA, such as methyl DNA binding proteins and zinc-finger proteins 
have been implicated in the regulation of L1 expression. For example, the 
methyl-CpG-binding protein 2 (MECP2) associates with L1 promoters and has 
been reported to repress L1 expression in neural stem cells and in transformed 
human cell lines (Yu et al. 2001, Muotri et al. 2010). Additionally, L1 activity is 
reported to be higher in the brains of MeCP2 knockout mice and in the brains of 
patients with Rett Syndrome, a neurodevelopmental disorder typically caused by 
mutations in MeCP2 (Muotri et al. 2010). Recent studies have also  provided 
data suggesting that the several KRAB zinc-finger proteins as well as the 
promyelocytic Leukemia zinc finger protein (PLZF) may target genomic L1 and/or 
SVA elements for epigenetic silencing (Puszyk et al. 2013, Castro-Diaz et al. 
2014, Jacobs et al. 2014). 
Small RNA-mediated gene silencing 
 RNA interference (RNAi) is a highly conserved gene silencing mechanism 
in eukaryotes that is associated with gene regulation, imprinting, and silencing 
transposable elements. In RNAi, small silencing RNAs ranging between 21-31 nt 
are loaded onto Argonaute protein family members to form an RNA-induced 
silencing complex (RISC), which targets cellular mRNAs for translational 
inhibition and/or degradation. Two small RNA classes that target transposable 
elements include: small interfering RNAs (siRNAs) and PIWI-interacting RNAs 
(piRNAs).  
 siRNA: siRNAs are Dicer-dependent small RNAs (~21 nucleotide) that 
have  been demonstrated to silence transposons in certain plant and invertebrate 
species (Saito and Siomi 2010, Castel and Martienssen 2013). Recent evidence 
suggests that siRNA may also silence transposable elements in mammals. For 
example, a recent study showed that most siRNAs in developing mouse oocytes 
correspond to retrotransposon sequences, and that LTR retrotransposon 
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transcripts are increased in oocytes from Dicer knockout mice (Watanabe et al. 
2008). Finally, studies using cultured cells suggest that siRNAs may silence L1s 
in human tumor-derived cell lines (Soifer et al. 2005, Yang and Kazazian 2006) 
and possibly in mouse ESCs (Ciaudo et al. 2013).  
 piRNA and PIWI proteins: PIWI (p-element induced wimpy testis) - 
interacting RNAs (piRNAs) are short silencing RNAs (~26-31 nt) that function in a 
highly specialized RNA interference (RNAi) pathway that silences transposable 
elements in germline cells of several different animal species (Aravin et al. 2007, 
Siomi et al. 2011). In the piRNA pathway, transposable element piRNAs 
associate with PIWI  proteins, which are germline specific argonaute protein 
family members to form the piRNA induced silencing complex (piRISC). The 
piRISC targets expressed transposable element mRNA sequences for 
destruction (Aravin et al. 2006, Girard et al. 2006, Vagin et al. 2006). A 
distinguishing feature of the piRNA pathway is the existence of a piRNA 
amplification loop called the ping-pong cycle, which generates additional piRNAs 
that target transposable elements (Brennecke et al. 2007, Gunawardane et al. 
2007).  
 During the ping-pong cycle, once the piRISC cleaves transposable 
elements RNAs, the cleaved transposon RNAs, termed secondary piRNAs, are 
loaded onto a different PIWI protein family member to form a secondary piRISC 
(Siomi et al. 2011). The secondary piRISC is then thought to facilitate the 
processing of additional transposable element piRNAs, thus adding to the 
existing pool of piRISC complexes that target expressed transposable element 
RNAs. In principle, transposable element sequences that are most highly 
expressed (i.e., most active) will preferentially generate additional piRISC 
complexes that target themselves. Thus, the piRNA ping-pong pathway is 
thought to serve as an adaptive defense mechanism against active transposable 
elements in the germline (Aravin et al. 2007, Siomi et al. 2011).  
 Several studies suggest that the piRNA pathway is required to silence 
transposable elements in the mammalian germline. In mice, a substantial 
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proportion of germline pre-pachytene piRNAs are derived from actively 
transcribed L1, SINE and LTR transposon sequences (Aravin et al. 2007, Aravin 
et al. 2008).  Mouse studies have demonstrated a significant increase in L1 and 
IAP expression in the testis of mutant male mice deficient in the mouse PIWI 
protein, MILI (Piwi-Like RNA-Mediated Gene Silencing 2 (PIWIL2)) (Aravin et al. 
2007). Notably, mutant male mice that lack functional mouse PIWI proteins, MILI 
and/or MIWI2 (Piwi-Like RNA-Mediated Gene Silencing 4 (PIWIL4)) display 
phenotypes reminiscent of those observed in male mice lacking functional 
Dnmt3L (Bourc'his and Bestor 2004) including sterility, massive de-repression of  
L1 and IAP elements and a corresponding demethylation of L1 sequences 
(Carmell et al. 2007, Aravin et al. 2008, Kuramochi-Miyagawa et al. 2008). 
 The loss in methylation of L1 and IAP element sequences in MILI and 
MIWI2 mutant mice suggests that piRNAs also may be involved in establishing 
de novo methylation of genomic transposable elements sequences (Carmell et 
al. 2007, Aravin et al. 2008). Recent evidence suggests that mammalian piRNAs 
may also be involved in establishing repressive histone methylation to silence L1 
expression in the germline (Di Giacomo et al. 2013, Pezic et al. 2014). Thus 
piRNAs seem to be involved in a coordinated defense against transposable 
elements that includes posttranscriptional destruction of transposable elements 
RNAs as well as epigenetic DNA modifications that silence transposable 
elements expression. 
Posttranscriptional processing of L1 transcripts 
 Certain evidence suggests that L1 expression could be regulated by RNA 
splicing. Recent studies have demonstrated that L1 sequences encode a number 
of splice donor and acceptor sites that can result in extensive splicing of L1 RNA 
in human and mouse cells  (Belancio et al. 2006, Belancio et al. 2008). 
Examination of various human tissues and human cultured cell lines has 
revealed that L1 RNA is expressed in a range of somatic tissues  and that the 
level of L1 mRNA processing (i.e., splicing) varies significantly among different 
human tissues and cell types (Belancio et al. 2010). These data suggest that 
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although L1 RNA may be normally expressed in certain adult somatic tissues, 
that posttranscriptional RNA splicing might limit the expression of full-length L1 
RNA and thereby limit the level of L1 retrotransposition in somatic tissues. 
 
RNA-binding proteins 
 Cytoplasmic RNA binding proteins also may function in the 
posttranscriptional regulation of L1 retrotransposition. A number of studies have 
demonstrated that L1 RNPs associate with a variety of cellular RNA binding 
proteins (Goodier et al. 2007, Dai et al. 2012, Goodier et al. 2013, Taylor et al. 
2013). For example, immunofluorescence microscopy experiments have 
demonstrated that L1 ORF1p co-localizes with cytoplasmic stress granule (SG) 
proteins, including eIF3 (eukaryotic translation initiation factor 3), G3BP (GTPase 
Activating Protein (SH3 Domain) Binding Protein), and EIF2C2 (Argonaute 2 or 
Ago2) (Doucet et al. 2010, Goodier et al. 2010, Goodier et al. 2013). Stress 
granules are cytoplasmic RNP complexes that form in response to cellular stress 
and are thought to function in cytoplasmic mRNA metabolism and/or translation 
repression (Anderson and Kedersha 2008, Buchan and Parker 2009). Notably, 
SG and/or cytoplasmic processing body (PBs) formation is suppressed by some 
viruses, which suggests that  SGs and PBs may serve a protective function 
during viral infections (Reineke and Lloyd 2013). Thus, it has been hypothesized 
that SGs and/or cellular RNA binding proteins may function to modulate L1 
retrotransposition (Goodier et al. 2007). 
Host antiviral proteins 
 Antiviral proteins typically function to restrict viral infectivity by recognizing 
specific viral components (e.g., viral RNA and/or proteins) and blocking some 
aspect of the viral infectivity cycle (Goff 2004, Yan and Chen 2012, Zheng et al. 
2012). A growing number of studies have demonstrated that host cell antiviral 
proteins also are capable of restricting L1 retrotransposition and the activity of 
other endogenous retrotransposons, suggesting a possible interrelationship 
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between the host cell response to viruses and the host cell response to 
transposable elements. 
 APOBEC3 proteins: In humans, there are seven APOBEC3 
(apolipoprotein B mRNA editing enzyme, catalytic polypeptide-like3) genes that 
encode a small family of cytidine deaminases with RNA editing and/or DNA 
mutator activity (Chiu and Greene 2008). The finding that APOBEC3G (A3G) 
could restrict the activity of vif-deficient HIV-1 provided the first evidence that 
APOBEC3 proteins function as antiviral factors (Sheehy et al. 2002).  
Subsequent studies revealed that A3G also inhibits the activity of endogenous 
retroviruses and Alu elements suggesting that APOBEC3 genes might also 
function to restrict the activity of endogenous retrotransposons. Subsequent 
characterization of APOBEC3 genes by several labs has revealed that 
APOBEC3A (A3A), APOBEC3B (A3B), APOBEC3C (A3C) and APOBEC3F 
(A3F) inhibit L1 retrotransposition (Bogerd et al. 2006, Chen et al. 2006, 
Muckenfuss et al. 2006, Stenglein and Harris 2006, Richardson et al. 2014) and 
that A3A, A3B and A3G are able to inhibit Alu retrotransposition (Bogerd et al. 
2006, Chiu et al. 2006). 
 APOBEC3 proteins may restrict retroviral activity through a deaminase-
dependent mechanism, which involves editing of viral nucleic acid sequences, or 
by a deaminase-independent mechanism, which likely involves binding to viral 
RNA and blocking the procession of retroviral RT (Chiu and Greene 2008). Cell 
culture experiments have demonstrated that A3B and A3C mutants that lack 
enzymatic activity are able to inhibit L1 retrotransposition suggesting that some 
APOBEC3 proteins may inhibit L1 by a deaminase-independent mechanism 
(Bogerd et al. 2006, Horn et al. 2013). Notably, A3G-mediated restriction of Alu 
retrotransposition may also involve a deaminase-independent mechanism (Chiu 
et al. 2006). With this being stated, the localization of APOBEC3 proteins to the 
nucleus and the extensive editing of viral sequences suggest a cytidine 
deaminase-dependent mechanism could also apply to L1. (Bogerd et al. 2006). 
Notably, a recent study suggests that A3A may inhibit L1 retrotransposition by 
deaminating transiently exposed single-strand DNA during L1 integration 
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(Richardson et al. 2014) suggesting that deaminase activity may be required for 
A3A-mediated restriction.  
 Aicardi-Goutières syndrome (AGS) Genes: The three prime repair 
exonuclease 1 (TREX1) is the most abundant 3'-5' DNA exonuclease in cells. 
Mutations in the TREX1 gene are associated with several autoimmune diseases 
including Aicardi-Goutières syndrome (AGS), familial chilblain lupus, and 
Systemic Lupus Erythematosus (SLE) (Kavanagh et al. 2008, Volkman and 
Stetson 2014). In a recent study, elevated levels of single stranded DNA from L1 
and IAP elements was detected in TREX1 knockout mice suggesting that TREX1 
might be involved in regulating endogenous retrotransposon activity. 
Experiments using cultured cells further demonstrated that overexpression of 
TREX1 restricts L1 retrotransposition and that TREX1 mutants deficient in 
catalytic activity were unable to mediate L1 inhibition (Stetson et al. 2008). 
Despite these observations how TREX1 restricts L1 retrotransposition remains 
unknown, but TREX1 restriction is thought to involve exonuclease activity. 
 Another cellular AGS gene that has been demonstrated to restrict the 
activity of L1 retrotransposition is SAM Domain and HD Domain 1 (SAMHD1) 
gene. Mutations in SAMHD1 are associated with several human autoimmune 
disorders including AGS and SLE (Crow and Rehwinkel 2009). SAMHD1 was 
initially identified as an HIV-1 restriction factor in myeloid immune cells in screens 
to identify host cell factors that associate with the HIV-1 lentiviral auxiliary 
protein, Vpx (Hrecka et al. 2011, Laguette et al. 2011). The SAMHD1 protein 
catalyzes the hydrolysis of deoxynucleoside triphosphates (dNTP). SAMHD1 is 
thought to restrict retroviral activity in non-cycling cells by depleting cellular dNTP 
stores, which limits the supply of dNTPs available for the retroviral reverse 
transcription reaction (Ayinde et al. 2012). A recent study demonstrated that 
SAMHD1 restricts human and murine L1s in cell culture based retrotransposition 
assays. Interestingly, SAMHD1 mutants deficient in hydrolase activity were still 
able to inhibit L1 retrotransposition, suggesting that SAMHD1 may restrict 
retroviruses and L1 by different mechanisms (Zhao et al. 2013).  
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 MOV10 and RNase L: Moloney leukemia virus 10 (MOV10) is an RNA 
helicase that has been demonstrated to inhibit the activity of HIV-1 and other 
retroviruses (Zheng et al. 2012, Gregersen et al. 2014). Several recent studies 
have reported that MOV10 can also restrict the activity of L1, Alu and mouse LTR 
retrotransposons (Arjan-Odedra et al. 2012, Goodier et al. 2012, Li et al. 2013). 
How MOV10 restricts retrotransposition is not known; however, evidence 
suggests that MOV10 binds to L1 RNA and may interfere with the expression of 
L1 ORF1p and/or with the reverse transcription of L1 cDNA (Goodier et al. 2012, 
Gregersen et al. 2014). Notably, recent evidence suggests that the MOV10 
paralog, MOV10L, may also restrict the activity of endogenous retroelements in 
mice (Frost et al. 2010, Zheng et al. 2010). Finally, a recent study has 
demonstrated that the 2',5'-oligoadenylate (2-5A) synthetase (OAS)-RNase L 
system may also restrict endogenous retroelements (Zhang et al. 2014). In this 
study, the authors demonstrated that RNase L inhibits the activity of L1 and IAP 
elements in cultured cell assays. Mechanistic analyses showed that RNase L 
decreases the expression of L1 RNA and proteins suggesting that RNase L 
might directly target L1 RNA for degradation.  
 
Closing Remarks 
 Barbara McClintock's discovery of transposons in maize occurred at a 
time before the discovery of the DNA double helix when genes were thought to 
be arranged neatly on chromosomes like beads-on-a-string (McClintock 1950, 
McClintock 1984). The discovery and continued study of transposable elements 
has revealed that genomes are not static, but are constantly changing and 
evolving. Notably, the finding that maize transposable elements could modify the 
expression of other maize genes was one of the first studied examples of a gene 
control system (Mcclintock 1961). For many years that followed these landmark 
discoveries, transposable elements remained underappreciated and perhaps 
were mostly thought of as rather useless junk. This outdated view has been 
challenged by recent scientific advancements such as the sequencing of the 
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human genome which have shown that active transposition can have a major 
impact on genomic DNA structure and function (Lander et al. 2001). Indeed, the 
initial discovery that L1 was active humans, the subsequent development of 
assays to test retrotransposition activity, and advancements in DNA sequencing 
technologies have enabled researchers to demonstrate that L1 retrotransposition 
continues to influence the human genome through mutational processes that can 
sometimes cause genetic diseases and/or generate genomic sequence changes 
that contribute to inter- and intra-individual diversity in the human population. 
Recent studies now suggest that somatic L1 retrotransposition  may even 
influence  the developing mammalian brain (Muotri et al. 2005, Coufal et al. 
2009, Baillie et al. 2011, Evrony et al. 2012, Evrony et al. 2015, Upton et al. 
2015). Notwithstanding, there are many important questions that should be 
addressed in future L1 studies such as how L1 integration is completed, how the 
host cell regulates L1 retrotransposition, and how if at all does L1 
retrotransposition influence development of the mammalian brain. The main 
focus of this thesis is to further explore the question of what host cell factors are 
involved in regulating L1 retrotransposition. 
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Figure 1.1: Transposable elements and corn kernel variegation in maize. 
Top panel: Image of variegated (i.e., purple dots on colorless white background) 
corn kernels. The image is reproduced with permission from Dr. Gerry Neuffer 
and the maize genetics and genomics database (Lawrence et al. 2004). Bottom 
panel: The insertion of a transposable element (orange rectangle) into a gene 
that controls corn kernel color (dark purple rectangle) turns off gene expression 
resulting in colorless corn kernels (colorless corn kernels in top panel). If the 
transposable element transposes out of the gene during corn kernel 
development, gene expression is turned back on giving rise to colored sectors or 
spots on a colorless background. Large spots result from transposition occurring 
early in development and small spots result from transposition occurring late in 
development. 
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Figure 1.2: Transposable element content of the human genome. 
Approximately 46% of the human genome is comprised of transposable element 
(TE) sequences. Only ~1.5% of the genome is known to encode proteins. The 
distribution (% of total human genome) of the major types of human TE is 
indicated to the left of the pie chart (Lander et al. 2001).  
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Figure 1.3: Schematic diagram of the major transposable elements in the 
human genome. 
A) Diagram of a human DNA transposon. Human DNA transposons are ~2-3 kb 
in length and typically encode a transposase enzyme (orange rectangle) that is 
flanked by short inverted tandem repeat sequences (white triangles). B) Diagram 
of a human LTR retrotransposon (human endogenous retrovirus or HERV). 
HERVs are flanked by long tandem repeats (LTRs) that surround structural and 
reverse transcriptase genes similar to retroviral gag and pol genes respectively. 
Some HERVs may also encode a non-functional envelope (env) gene. (C-E) 
Human non-LTR retrotransposons C) Schematic of an autonomous human L1 
element. L1 is ~6 kb in length and encodes a 5' UTR that promotes L1 
transcription. The 5' untranslated region (5' UTR) is followed by two ORFs that 
are separated by a 63 bp intergenic spacer and a short 3' UTR that terminates in 
a variable length poly adenosine tract. ORF1 encodes an ~40 kDa nucleic acid 
binding protein (ORF1p) and ORF2 encodes ORF2p, an ~150 kDa protein with 
RT and EN activities. Both L1 proteins are required for L1 retrotransposition. D) 
Schematic diagram of a human Alu element. Alu is non-autonomous and 
therefore requires the L1-encoded proteins in order to retrotranspose. Human Alu 
elements are ~300 bp in length and exhibit a dimeric sequence arrangement that 
consists of diverged left and right monomers (dark green and light green 
rectangles respectively) that are derived from 7SL RNA and are separated by a 
short poly adenosine tract. Alu elements end in a variable length poly adenosine 
tail. E) Diagram of a processed pseudogene. Processed pseudogenes are non-
functional genes that result from the retrotransposition of cellular mRNAs by the 
L1-encoded protein machinery. Processed pseudogenes resemble cellular 
mRNAs and typically are comprised of 5' and 3' UTRs (grey rectangles), coding 
exons (blue boxes with numbers indicating individual exons (1-3 in this 
example)), and a variable length poly adenosine tail (see main text for 
references). 
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Figure 1.3: Schematic diagram of the major transposable elements in the 
human genome. 
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Figure 1.4: Diagram of the L1 retrotransposition cycle. 
Following transcription of a genomic L1 element (red rectangle), the resulting L1 
mRNA is exported to the cytoplasm. The L1 mRNA is translated in the cytoplasm 
to produce ORF1p (blue circle) and ORF2p (yellow circle), which preferentially 
bind to the L1 mRNA (cis preference) to form a L1 ribonucleoprotein particle (L1 
RNP). The L1-encoded proteins may also act in trans to retrotranspose Alu 
(green RNA structure) or other cellular RNAs (e.g., SVA, mRNA, etc.). Once 
components of the L1 RNP enter the nucleus, a new L1 copy is integrated into 
genomic DNA by the process of target site primed reverse transcription (TPRT). 
For L1 TPRT, ORF2p EN makes a single-strand nick in genomic DNA at a 
degenerate consensus sequence (5'-TTTT/A-3', where "/" denotes the nick) to 
expose a free 3'-OH that can be used by the ORF2p RT as a primer to initiate L1 
reverse transcription. The L1 ORF2p RT uses the L1 mRNA as a template to 
synthesize an antisense L1 cDNA copy (red line) directly onto the exposed 
genomic DNA strand. How the remaining steps of L1 integration occur requires 
further investigation, but may involve other host cell proteins such as DNA repair 
enzymes. 
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Figure 1.4: Diagram of the L1 retrotransposition cycle. 
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Figure 1.5: Examples of how L1 impacts human genomic DNA. 
A) L1 (blue rectangle) can insert into a gene (orange rectangle) and disrupt 
normal gene expression. B) L1 insertions can result in deletions of genomic DNA 
(black rectangle represents genomic DNA sequence that is deleted). C) L1 can 
retrotranspose genomic DNA sequences that lie adjacent to the 5' end (a 5' 
transduction; light grey rectangle) or the 3' end (3' transduction; black rectangle) 
of the L1 element. D) L1 encoded proteins (blue circle) can mobilize Alu (green 
rectangle) and/or other cellular RNAs (e.g., SVA, mRNA, etc.) in trans. E) A L1 
insertion into gene coding region such as an intron (grey rectangles; exons are 
yellow, orange, green rectangles numbered 1-3 respectively) could result in 
premature polyadenylation and produce a truncated RNA transcript 
(yellow/orange rectangle), or a missplicing event resulting in an RNA transcript 
that is missing an exon (yellow/green rectangle) F) Post-insertional illegitimate 
recombination event (zigzag arrowed line) between non-allelic L1 sequences 
(blue rectangles) could result in the duplication (bottom left) or deletion (bottom 
right) of genomic DNA segments (grey rectangle). 
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Figure 1.5: Examples of how L1 impacts human genomic DNA. 
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Figure 1.6: Host cell mechanisms that restrict L1 activity. 
Host cell mechanisms may function to regulate several phases (numbered 1-5) of 
the L1 retrotransposition cycle. 1) Epigenetic modification of genomic L1 
sequences such as cytosine methylation at L1 promoters is thought to limit L1 
expression. 2) Expressed L1 RNA may be subject to alternative splicing and or 
regulation by splicing factors such as hnRNPL, which limits expression of full-
length L1 RNA. The piRNA pathway may target the destruction of L1 transcripts 
in germline cells. 3) Host cell antiviral proteins (e.g., MOV10, RNase L) may 
prevent the accumulation of L1 RNA and/or proteins in the cytoplasm. 4) 
Cytoplasmic stress granules (SGs) may function to sequester components of the 
L1 RNP (i.e., L1 RNA and/or L1-encoded proteins) in the cytoplasm. 5) Certain 
host antiviral proteins (e.g., APOBEC3A (A3A), SAMHD1) also may target the 
production of L1 cDNA by various mechanisms (see main text).  
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Figure 1.6: Host cell mechanisms that restrict L1 activity. 
   
 47 
References 
Alisch, R. S., J. L. Garcia-Perez, A. R. Muotri, F. H. Gage and J. V. Moran, 
"Unconventional translation of mammalian LINE-1 retrotransposons." Genes 
Dev, 2006  20(2): 210-224. 
Alves, G., A. Tatro and T. Fanning, "Differential methylation of human LINE-1 
retrotransposons in malignant cells." Gene, 1996  176(1-2): 39-44. 
An, W., J. S. Han, S. J. Wheelan, E. S. Davis, C. E. Coombes, P. Ye, C. Triplett 
and J. D. Boeke, "Active retrotransposition by a synthetic L1 element in mice." 
Proc Natl Acad Sci U S A, 2006  103(49): 18662-18667. 
Anderson, P. and N. Kedersha, "Stress granules: the Tao of RNA triage." Trends 
Biochem Sci, 2008  33(3): 141-150. 
Aravin, A., D. Gaidatzis, S. Pfeffer, M. Lagos-Quintana, P. Landgraf, N. Iovino, P. 
Morris, M. J. Brownstein, S. Kuramochi-Miyagawa, T. Nakano, M. Chien, J. J. 
Russo, J. Ju, R. Sheridan, C. Sander, M. Zavolan and T. Tuschl, "A novel class 
of small RNAs bind to MILI protein in mouse testes." Nature, 2006  442(7099): 
203-207. 
Aravin, A. A., G. J. Hannon and J. Brennecke, "The Piwi-piRNA Pathway 
Provides an Adaptive Defense in the Transposon Arms Race." Science, 2007  
318(5851): 761-764. 
Aravin, A. A., R. Sachidanandam, D. Bourc'his, C. Schaefer, D. Pezic, K. F. Toth, 
T. Bestor and G. J. Hannon, "A piRNA pathway primed by individual transposons 
is linked to de novo DNA methylation in mice." Mol Cell, 2008  31(6): 785-799. 
Aravin, A. A., R. Sachidanandam, A. Girard, K. Fejes-Toth and G. J. Hannon, 
"Developmentally regulated piRNA clusters implicate MILI in transposon control." 
Science, 2007  316(5825): 744-747. 
Arjan-Odedra, S., C. M. Swanson, N. M. Sherer, S. M. Wolinsky and M. H. 
Malim, "Endogenous MOV10 inhibits the retrotransposition of endogenous 
retroelements but not the replication of exogenous retroviruses." Retrovirology, 
2012  9: 53. 
Athanikar, J. N., R. M. Badge and J. V. Moran, "A YY1-binding site is required for 
accurate human LINE-1 transcription initiation." Nucleic Acids Res, 2004  32(13): 
3846-3855. 
Ayinde, D., N. Casartelli and O. Schwartz, "Restricting HIV the SAMHD1 way: 
through nucleotide starvation." Nat Rev Microbiol, 2012  10(10): 675-680. 
Bailey, J. A., Z. Gu, R. A. Clark, K. Reinert, R. V. Samonte, S. Schwartz, M. D. 
Adams, E. W. Myers, P. W. Li and E. E. Eichler, "Recent segmental duplications 
in the human genome." Science, 2002  297(5583): 1003-1007. 
Bailey, J. A., G. Liu and E. E. Eichler, "An Alu transposition model for the origin 
and expansion of human segmental duplications." Am J Hum Genet, 2003  73(4): 
823-834. 
 48 
Baillie, J. K., M. W. Barnett, K. R. Upton, D. J. Gerhardt, T. A. Richmond, F. De 
Sapio, P. M. Brennan, P. Rizzu, S. Smith, M. Fell, R. T. Talbot, S. Gustincich, T. 
C. Freeman, J. S. Mattick, D. A. Hume, P. Heutink, P. Carninci, J. A. Jeddeloh 
and G. J. Faulkner, "Somatic retrotransposition alters the genetic landscape of 
the human brain." Nature, 2011  479(7374): 534-537. 
Bannert, N. and R. Kurth, "The evolutionary dynamics of human endogenous 
retroviral families." Annual review of genomics and human genetics, 2006  7: 
149-173. 
Basame, S., P. Wai-Lun Li, G. Howard, D. Branciforte, D. Keller and S. L. Martin, 
"Spatial Assembly and RNA Binding Stoichiometry of a LINE-1 Protein Essential 
for Retrotransposition." J Mol Biol, 2006. 
Beauregard, A., M. J. Curcio and M. Belfort, "The take and give between 
retrotransposable elements and their hosts." Annu Rev Genet, 2008  42: 587-
617. 
Beck, C. R., P. Collier, C. Macfarlane, M. Malig, J. M. Kidd, E. E. Eichler, R. M. 
Badge and J. V. Moran, "LINE-1 retrotransposition activity in human genomes." 
Cell, 2010  141(7): 1159-1170. 
Beck, C. R., J. L. Garcia-Perez, R. M. Badge and J. V. Moran, "LINE-1 elements 
in structural variation and disease." Annu Rev Genomics Hum Genet, 2011  12: 
187-215. 
Becker, K. G., G. D. Swergold, K. Ozato and R. E. Thayer, "Binding of the 
ubiquitous nuclear transcription factor YY1 to a cis regulatory sequence in the 
human LINE-1 transposable element." Hum Mol Genet, 1993  2(10): 1697-1702. 
Belancio, V. P., D. J. Hedges and P. Deininger, "LINE-1 RNA splicing and 
influences on mammalian gene expression." Nucleic Acids Research, 2006  
34(5): 1512-1521. 
Belancio, V. P., A. M. Roy-Engel and P. Deininger, "The impact of multiple splice 
sites in human L1 elements." Gene, 2008  411(1-2): 38-45. 
Belancio, V. P., A. M. Roy-Engel, R. R. Pochampally and P. Deininger, "Somatic 
expression of LINE-1 elements in human tissues." Nucleic Acids Res, 2010  
38(12): 3909-3922. 
Bestor, T. H., "Cytosine methylation mediates sexual conflict." Trends Genet, 
2003  19(4): 185-190. 
Boeke, J. D., D. J. Garfinkel, C. A. Styles and G. R. Fink, "Ty elements transpose 
through an RNA intermediate." Cell, 1985  40(3): 491-500. 
Bogerd, H. P., H. L. Wiegand, A. E. Hulme, J. L. Garcia-Perez, K. S. O'Shea, J. 
V. Moran and B. R. Cullen, "Cellular inhibitors of long interspersed element 1 and 
Alu retrotransposition." Proc Natl Acad Sci U S A, 2006  103(23): 8780-8785. 
Bourc'his, D. and T. H. Bestor, "Meiotic catastrophe and retrotransposon 
reactivation in male germ cells lacking Dnmt3L." Nature, 2004  431(7004): 96-99. 
 49 
Bradley, J., A. Baltus, H. Skaletsky, M. Royce-Tolland, K. Dewar and D. C. Page, 
"An X-to-autosome retrogene is required for spermatogenesis in mice." Nat 
Genet, 2004  36(8): 872-876. 
Branciforte, D. and S. L. Martin, "Developmental and cell type specificity of LINE-
1 expression in mouse testis: implications for transposition." Mol Cell Biol, 1994  
14(4): 2584-2592. 
Bratthauer, G. L. and T. G. Fanning, "LINE-1 retrotransposon expression in 
pediatric germ cell tumors." Cancer, 1993  71(7): 2383-2386. 
Brennan, G., Y. Kozyrev and S.-L. Hu, "TRIMCyp expression in Old World 
primates Macaca nemestrina and Macaca fascicularis." Proceedings of the 
National Academy of Sciences, 2008  105(9): 3569-3574. 
Brennecke, J., A. A. Aravin, A. Stark, M. Dus, M. Kellis, R. Sachidanandam and 
G. J. Hannon, "Discrete small RNA-generating loci as master regulators of 
transposon activity in Drosophila." Cell, 2007  128(6): 1089-1103. 
Brooks, M., W. Gu, J. Barnas, J. Ray and K. Ray, "A Line 1 insertion in the 
Factor IX gene segregates with mild hemophilia B in dogs." Mammalian Genome, 
2003  14(11): 788-795. 
Brouha, B., C. Meischl, E. Ostertag, M. de Boer, Y. Zhang, H. Neijens, D. Roos 
and H. H. Kazazian, Jr., "Evidence consistent with human L1 retrotransposition in 
maternal meiosis I." Am J Hum Genet, 2002  71(2): 327-336. 
Brouha, B., J. Schustak, R. M. Badge, S. Lutz-Prigge, A. H. Farley, J. V. Moran 
and H. H. Kazazian, Jr., "Hot L1s account for the bulk of retrotransposition in the 
human population." Proc Natl Acad Sci U S A, 2003  100(9): 5280-5285. 
Buchan, J. R. and R. Parker, "Eukaryotic Stress Granules: The Ins and Outs of 
Translation." Molecular Cell, 2009  36(6): 932-941. 
Burgess, D. L., D. C. Kohrman, J. Galt, N. W. Plummer, J. M. Jones, B. Spear 
and M. H. Meisler, "Mutation of a new sodium channel gene, Scn8a, in the 
mouse mutant 'motor endplate disease'." Nature genetics, 1995  10(4): 461-465. 
Burwinkel, B. and M. W. Kilimann, "Unequal homologous recombination between 
LINE-1 elements as a mutational mechanism in human genetic disease." J Mol 
Biol, 1998  277(3): 513-517. 
Buzdin, A., S. Ustyugova, E. Gogvadze, T. Vinogradova, Y. Lebedev and E. 
Sverdlov, "A new family of chimeric retrotranscripts formed by a full copy of U6 
small nuclear RNA fused to the 3' terminus of l1." Genomics, 2002  80(4): 402-
406. 
Callahan, K. E., A. B. Hickman, C. E. Jones, R. Ghirlando and A. V. Furano, 
"Polymerization and nucleic acid-binding properties of human L1 ORF1 protein." 
Nucleic Acids Res, 2012  40(2): 813-827. 
Carmell, M. A., A. l. Girard, H. J. G. van de Kant, D. Bourc'his, T. H. Bestor, D. G. 
de Rooij and G. J. Hannon, "MIWI2 Is Essential for Spermatogenesis and 
 50 
Repression of Transposons in the Mouse Male Germline." Developmental Cell, 
2007  12(4): 503-514. 
Castel, S. E. and R. A. Martienssen, "RNA interference in the nucleus: roles for 
small RNAs in transcription, epigenetics and beyond." Nat Rev Genet, 2013  
14(2): 100-112. 
Castro-Diaz, N., G. Ecco, A. Coluccio, A. Kapopoulou, B. Yazdanpanah, M. 
Friedli, J. Duc, S. M. Jang, P. Turelli and D. Trono, "Evolutionally dynamic L1 
regulation in embryonic stem cells." Genes & Development, 2014  28(13): 1397-
1409. 
Chen, H., C. E. Lilley, Q. Yu, D. V. Lee, J. Chou, I. Narvaiza, N. R. Landau and 
M. D. Weitzman, "APOBEC3A is a potent inhibitor of adeno-associated virus and 
retrotransposons." Curr Biol, 2006  16(5): 480-485. 
Chen, J., A. Rattner and J. Nathans, "Effects of L1 retrotransposon insertion on 
transcript processing, localization and accumulation: lessons from the retinal 
degeneration 7 mouse and implications for the genomic ecology of L1 elements." 
Hum Mol Genet, 2006  15(13): 2146-2156. 
Chen, J. M., P. D. Stenson, D. N. Cooper and C. Ferec, "A systematic analysis of 
LINE-1 endonuclease-dependent retrotranspositional events causing human 
genetic disease." Hum Genet, 2005  117(5): 411-427. 
Chiu, Y.-L., H. E. Witkowska, S. C. Hall, M. Santiago, V. B. Soros, C. c. Esnault, 
T. Heidmann and W. C. Greene, "High-molecular-mass APOBEC3G complexes 
restrict Alu retrotransposition." Proceedings of the National Academy of 
Sciences, 2006  103(42): 15588-15593. 
Chiu, Y. L. and W. C. Greene, "The APOBEC3 cytidine deaminases: an innate 
defensive network opposing exogenous retroviruses and endogenous 
retroelements." Annu Rev Immunol, 2008  26: 317-353. 
Chu, W. M., W. M. Liu and C. W. Schmid, "RNA polymerase III promoter and 
terminator elements affect Alu RNA expression." Nucleic Acids Research, 1995  
23(10): 1750-1757. 
Ciaudo, C., F. Jay, I. Okamoto, C. J. Chen, A. Sarazin, N. Servant, E. Barillot, E. 
Heard and O. Voinnet, "RNAi-dependent and independent control of LINE1 
accumulation and mobility in mouse embryonic stem cells." PLoS Genet, 2013  
9(11): e1003791. 
Clements, A. P. and M. F. Singer, "The human LINE-1 reverse transcriptase: 
Effect of deletions outside the common reverse transcriptase domain." Nucleic 
Acids Research, 1998  26(15): 3528-3535. 
Conrad, B., R. N. Weissmahr, J. Boni, R. Arcari, J. Schupbach and B. Mach, "A 
human endogenous retroviral superantigen as candidate autoimmune gene in 
type I diabetes." Cell, 1997  90(2): 303-313. 
Cordaux, R. and M. A. Batzer, "The impact of retrotransposons on human 
genome evolution." Nat Rev Genet, 2009  10(10): 691-703. 
 51 
Cost, G. J., A. Golding, M. S. Schlissel and J. D. Boeke, "Target DNA 
chromatinization modulates nicking by L1 endonuclease." Nucleic Acids Res, 
2001  29(2): 573-577. 
Coufal, N. G., J. L. Garcia-Perez, G. E. Peng, G. W. Yeo, Y. Mu, M. T. Lovci, M. 
Morell, K. S. O'Shea, J. V. Moran and F. H. Gage, "L1 retrotransposition in 
human neural progenitor cells." Nature, 2009  460(7259): 1127-1131. 
Craig, N. L., R. Craigie, M. Gellert and A. M. Lambowitz, "Mobile DNA II. 
American Society for Microbiology Press." Washington, DC, 2002. 
Crow, Y. J. and J. Rehwinkel, "Aicardi-Goutieres syndrome and related 
phenotypes: linking nucleic acid metabolism with autoimmunity." Hum Mol Genet, 
2009  18(R2): R130-136. 
Dai, L., M. S. Taylor, K. A. O'Donnell and J. D. Boeke, "Poly(A) binding protein 
C1 is essential for efficient L1 retrotransposition and affects L1 RNP formation." 
Mol Cell Biol, 2012  32(21): 4323-4336. 
Damert, A., J. Raiz, A. V. Horn, J. Lower, H. Wang, J. Xing, M. A. Batzer, R. 
Lower and G. G. Schumann, "5'-Transducing SVA retrotransposon groups 
spread efficiently throughout the human genome." Genome Res, 2009  19(11): 
1992-2008. 
de Koning, A. P. J., W. Gu, T. A. Castoe, M. A. Batzer and D. D. Pollock, 
"Repetitive elements may comprise over two-thirds of the human genome." PLoS 
genetics, 2011  7(12): e1002384. 
Deininger, P. L., D. J. Jolly, C. M. Rubin, T. Friedmann and C. W. Schmid, "Base 
sequence studies of 300 nucleotide renatured repeated human DNA clones." 
Journal of Molecular Biology, 1981  151(1): 17-33. 
Dewannieux, M., C. Esnault and T. Heidmann, "LINE-mediated retrotransposition 
of marked Alu sequences." Nat Genet, 2003  35(1): 41-48. 
Di Giacomo, M., S. Comazzetto, H. Saini, S. De Fazio, C. Carrieri, M. Morgan, L. 
Vasiliauskaite, V. Benes, A. J. Enright and D. O'Carroll, "Multiple epigenetic 
mechanisms and the piRNA pathway enforce LINE1 silencing during adult 
spermatogenesis." Mol Cell, 2013  50(4): 601-608. 
Dmitriev, S. E., D. E. Andreev, I. M. Terenin, I. A. Olovnikov, V. S. Prassolov, W. 
C. Merrick and I. N. Shatsky, "Efficient translation initiation directed by the 900-
nucleotide-long and GC-rich 5' untranslated region of the human retrotransposon 
LINE-1 mRNA is strictly cap dependent rather than internal ribosome entry site 
mediated." Mol Cell Biol, 2007  27(13): 4685-4697. 
Dombroski, B. A., Q. Feng, S. L. Mathias, D. M. Sassaman, A. F. Scott, H. H. 
Kazazian, Jr. and J. D. Boeke, "An in vivo assay for the reverse transcriptase of 
human retrotransposon L1 in Saccharomyces cerevisiae." Mol Cell Biol, 1994  
14(7): 4485-4492. 
 52 
Dombroski, B. A., S. L. Mathias, E. Nanthakumar, A. F. Scott and H. H. 
Kazazian, Jr., "Isolation of an active human transposable element." Science, 
1991  254(5039): 1805-1808. 
Doolittle, W. F. and C. Sapienza, "Selfish genes, the phenotype paradigm and 
genome evolution." Nature, 1980  284(5757): 601-603. 
Doucet, A. J., A. E. Hulme, E. Sahinovic, D. A. Kulpa, J. B. Moldovan, H. C. 
Kopera, J. N. Athanikar, M. Hasnaoui, A. Bucheton, J. V. Moran and N. Gilbert, 
"Characterization of LINE-1 ribonucleoprotein particles." PLoS Genet, 2010  
6(10): e1001150. 
Eickbush, T. H., "Telomerase and retrotransposons: which came first?" Science, 
1997  277(5328): 911-912. 
Ergun, S., C. Buschmann, J. Heukeshoven, K. Dammann, F. Schnieders, H. 
Lauke, F. Chalajour, N. Kilic, W. H. Stratling and G. G. Schumann, "Cell type-
specific expression of LINE-1 open reading frames 1 and 2 in fetal and adult 
human tissues." J Biol Chem, 2004  279(26): 27753-27763. 
Esnault, C., J. Maestre and T. Heidmann, "Human LINE retrotransposons 
generate processed pseudogenes." Nat Genet, 2000  24(4): 363-367. 
Evrony, G. D., X. Cai, E. Lee, L. B. Hills, P. C. Elhosary, H. S. Lehmann, J. J. 
Parker, K. D. Atabay, E. C. Gilmore, A. Poduri, P. J. Park and C. A. Walsh, 
"Single-neuron sequencing analysis of L1 retrotransposition and somatic 
mutation in the human brain." Cell, 2012  151(3): 483-496. 
Evrony, G. D., E. Lee, B. K. Mehta, Y. Benjamini, R. M. Johnson, X. Cai, L. Yang, 
P. Haseley, H. S. Lehmann, P. J. Park and C. A. Walsh, "Cell lineage analysis in 
human brain using endogenous retroelements." Neuron, 2015  85(1): 49-59. 
Ewing, A. D. and H. H. Kazazian, Jr., "High-throughput sequencing reveals 
extensive variation in human-specific L1 content in individual human genomes." 
Genome Res, 2010  20(9): 1262-1270. 
Fadloun, A., S. p. Le Gras, B. Jost, C. l. Ziegler-Birling, H. Takahashi, E. Gorab, 
P. Carninci and M.-E. Torres-Padilla, "Chromatin signatures and retrotransposon 
profiling in mouse embryos reveal regulation of LINE-1 by RNA." Nat Struct Mol 
Biol, 2013  advance online publication. 
Fanning, T. and M. Singer, "The LINE-1 DNA sequences in four mammalian 
orders predict proteins that conserve homologies to retrovirus proteins." Nucleic 
Acids Res, 1987  15(5): 2251-2260. 
Faulkner, G. J., Y. Kimura, C. O. Daub, S. Wani, C. Plessy, K. M. Irvine, K. 
Schroder, N. Cloonan, A. L. Steptoe, T. Lassmann, K. Waki, N. Hornig, T. 
Arakawa, H. Takahashi, J. Kawai, A. R. Forrest, H. Suzuki, Y. Hayashizaki, D. A. 
Hume, V. Orlando, S. M. Grimmond and P. Carninci, "The regulated 
retrotransposon transcriptome of mammalian cells." Nat Genet, 2009  41(5): 563-
571. 
 53 
Feng, Q., J. V. Moran, H. H. Kazazian, Jr. and J. D. Boeke, "Human L1 
retrotransposon encodes a conserved endonuclease required for 
retrotransposition." Cell, 1996  87(5): 905-916. 
Fitch, D. H., W. J. Bailey, D. A. Tagle, M. Goodman, L. Sieu and J. L. Slightom, 
"Duplication of the gamma-globin gene mediated by L1 long interspersed 
repetitive elements in an early ancestor of simian primates." Proc Natl Acad Sci 
U S A, 1991  88(16): 7396-7400. 
Frost, R. J. A., F. K. Hamra, J. A. Richardson, X. Qi, R. Bassel-Duby and E. N. 
Olson, "MOV10L1 is necessary for protection of spermatocytes against 
retrotransposons by Piwi-interacting RNAs." Proceedings of the National 
Academy of Sciences, 2010  107(26): 11847-11852. 
Galli, U. M., M. Sauter, B. Lecher, S. Maurer, H. Herbst, K. Roemer and N. 
Mueller-Lantzsch, "Human endogenous retrovirus rec interferes with germ cell 
development in mice and may cause carcinoma in situ, the predecessor lesion of 
germ cell tumors." Oncogene, 2005  24(19): 3223-3228. 
Garcia-Perez, J. L., A. J. Doucet, A. Bucheton, J. V. Moran and N. Gilbert, 
"Distinct mechanisms for trans-mediated mobilization of cellular RNAs by the 
LINE-1 reverse transcriptase." Genome Res, 2007  17(5): 602-611. 
Garcia-Perez, J. L., M. C. N. Marchetto, A. R. Muotri, N. G. Coufal, F. H. Gage, 
K. S. O'Shea and J. V. Moran, "LINE-1 retrotransposition in human embryonic 
stem cells." Human Molecular Genetics, 2007  16(13): 1569-1577. 
Garcia-Perez, J. L., M. Morell, J. O. Scheys, D. A. Kulpa, S. Morell, C. C. Carter, 
G. D. Hammer, K. L. Collins, K. S. O/'Shea, P. Menendez and J. V. Moran, 
"Epigenetic silencing of engineered L1 retrotransposition events in human 
embryonic carcinoma cells." Nature, 2010  466(7307): 769-773. 
Georgiou, I., D. Noutsopoulos, E. Dimitriadou, G. Markopoulos, A. Apergi, L. 
Lazaros, T. Vaxevanoglou, K. Pantos, M. Syrrou and T. Tzavaras, 
"Retrotransposon RNA expression and evidence for retrotransposition events in 
human oocytes." Hum Mol Genet, 2009  18(7): 1221-1228. 
Gibbs, R. A., G. M. Weinstock, M. L. Metzker, D. M. Muzny, E. J. Sodergren, S. 
Scherer, G. Scott, D. Steffen, K. C. Worley, P. E. Burch, G. Okwuonu, S. Hines, 
L. Lewis, C. DeRamo, O. Delgado, S. Dugan-Rocha, G. Miner, M. Morgan, A. 
Hawes, R. Gill, Celera, R. A. Holt, M. D. Adams, P. G. Amanatides, H. Baden-
Tillson, M. Barnstead, S. Chin, C. A. Evans, S. Ferriera, C. Fosler, A. Glodek, Z. 
Gu, D. Jennings, C. L. Kraft, T. Nguyen, C. M. Pfannkoch, C. Sitter, G. G. Sutton, 
J. C. Venter, T. Woodage, D. Smith, H. M. Lee, E. Gustafson, P. Cahill, A. Kana, 
L. Doucette-Stamm, K. Weinstock, K. Fechtel, R. B. Weiss, D. M. Dunn, E. D. 
Green, R. W. Blakesley, G. G. Bouffard, P. J. De Jong, K. Osoegawa, B. Zhu, M. 
Marra, J. Schein, I. Bosdet, C. Fjell, S. Jones, M. Krzywinski, C. Mathewson, A. 
Siddiqui, N. Wye, J. McPherson, S. Zhao, C. M. Fraser, J. Shetty, S. Shatsman, 
K. Geer, Y. Chen, S. Abramzon, W. C. Nierman, P. H. Havlak, R. Chen, K. J. 
Durbin, A. Egan, Y. Ren, X. Z. Song, B. Li, Y. Liu, X. Qin, S. Cawley, K. C. 
Worley, A. J. Cooney, L. M. D'Souza, K. Martin, J. Q. Wu, M. L. Gonzalez-Garay, 
 54 
A. R. Jackson, K. J. Kalafus, M. P. McLeod, A. Milosavljevic, D. Virk, A. Volkov, 
D. A. Wheeler, Z. Zhang, J. A. Bailey, E. E. Eichler, E. Tuzun, E. Birney, E. 
Mongin, A. Ureta-Vidal, C. Woodwark, E. Zdobnov, P. Bork, M. Suyama, D. 
Torrents, M. Alexandersson, B. J. Trask, J. M. Young, H. Huang, H. Wang, H. 
Xing, S. Daniels, D. Gietzen, J. Schmidt, K. Stevens, U. Vitt, J. Wingrove, F. 
Camara, M. Mar Alba, J. F. Abril, R. Guigo, A. Smit, I. Dubchak, E. M. Rubin, O. 
Couronne, A. Poliakov, N. Hubner, D. Ganten, C. Goesele, O. Hummel, T. 
Kreitler, Y. A. Lee, J. Monti, H. Schulz, H. Zimdahl, H. Himmelbauer, H. Lehrach, 
H. J. Jacob, S. Bromberg, J. Gullings-Handley, M. I. Jensen-Seaman, A. E. 
Kwitek, J. Lazar, D. Pasko, P. J. Tonellato, S. Twigger, C. P. Ponting, J. M. 
Duarte, S. Rice, L. Goodstadt, S. A. Beatson, R. D. Emes, E. E. Winter, C. 
Webber, P. Brandt, G. Nyakatura, M. Adetobi, F. Chiaromonte, L. Elnitski, P. 
Eswara, R. C. Hardison, M. Hou, D. Kolbe, K. Makova, W. Miller, A. Nekrutenko, 
C. Riemer, S. Schwartz, J. Taylor, S. Yang, Y. Zhang, K. Lindpaintner, T. D. 
Andrews, M. Caccamo, M. Clamp, L. Clarke, V. Curwen, R. Durbin, E. Eyras, S. 
M. Searle, G. M. Cooper, S. Batzoglou, M. Brudno, A. Sidow, E. A. Stone, J. C. 
Venter, B. A. Payseur, G. Bourque, C. Lopez-Otin, X. S. Puente, K. Chakrabarti, 
S. Chatterji, C. Dewey, L. Pachter, N. Bray, V. B. Yap, A. Caspi, G. Tesler, P. A. 
Pevzner, D. Haussler, K. M. Roskin, R. Baertsch, H. Clawson, T. S. Furey, A. S. 
Hinrichs, D. Karolchik, W. J. Kent, K. R. Rosenbloom, H. Trumbower, M. 
Weirauch, D. N. Cooper, P. D. Stenson, B. Ma, M. Brent, M. Arumugam, D. 
Shteynberg, R. R. Copley, M. S. Taylor, H. Riethman, U. Mudunuri, J. Peterson, 
M. Guyer, A. Felsenfeld, S. Old, S. Mockrin and F. Collins, "Genome sequence of 
the Brown Norway rat yields insights into mammalian evolution." Nature, 2004  
428(6982): 493-521. 
Gilbert, N., S. Lutz, T. A. Morrish and J. V. Moran, "Multiple fates of l1 
retrotransposition intermediates in cultured human cells." Mol Cell Biol, 2005  
25(17): 7780-7795. 
Gilbert, N., S. Lutz-Prigge and J. V. Moran, "Genomic deletions created upon 
LINE-1 retrotransposition." Cell, 2002  110(3): 315-325. 
Gilbert, W., "Why genes in pieces?" Nature, 1978  271(5645): 501-501. 
Girard, A., R. Sachidanandam, G. J. Hannon and M. A. Carmell, "A germline-
specific class of small RNAs binds mammalian Piwi proteins." Nature, 2006  
442(7099): 199-202. 
Goff, S. P., "Retrovirus restriction factors." Mol Cell, 2004  16(6): 849-859. 
Goll, M. G. and T. H. Bestor, "Eukaryotic cytosine methyltransferases." Annual 
Review of Biochemistry, 2005  74: 481-514. 
Goodier, J. L., L. E. Cheung and H. H. Kazazian, Jr., "MOV10 RNA helicase is a 
potent inhibitor of retrotransposition in cells." PLoS Genet, 2012  8(10): 
e1002941. 
Goodier, J. L., L. E. Cheung and H. H. Kazazian, Jr., "Mapping the LINE1 ORF1 
protein interactome reveals associated inhibitors of human retrotransposition." 
Nucleic Acids Res, 2013. 
 55 
Goodier, J. L., P. K. Mandal, L. Zhang and H. H. Kazazian, Jr., "Discrete 
subcellular partitioning of human retrotransposon RNAs despite a common 
mechanism of genome insertion." Hum Mol Genet, 2010  19(9): 1712-1725. 
Goodier, J. L., E. M. Ostertag, K. A. Engleka, M. C. Seleme and H. H. Kazazian, 
Jr., "A potential role for the nucleolus in L1 retrotransposition." Hum Mol Genet, 
2004  13(10): 1041-1048. 
Goodier, J. L., E. M. Ostertag and H. H. Kazazian, Jr., "Transduction of 3'-
flanking sequences is common in L1 retrotransposition." Hum Mol Genet, 2000  
9(4): 653-657. 
Goodier, J. L., L. Zhang, M. R. Vetter and H. H. Kazazian, Jr., "LINE-1 ORF1 
protein localizes in stress granules with other RNA-binding proteins, including 
components of RNA interference RNA-induced silencing complex." Mol Cell Biol, 
2007  27(18): 6469-6483. 
Gregersen, L. H., M. Schueler, M. Munschauer, G. Mastrobuoni, W. Chen, S. 
Kempa, C. Dieterich and M. Landthaler, "MOV10 Is a 5' to 3' RNA helicase 
contributing to UPF1 mRNA target degradation by translocation along 3' UTRs." 
Mol Cell, 2014  54(4): 573-585. 
Grimaldi, G., J. Skowronski and M. F. Singer, "Defining the beginning and end of 
KpnI family segments." EMBO J, 1984  3(8): 1753-1759. 
Gunawardane, L. S., K. Saito, K. M. Nishida, K. Miyoshi, Y. Kawamura, T. 
Nagami, H. Siomi and M. C. Siomi, "A Slicer-Mediated Mechanism for Repeat-
Associated siRNA 5' End Formation in Drosophila." Science, 2007  315(5818): 
1587-1590. 
Han, J. S., S. T. Szak and J. D. Boeke, "Transcriptional disruption by the L1 
retrotransposon and implications for mammalian transcriptomes." Nature, 2004  
429(6989): 268-274. 
Han, K., J. Lee, T. J. Meyer, P. Remedios, L. Goodwin and M. A. Batzer, "L1 
recombination-associated deletions generate human genomic variation." Proc 
Natl Acad Sci U S A, 2008  105(49): 19366-19371. 
Han, K., S. K. Sen, J. Wang, P. A. Callinan, J. Lee, R. Cordaux, P. Liang and M. 
A. Batzer, "Genomic rearrangements by LINE-1 insertion-mediated deletion in 
the human and chimpanzee lineages." Nucleic Acids Res, 2005  33(13): 4040-
4052. 
Hancks, D. C., A. D. Ewing, J. E. Chen, K. Tokunaga and H. H. Kazazian, "Exon-
trapping mediated by the human retrotransposon SVA." Genome Research, 2009  
19(11): 1983-1991. 
Hancks, D. C., J. L. Goodier, P. K. Mandal, L. E. Cheung and H. H. Kazazian, 
"Retrotransposition of marked SVA elements by human L1s in cultured cells." 
Human Molecular Genetics, 2011  20(17): 3386-3400. 
Hancks, D. C. and H. H. Kazazian, Jr., "Active human retrotransposons: variation 
and disease." Curr Opin Genet Dev, 2012  22(3): 191-203. 
 56 
Hata, K. and Y. Sakaki, "Identification of critical CpG sites for repression of L1 
transcription by DNA methylation." Gene, 1997  189(2): 227-234. 
Hattori, M., S. Kuhara, O. Takenaka and Y. Sakaki, "L1 family of repetitive DNA 
sequences in primates may be derived from a sequence encoding a reverse 
transcriptase-related protein." Nature, 1986  321(6070): 625-628. 
Helman, E., M. S. Lawrence, C. Stewart, C. Sougnez, G. Getz and M. Meyerson, 
"Somatic retrotransposition in human cancer revealed by whole-genome and 
exome sequencing." Genome Res, 2014  24(7): 1053-1063. 
Higashimoto, K., T. Maeda, J. Okada, Y. Ohtsuka, K. Sasaki, A. Hirose, M. 
Nomiyama, T. Takayanagi, R. Fukuzawa, H. Yatsuki, K. Koide, K. Nishioka, K. 
Joh, Y. Watanabe, K.-i. Yoshiura and H. Soejima, "Homozygous deletion of 
DIS3L2 exon 9 due to non-allelic homologous recombination between LINE-1s in 
a Japanese patient with Perlman syndrome." Eur J Hum Genet, 2013  21(11): 
1316-1319. 
Hohjoh, H. and M. F. Singer, "Cytoplasmic ribonucleoprotein complexes 
containing human LINE-1 protein and RNA." EMBO J, 1996  15(3): 630-639. 
Hohjoh, H. and M. F. Singer, "Ribonuclease and high salt sensitivity of the 
ribonucleoprotein complex formed by the human LINE-1 retrotransposon." J Mol 
Biol, 1997  271(1): 7-12. 
Hohjoh, H. and M. F. Singer, "Sequence-specific single-strand RNA binding 
protein encoded by the human LINE-1 retrotransposon." EMBO J, 1997  16(19): 
6034-6043. 
Holmes, S. E., B. A. Dombroski, C. M. Krebs, C. D. Boehm and H. H. Kazazian, 
Jr., "A new retrotransposable human L1 element from the LRE2 locus on 
chromosome 1q produces a chimaeric insertion." Nat Genet, 1994  7(2): 143-
148. 
Holmes, S. E., M. F. Singer and G. D. Swergold, "Studies on p40, the leucine 
zipper motif-containing protein encoded by the first open reading frame of an 
active human LINE-1 transposable element." J Biol Chem, 1992  267(28): 19765-
19768. 
Horn, A. V., S. Klawitter, U. Held, A. Berger, A. A. Jaguva Vasudevan, A. Bock, 
H. Hofmann, K. M. Hanschmann, J. H. Trosemeier, E. Flory, R. A. Jabulowsky, J. 
S. Han, J. Lower, R. Lower, C. Munk and G. G. Schumann, "Human LINE-1 
restriction by APOBEC3C is deaminase independent and mediated by an ORF1p 
interaction that affects LINE reverse transcriptase activity." Nucleic Acids Res, 
2013. 
Howell, R. and K. Usdin, "The ability to form intrastrand tetraplexes is an 
evolutionarily conserved feature of the 3' end of L1 retrotransposons." Mol Biol 
Evol, 1997  14(2): 144-155. 
Hrecka, K., C. Hao, M. Gierszewska, S. K. Swanson, M. Kesik-Brodacka, S. 
Srivastava, L. Florens, M. P. Washburn and J. Skowronski, "Vpx relieves 
 57 
inhibition of HIV-1 infection of macrophages mediated by the SAMHD1 protein." 
Nature, 2011  474(7353): 658-661. 
Iskow, R. C., M. T. McCabe, R. E. Mills, S. Torene, W. S. Pittard, A. F. Neuwald, 
E. G. Van Meir, P. M. Vertino and S. E. Devine, "Natural mutagenesis of human 
genomes by endogenous retrotransposons." Cell, 2010  141(7): 1253-1261. 
Jacobs, F. M., D. Greenberg, N. Nguyen, M. Haeussler, A. D. Ewing, S. 
Katzman, B. Paten, S. R. Salama and D. Haussler, "An evolutionary arms race 
between KRAB zinc-finger genes ZNF91/93 and SVA/L1 retrotransposons." 
Nature, 2014  516(7530): 242-245. 
Janousek, V., R. C. Karn and C. M. Laukaitis, "The role of retrotransposons in 
gene family expansions: insights from the mouse Abp gene family." BMC Evol 
Biol, 2013  13: 107. 
Januszyk, K., P. W. Li, V. Villareal, D. Branciforte, H. Wu, Y. Xie, J. Feigon, J. A. 
Loo, S. L. Martin and R. T. Clubb, "Identification and solution structure of a highly 
conserved C-terminal domain within ORF1p required for retrotransposition of 
long interspersed nuclear element-1." J Biol Chem, 2007  282(34): 24893-24904. 
Kajikawa, M., T. Sugano, R. Sakurai and N. Okada, "Low dependency of 
retrotransposition on the ORF1 protein of the zebrafish LINE, ZfL2-1." Gene, 
2012  499(1): 41-47. 
Kano, H., I. Godoy, C. Courtney, M. R. Vetter, G. L. Gerton, E. M. Ostertag and 
H. H. Kazazian, Jr., "L1 retrotransposition occurs mainly in embryogenesis and 
creates somatic mosaicism." Genes Dev, 2009  23(11): 1303-1312. 
Kapitonov, V. V. and J. Jurka, "RAG1 core and V(D)J recombination signal 
sequences were derived from Transib transposons." PLoS Biol, 2005  3(6): e181. 
Kavanagh, D., D. Spitzer, P. H. Kothari, A. Shaikh, M. K. Liszewski, A. Richards 
and J. P. Atkinson, "New roles for the major human 3'-5' exonuclease TREX1 in 
human disease." Cell Cycle, 2008  7(12): 1718-1725. 
Kazazian, H. H., Jr., C. Wong, H. Youssoufian, A. F. Scott, D. G. Phillips and S. 
E. Antonarakis, "Haemophilia A resulting from de novo insertion of L1 sequences 
represents a novel mechanism for mutation in man." Nature, 1988  332(6160): 
164-166. 
Khazina, E., V. Truffault, R. Buttner, S. Schmidt, M. Coles and O. Weichenrieder, 
"Trimeric structure and flexibility of the L1ORF1 protein in human L1 
retrotransposition." Nat Struct Mol Biol, 2011  18(9): 1006-1014. 
Khazina, E. and O. Weichenrieder, "Non-LTR retrotransposons encode 
noncanonical RRM domains in their first open reading frame." Proceedings of the 
National Academy of Sciences, 2009  106(3): 731-736. 
Kohrman, D. C., J. B. Harris and M. H. Meisler, "Mutation detection in the med 
and medJ alleles of the sodium channel Scn8a. Unusual splicing due to a minor 
class AT-AC intron." The Journal of biological chemistry, 1996  271(29): 17576-
17581. 
 58 
Kulpa, D. A. and J. V. Moran, "Ribonucleoprotein particle formation is necessary 
but not sufficient for LINE-1 retrotransposition." Hum Mol Genet, 2005  14(21): 
3237-3248. 
Kulpa, D. A. and J. V. Moran, "Cis-preferential LINE-1 reverse transcriptase 
activity in ribonucleoprotein particles." Nat Struct Mol Biol, 2006  13(7): 655-660. 
Kuramochi-Miyagawa, S., T. Watanabe, K. Gotoh, Y. Totoki, A. Toyoda, M. 
Ikawa, N. Asada, K. Kojima, Y. Yamaguchi, T. W. Ijiri, K. Hata, E. Li, Y. Matsuda, 
T. Kimura, M. Okabe, Y. Sakaki, H. Sasaki and T. Nakano, "DNA methylation of 
retrotransposon genes is regulated by Piwi family members MILI and MIWI2 in 
murine fetal testes." Genes Dev, 2008  22(7): 908-917. 
Laguette, N., B. Sobhian, N. Casartelli, M. Ringeard, C. Chable-Bessia, E. 
Segeral, A. Yatim, S. Emiliani, O. Schwartz and M. Benkirane, "SAMHD1 is the 
dendritic- and myeloid-cell-specific HIV-1 restriction factor counteracted by Vpx." 
Nature, 2011  474(7353): 654-657. 
Lander, E. S., L. M. Linton, B. Birren, C. Nusbaum, M. C. Zody, J. Baldwin, K. 
Devon, K. Dewar, M. Doyle, W. FitzHugh, R. Funke, D. Gage, K. Harris, A. 
Heaford, J. Howland, L. Kann, J. Lehoczky, R. LeVine, P. McEwan, K. 
McKernan, J. Meldrim, J. P. Mesirov, C. Miranda, W. Morris, J. Naylor, C. 
Raymond, M. Rosetti, R. Santos, A. Sheridan, C. Sougnez, N. Stange-Thomann, 
N. Stojanovic, A. Subramanian, D. Wyman, J. Rogers, J. Sulston, R. Ainscough, 
S. Beck, D. Bentley, J. Burton, C. Clee, N. Carter, A. Coulson, R. Deadman, P. 
Deloukas, A. Dunham, I. Dunham, R. Durbin, L. French, D. Grafham, S. Gregory, 
T. Hubbard, S. Humphray, A. Hunt, M. Jones, C. Lloyd, A. McMurray, L. 
Matthews, S. Mercer, S. Milne, J. C. Mullikin, A. Mungall, R. Plumb, M. Ross, R. 
Shownkeen, S. Sims, R. H. Waterston, R. K. Wilson, L. W. Hillier, J. D. 
McPherson, M. A. Marra, E. R. Mardis, L. A. Fulton, A. T. Chinwalla, K. H. Pepin, 
W. R. Gish, S. L. Chissoe, M. C. Wendl, K. D. Delehaunty, T. L. Miner, A. 
Delehaunty, J. B. Kramer, L. L. Cook, R. S. Fulton, D. L. Johnson, P. J. Minx, S. 
W. Clifton, T. Hawkins, E. Branscomb, P. Predki, P. Richardson, S. Wenning, T. 
Slezak, N. Doggett, J. F. Cheng, A. Olsen, S. Lucas, C. Elkin, E. Uberbacher, M. 
Frazier, R. A. Gibbs, D. M. Muzny, S. E. Scherer, J. B. Bouck, E. J. Sodergren, 
K. C. Worley, C. M. Rives, J. H. Gorrell, M. L. Metzker, S. L. Naylor, R. S. 
Kucherlapati, D. L. Nelson, G. M. Weinstock, Y. Sakaki, A. Fujiyama, M. Hattori, 
T. Yada, A. Toyoda, T. Itoh, C. Kawagoe, H. Watanabe, Y. Totoki, T. Taylor, J. 
Weissenbach, R. Heilig, W. Saurin, F. Artiguenave, P. Brottier, T. Bruls, E. 
Pelletier, C. Robert, P. Wincker, D. R. Smith, L. Doucette-Stamm, M. Rubenfield, 
K. Weinstock, H. M. Lee, J. Dubois, A. Rosenthal, M. Platzer, G. Nyakatura, S. 
Taudien, A. Rump, H. Yang, J. Yu, J. Wang, G. Huang, J. Gu, L. Hood, L. 
Rowen, A. Madan, S. Qin, R. W. Davis, N. A. Federspiel, A. P. Abola, M. J. 
Proctor, R. M. Myers, J. Schmutz, M. Dickson, J. Grimwood, D. R. Cox, M. V. 
Olson, R. Kaul, C. Raymond, N. Shimizu, K. Kawasaki, S. Minoshima, G. A. 
Evans, M. Athanasiou, R. Schultz, B. A. Roe, F. Chen, H. Pan, J. Ramser, H. 
Lehrach, R. Reinhardt, W. R. McCombie, M. de la Bastide, N. Dedhia, H. 
Blocker, K. Hornischer, G. Nordsiek, R. Agarwala, L. Aravind, J. A. Bailey, A. 
Bateman, S. Batzoglou, E. Birney, P. Bork, D. G. Brown, C. B. Burge, L. Cerutti, 
 59 
H. C. Chen, D. Church, M. Clamp, R. R. Copley, T. Doerks, S. R. Eddy, E. E. 
Eichler, T. S. Furey, J. Galagan, J. G. Gilbert, C. Harmon, Y. Hayashizaki, D. 
Haussler, H. Hermjakob, K. Hokamp, W. Jang, L. S. Johnson, T. A. Jones, S. 
Kasif, A. Kaspryzk, S. Kennedy, W. J. Kent, P. Kitts, E. V. Koonin, I. Korf, D. 
Kulp, D. Lancet, T. M. Lowe, A. McLysaght, T. Mikkelsen, J. V. Moran, N. Mulder, 
V. J. Pollara, C. P. Ponting, G. Schuler, J. Schultz, G. Slater, A. F. Smit, E. 
Stupka, J. Szustakowski, D. Thierry-Mieg, J. Thierry-Mieg, L. Wagner, J. Wallis, 
R. Wheeler, A. Williams, Y. I. Wolf, K. H. Wolfe, S. P. Yang, R. F. Yeh, F. Collins, 
M. S. Guyer, J. Peterson, A. Felsenfeld, K. A. Wetterstrand, A. Patrinos, M. J. 
Morgan, P. de Jong, J. J. Catanese, K. Osoegawa, H. Shizuya, S. Choi and Y. J. 
Chen, "Initial sequencing and analysis of the human genome." Nature, 2001  
409(6822): 860-921. 
Lawrence, C. J., Q. Dong, M. L. Polacco, T. E. Seigfried and V. Brendel, 
"MaizeGDB, the community database for maize genetics and genomics." Nucleic 
acids research, 2004  32(Database issue): D393-397. 
Lee, E., R. Iskow, L. Yang, O. Gokcumen, P. Haseley, L. J. Luquette, 3rd, J. G. 
Lohr, C. C. Harris, L. Ding, R. K. Wilson, D. A. Wheeler, R. A. Gibbs, R. 
Kucherlapati, C. Lee, P. V. Kharchenko and P. J. Park, "Landscape of somatic 
retrotransposition in human cancers." Science, 2012  337(6097): 967-971. 
Lee, J., K. Han, T. J. Meyer, H.-S. Kim and M. A. Batzer, "Chromosomal 
Inversions between Human and Chimpanzee Lineages Caused by 
Retrotransposons." PLoS One, 2008  3(12): e4047. 
Leibold, D. M., G. D. Swergold, M. F. Singer, R. E. Thayer, B. A. Dombroski and 
T. G. Fanning, "Translation of LINE-1 DNA elements in vitro and in human cells." 
Proc Natl Acad Sci U S A, 1990  87(18): 6990-6994. 
Li, P. W., J. Li, S. L. Timmerman, L. A. Krushel and S. L. Martin, "The dicistronic 
RNA from the mouse LINE-1 retrotransposon contains an internal ribosome entry 
site upstream of each ORF: implications for retrotransposition." Nucleic Acids 
Res, 2006  34(3): 853-864. 
Li, W., L. Prazak, N. Chatterjee, S. Gruninger, L. Krug, D. Theodorou and J. 
Dubnau, "Activation of transposable elements during aging and neuronal decline 
in Drosophila." Nat Neurosci, 2013  16(5): 529-531. 
Li, X., J. Zhang, R. Jia, V. Cheng, X. Xu, W. Qiao, F. Guo, C. Liang and S. Cen, 
"The MOV10 helicase inhibits LINE-1 mobility." J Biol Chem, 2013  288(29): 
21148-21160. 
Lin, L., J. Faraco, R. Li, H. Kadotani, W. Rogers, X. Lin, X. Qiu, P. J. de Jong, S. 
Nishino and E. Mignot, "The sleep disorder canine narcolepsy is caused by a 
mutation in the hypocretin (orexin) receptor 2 gene." Cell, 1999  98(3): 365-376. 
Long, M., E. Betran, K. Thornton and W. Wang, "The origin of new genes: 
glimpses from the young and old." Nat Rev Genet, 2003  4(11): 865-875. 
 60 
Luan, D. D., M. H. Korman, J. L. Jakubczak and T. H. Eickbush, "Reverse 
transcription of R2Bm RNA is primed by a nick at the chromosomal target site: a 
mechanism for non-LTR retrotransposition." Cell, 1993  72(4): 595-605. 
Macfarlane, C. M., P. Collier, R. Rahbari, C. R. Beck, J. F. Wagstaff, S. Igoe, J. 
V. Moran and R. M. Badge, "Transduction-Specific ATLAS Reveals a Cohort of 
Highly Active L1 Retrotransposons in Human Populations." Human Mutation, 
2013  34(7): 974-985. 
Macia, A., M. Munoz-Lopez, J. L. Cortes, R. K. Hastings, S. Morell, G. Lucena-
Aguilar, J. A. Marchal, R. M. Badge and J. L. Garcia-Perez, "Epigenetic control of 
retrotransposon expression in human embryonic stem cells." Mol Cell Biol, 2011  
31(2): 300-316. 
Malik, H. S., W. D. Burke and T. H. Eickbush, "The age and evolution of non-LTR 
retrotransposable elements." Mol Biol Evol, 1999  16(6): 793-805. 
Malki, S., G. W. van der Heijden, K. A. O'Donnell, S. L. Martin and A. Bortvin, "A 
role for retrotransposon LINE-1 in fetal oocyte attrition in mice." Developmental 
cell, 2014  29(5): 521-533. 
Marques, A. C., I. Dupanloup, N. Vinckenbosch, A. Reymond and H. 
Kaessmann, "Emergence of Young Human Genes after a Burst of Retroposition 
in Primates." PLoS Biol, 2005  3(11): e357. 
Martienssen, R., "Transposons, DNA methylation and gene control." Trends in 
Genetics, 1998  14(7): 263-264. 
Martin, S. L., "Ribonucleoprotein particles with LINE-1 RNA in mouse embryonal 
carcinoma cells." Mol Cell Biol, 1991  11(9): 4804-4807. 
Martin, S. L. and D. Branciforte, "Synchronous expression of LINE-1 RNA and 
protein in mouse embryonal carcinoma cells." Mol Cell Biol, 1993  13(9): 5383-
5392. 
Martin, S. L., D. Branciforte, D. Keller and D. L. Bain, "Trimeric structure for an 
essential protein in L1 retrotransposition." Proc Natl Acad Sci U S A, 2003  
100(24): 13815-13820. 
Martin, S. L., D. Bushman, F. Wang, P. W. Li, A. Walker, J. Cummiskey, D. 
Branciforte and M. C. Williams, "A single amino acid substitution in ORF1 
dramatically decreases L1 retrotransposition and provides insight into nucleic 
acid chaperone activity." Nucleic Acids Res, 2008  36(18): 5845-5854. 
Martin, S. L. and F. D. Bushman, "Nucleic acid chaperone activity of the ORF1 
protein from the mouse LINE-1 retrotransposon." Mol Cell Biol, 2001  21(2): 467-
475. 
Martin, S. L., M. Cruceanu, D. Branciforte, P. Wai-Lun Li, S. C. Kwok, R. S. 
Hodges and M. C. Williams, "LINE-1 retrotransposition requires the nucleic acid 
chaperone activity of the ORF1 protein." J Mol Biol, 2005  348(3): 549-561. 
 61 
Martin, S. L., J. Li and J. A. Weisz, "Deletion analysis defines distinct functional 
domains for protein-protein and nucleic acid interactions in the ORF1 protein of 
mouse LINE-1." J Mol Biol, 2000  304(1): 11-20. 
Mathias, S. L., A. F. Scott, H. H. Kazazian, Jr., J. D. Boeke and A. Gabriel, 
"Reverse transcriptase encoded by a human transposable element." Science, 
1991  254(5039): 1808-1810. 
McCarrey, J. R., "Molecular evolution of the human Pgk-2 retroposon." Nucleic 
Acids Res, 1990  18(4): 949-955. 
McCarrey, J. R. and K. Thomas, "Human testis-specific PGK gene lacks introns 
and possesses characteristics of a processed gene." Nature, 1987  326(6112): 
501-505. 
McClintock, B., "The origin and behavior of mutable loci in maize." Proc Natl 
Acad Sci U S A, 1950  36(6): 344-355. 
McClintock, B., "Chromosome organization and genic expression." Cold Spring 
Harb Symp Quant Biol, 1951  16: 13-47. 
Mcclintock, B., "Some Parallels between Gene Control Systems in Maize and in 
Bacteria." American Naturalist, 1961  95(884): 265-277. 
McClintock, B., "The Significance of Responses of the Genome to Challenge." 
Science, 1984  226(4676): 792-801. 
McMillan, J. P. and M. F. Singer, "Translation of the human LINE-1 element, 
L1Hs." Proc Natl Acad Sci U S A, 1993  90(24): 11533-11537. 
Medstrand, P. and D. L. Mager, "Human-Specific Integrations of the HERV-K 
Endogenous Retrovirus Family." Journal of Virology, 1998  72(12): 9782-9787. 
Miki, Y., T. Katagiri, F. Kasumi, T. Yoshimoto and Y. Nakamura, "Mutation 
analysis in the BRCA2 gene in primary breast cancers." Nat Genet, 1996  13(2): 
245-247. 
Miki, Y., I. Nishisho, A. Horii, Y. Miyoshi, J. Utsunomiya, K. W. Kinzler, B. 
Vogelstein and Y. Nakamura, "Disruption of the APC Gene by a Retrotransposal 
Insertion of L1 Sequence in a Colon Cancer." Cancer Research, 1992  52(3): 
643-645. 
Mine, M., J. M. Chen, M. Brivet, I. Desguerre, D. Marchant, P. de Lonlay, A. 
Bernard, C. Ferec, M. Abitbol, D. Ricquier and C. Marsac, "A large genomic 
deletion in the PDHX gene caused by the retrotranspositional insertion of a full-
length LINE-1 element." Hum Mutat, 2007  28(2): 137-142. 
Mitra, R., X. Li, A. l. Kapusta, D. Mayhew, R. D. Mitra, C. d. Feschotte and N. L. 
Craig, "Functional characterization of piggyBat from the bat Myotis lucifugus 
unveils an active mammalian DNA transposon." Proceedings of the National 
Academy of Sciences, 2013  110(1): 234-239. 
Moran, J. V., R. J. DeBerardinis and H. H. Kazazian, Jr., "Exon shuffling by L1 
retrotransposition." Science, 1999  283(5407): 1530-1534. 
 62 
Moran, J. V., S. E. Holmes, T. P. Naas, R. J. DeBerardinis, J. D. Boeke and H. H. 
Kazazian, Jr., "High frequency retrotransposition in cultured mammalian cells." 
Cell, 1996  87(5): 917-927. 
Morse, B., P. G. Rotherg, V. J. South, J. M. Spandorfer and S. M. Astrin, 
"Insertional mutagenesis of the myc locus by a LINE-1 sequence in a human 
breast carcinoma." Nature, 1988  333(6168): 87-90. 
Muckenfuss, H., M. Hamdorf, U. Held, M. Perkovic, J. Lower, K. Cichutek, E. 
Flory, G. G. Schumann and C. Munk, "APOBEC3 proteins inhibit human LINE-1 
retrotransposition." J Biol Chem, 2006  281(31): 22161-22172. 
Mulhardt, C., M. Fischer, P. Gass, D. Simon-Chazottes, J.-L. Guenet, J. Kuhse, 
H. Betz and C.-M. Becker, "The spastic mouse: Aberrant splicing of glycine 
receptor Œ≤ subunit mRNA caused by intronic insertion of Ll element." Neuron, 
1994  13(4): 1003-1015. 
Muotri, A. R., V. T. Chu, M. C. Marchetto, W. Deng, J. V. Moran and F. H. Gage, 
"Somatic mosaicism in neuronal precursor cells mediated by L1 
retrotransposition." Nature, 2005  435(7044): 903-910. 
Muotri, A. R., M. C. Marchetto, N. G. Coufal, R. Oefner, G. Yeo, K. Nakashima 
and F. H. Gage, "L1 retrotransposition in neurons is modulated by MeCP2." 
Nature, 2010  468(7322): 443-446. 
Nakamura, M., N. Okada and M. Kajikawa, "Self-interaction, nucleic acid binding, 
and nucleic acid chaperone activities are unexpectedly retained in the unique 
ORF1p of zebrafish LINE." Mol Cell Biol, 2012  32(2): 458-469. 
Nisole, S. b., C. Lynch, J. P. Stoye and M. W. Yap, "A Trim5-cyclophilin A fusion 
protein found in owl monkey kidney cells can restrict HIV-1." Proceedings of the 
National Academy of Sciences of the United States of America, 2004  101(36): 
13324-13328. 
O'Donnell, K. A., W. An, C. T. Schrum, S. J. Wheelan and J. D. Boeke, 
"Controlled insertional mutagenesis using a LINE-1 (ORFeus) gene-trap mouse 
model." Proc Natl Acad Sci U S A, 2013  110(29): E2706-2713. 
Ohno, S., "So much "junk" DNA in our genome." Brookhaven Symp Biol, 1972  
23: 366-370. 
Orgel, L. E. and F. H. C. Crick, "Selfish DNA: the ultimate parasite." Nature, 1980  
284(5757): 604-607. 
Ostertag, E. M., R. J. DeBerardinis, J. L. Goodier, Y. Zhang, N. Yang, G. L. 
Gerton and H. H. Kazazian, Jr., "A mouse model of human L1 retrotransposition." 
Nat Genet, 2002  32(4): 655-660. 
Ostertag, E. M., J. L. Goodier, Y. Zhang and H. H. Kazazian, Jr., "SVA elements 
are nonautonomous retrotransposons that cause disease in humans." Am J Hum 
Genet, 2003  73(6): 1444-1451. 
 63 
Pace, J. K. and C. d. Feschotte, "The evolutionary history of human DNA 
transposons: Evidence for intense activity in the primate lineage." Genome 
Research, 2007  17(4): 422-432. 
Parker, H. G., B. M. VonHoldt, P. Quignon, E. H. Margulies, S. Shao, D. S. 
Mosher, T. C. Spady, A. Elkahloun, M. Cargill, P. G. Jones, C. L. Maslen, G. M. 
Acland, N. B. Sutter, K. Kuroki, C. D. Bustamante, R. K. Wayne and E. A. 
Ostrander, "An Expressed Fgf4 Retrogene Is Associated with Breed-Defining 
Chondrodysplasia in Domestic Dogs." Science, 2009  325(5943): 995-998. 
Pei, B., C. Sisu, A. Frankish, C. d. Howald, L. Habegger, X. J. Mu, R. Harte, S. 
Balasubramanian, A. Tanzer, M. Diekhans, A. Reymond, T. J. Hubbard, J. 
Harrow and M. B. Gerstein, "The GENCODE pseudogene resource." Genome 
Biology, 2012  13(9): R51-R51. 
Perepelitsa-Belancio, V. and P. Deininger, "RNA truncation by premature 
polyadenylation attenuates human mobile element activity." Nat Genet, 2003  
35(4): 363-366. 
Perrat, P. N., S. DasGupta, J. Wang, W. Theurkauf, Z. Weng, M. Rosbash and S. 
Waddell, "Transposition-driven genomic heterogeneity in the Drosophila brain." 
Science, 2013  340(6128): 91-95. 
Perreault, J., J. F. Noel, F. Briere, B. Cousineau, J. F. Lucier, J. P. Perreault and 
G. Boire, "Retropseudogenes derived from the human Ro/SS-A autoantigen-
associated hY RNAs." Nucleic Acids Res, 2005  33(6): 2032-2041. 
Pezic, D., S. A. Manakov, R. Sachidanandam and A. A. Aravin, "piRNA pathway 
targets active LINE1 elements to establish the repressive H3K9me3 mark in 
germ cells." Genes Dev, 2014  28(13): 1410-1428. 
Pickeral, O. K., W. Maka≈Çowski, M. S. Boguski and J. D. Boeke, "Frequent 
Human Genomic DNA Transduction Driven by LINE-1 Retrotransposition." 
Genome Research, 2000  10(4): 411-415. 
Pink, R. C., K. Wicks, D. P. Caley, E. K. Punch, L. Jacobs and D. R. Carter, 
"Pseudogenes: pseudo-functional or key regulators in health and disease?" RNA, 
2011  17(5): 792-798. 
Piskareva, O., S. Denmukhametova and V. Schmatchenko, "Functional reverse 
transcriptase encoded by the human LINE-1 from baculovirus-infected insect 
cells." Protein Expr Purif, 2003  28(1): 125-130. 
Piskareva, O., C. Ernst, N. Higgins and V. Schmatchenko, "The carboxy-terminal 
segment of the human LINE-1 ORF2 protein is involved in RNA binding." FEBS 
Open Bio, 2013  3(0): 433-437. 
Piskareva, O. and V. Schmatchenko, "DNA polymerization by the reverse 
transcriptase of the human L1 retrotransposon on its own template in vitro." 
FEBS Letters, 2006  580(2): 661-668. 
 64 
Prak, E. T., A. W. Dodson, E. A. Farkash and H. H. Kazazian, Jr., "Tracking an 
embryonic L1 retrotransposition event." Proc Natl Acad Sci U S A, 2003  100(4): 
1832-1837. 
Puszyk, W., T. Down, D. Grimwade, C. Chomienne, R. J. Oakey, E. Solomon 
and F. Guidez, "The epigenetic regulator PLZF represses L1 retrotransposition in 
germ and progenitor cells." EMBO J, 2013  32(13): 1941-1952. 
Raiz, J., A. Damert, S. Chira, U. Held, S. Klawitter, M. Hamdorf, J. Lower, W. H. 
Stratling, R. Lower and G. G. Schumann, "The non-autonomous retrotransposon 
SVA is trans-mobilized by the human LINE-1 protein machinery." Nucleic Acids 
Res, 2012  40(4): 1666-1683. 
Ray, D. A., H. J. T. Pagan, M. L. Thompson and R. D. Stevens, "Bats with hATs: 
Evidence for Recent DNA Transposon Activity in Genus Myotis." Molecular 
Biology and Evolution, 2007  24(3): 632-639. 
Reineke, L. C. and R. E. Lloyd, "Diversion of stress granules and P-bodies during 
viral infection." Virology, 2013  436(2): 255-267. 
Repanas, K., N. Zingler, L. E. Layer, G. G. Schumann, A. Perrakis and O. 
Weichenrieder, "Determinants for DNA target structure selectivity of the human 
LINE-1 retrotransposon endonuclease." Nucleic Acids Res, 2007  35(14): 4914-
4926. 
Richardson, S. R., A. J. Doucet, H. C. Kopera, J. B. Moldovan, J. L. Garcia-Perez 
and J. V. Moran, "The Influence of LINE-1 and SINE Retrotransposons on 
Mammalian Genomes." Microbiology Spectrum, 2015  3(2). 
Richardson, S. R., I. Narvaiza, R. A. Planegger, M. D. Weitzman and J. V. 
Moran, "APOBEC3A deaminates transiently exposed single-strand DNA during 
LINE-1 retrotransposition." Elife, 2014  3: e02008. 
Rozmahel, R., H. H. Heng, A. M. Duncan, X. M. Shi, J. M. Rommens and L. C. 
Tsui, "Amplification of CFTR exon 9 sequences to multiple locations in the 
human genome." Genomics, 1997  45(3): 554-561. 
Saito, K. and M. C. Siomi, "Small RNA-mediated quiescence of transposable 
elements in animals." Dev Cell, 2010  19(5): 687-697. 
Sambrook, J., "Adenovirus amazes at Cold Spring Harbor." Nature, 1977  
268(5616): 101-104. 
Sassaman, D. M., B. A. Dombroski, J. V. Moran, M. L. Kimberland, T. P. Naas, 
R. J. DeBerardinis, A. Gabriel, G. D. Swergold and H. H. Kazazian, Jr., "Many 
human L1 elements are capable of retrotransposition." Nat Genet, 1997  16(1): 
37-43. 
Sayah, D. M., E. Sokolskaja, L. Berthoux and J. Luban, "Cyclophilin A 
retrotransposition into TRIM5 explains owl monkey resistance to HIV-1." Nature, 
2004  430(6999): 569-573. 
Scott, A. F., B. J. Schmeckpeper, M. Abdelrazik, C. T. Comey, B. O'Hara, J. P. 
Rossiter, T. Cooley, P. Heath, K. D. Smith and L. Margolet, "Origin of the human 
 65 
L1 elements: proposed progenitor genes deduced from a consensus DNA 
sequence." Genomics, 1987  1(2): 113-125. 
Segal, Y., B. Peissel, A. Renieri, M. de Marchi, A. Ballabio, Y. Pei and J. Zhou, 
"LINE-1 elements at the sites of molecular rearrangements in Alport syndrome-
diffuse leiomyomatosis." Am J Hum Genet, 1999  64(1): 62-69. 
Selker, E. U., N. A. Tountas, S. H. Cross, B. S. Margolin, J. G. Murphy, A. P. Bird 
and M. Freitag, "The methylated component of the Neurospora crassa genome." 
Nature, 2003  422(6934): 893-897. 
Sen, S. K., K. Han, J. Wang, J. Lee, H. Wang, P. A. Callinan, M. Dyer, R. 
Cordaux, P. Liang and M. A. Batzer, "Human genomic deletions mediated by 
recombination between Alu elements." Am J Hum Genet, 2006  79(1): 41-53. 
Sheehy, A. M., N. C. Gaddis, J. D. Choi and M. H. Malim, "Isolation of a human 
gene that inhibits HIV-1 infection and is suppressed by the viral Vif protein." 
Nature, 2002  418(6898): 646-650. 
Shen, S. H., J. L. Slightom and O. Smithies, "A history of the human fetal globin 
gene duplication." Cell, 1981  26(2 Pt 2): 191-203. 
Shukla, R., K. R. Upton, M. Munoz-Lopez, D. J. Gerhardt, M. E. Fisher, T. 
Nguyen, P. M. Brennan, J. K. Baillie, A. Collino, S. Ghisletti, S. Sinha, F. Iannelli, 
E. Radaelli, A. Dos Santos, D. Rapoud, C. Guettier, D. Samuel, G. Natoli, P. 
Carninci, F. D. Ciccarelli, J. L. Garcia-Perez, J. Faivre and G. J. Faulkner, 
"Endogenous retrotransposition activates oncogenic pathways in hepatocellular 
carcinoma." Cell, 2013  153(1): 101-111. 
Sinnett, D., C. Richer, J. M. Deragon and D. Labuda, "Alu RNA secondary 
structure consists of two independent 7 SL RNA-like folding units." Journal of 
Biological Chemistry, 1991  266(14): 8675-8678. 
Siomi, M. C., K. Sato, D. Pezic and A. A. Aravin, "PIWI-interacting small RNAs: 
the vanguard of genome defence." Nat Rev Mol Cell Biol, 2011  12(4): 246-258. 
Skowronski, J., T. G. Fanning and M. F. Singer, "Unit-length line-1 transcripts in 
human teratocarcinoma cells." Mol Cell Biol, 1988  8(4): 1385-1397. 
Skowronski, J. and M. F. Singer, "Expression of a cytoplasmic LINE-1 transcript 
is regulated in a human teratocarcinoma cell line." Proceedings of the National 
Academy of Sciences, 1985  82(18): 6050-6054. 
Soifer, H. S., A. Zaragoza, M. Peyvan, M. A. Behlke and J. J. Rossi, "A potential 
role for RNA interference in controlling the activity of the human LINE-1 
retrotransposon." Nucleic Acids Res, 2005  33(3): 846-856. 
Solyom, S., A. D. Ewing, E. P. Rahrmann, T. Doucet, H. H. Nelson, M. B. Burns, 
R. S. Harris, D. F. Sigmon, A. Casella, B. Erlanger, S. Wheelan, K. R. Upton, R. 
Shukla, G. J. Faulkner, D. A. Largaespada and H. H. Kazazian, Jr., "Extensive 
somatic L1 retrotransposition in colorectal tumors." Genome Res, 2012  22(12): 
2328-2338. 
 66 
Soper, S. F., G. W. van der Heijden, T. C. Hardiman, M. Goodheart, S. L. Martin, 
P. de Boer and A. Bortvin, "Mouse maelstrom, a component of nuage, is 
essential for spermatogenesis and transposon repression in meiosis." Dev Cell, 
2008  15(2): 285-297. 
Speek, M., "Antisense promoter of human L1 retrotransposon drives transcription 
of adjacent cellular genes." Mol Cell Biol, 2001  21(6): 1973-1985. 
Stenglein, M. D. and R. S. Harris, "APOBEC3B and APOBEC3F inhibit L1 
retrotransposition by a DNA deamination-independent mechanism." J Biol Chem, 
2006  281(25): 16837-16841. 
Stetson, D. B., J. S. Ko, T. Heidmann and R. Medzhitov, "Trex1 prevents cell-
intrinsic initiation of autoimmunity." Cell, 2008  134(4): 587-598. 
Strichman-Almashanu, L. Z., M. Bustin and D. Landsman, "Retroposed copies of 
the HMG genes: a window to genome dynamics." Genome Res, 2003  13(5): 
800-812. 
Suter, C. M., D. I. Martin and R. L. Ward, "Hypomethylation of L1 
retrotransposons in colorectal cancer and adjacent normal tissue." Int J 
Colorectal Dis, 2004  19(2): 95-101. 
Swergold, G. D., "Identification, characterization, and cell specificity of a human 
LINE-1 promoter." Mol Cell Biol, 1990  10(12): 6718-6729. 
Symer, D. E., C. Connelly, S. T. Szak, E. M. Caputo, G. J. Cost, G. Parmigiani 
and J. D. Boeke, "Human l1 retrotransposition is associated with genetic 
instability in vivo." Cell, 2002  110(3): 327-338. 
Taniguchi-Ikeda, M., K. Kobayashi, M. Kanagawa, C. C. Yu, K. Mori, T. Oda, A. 
Kuga, H. Kurahashi, H. O. Akman, S. DiMauro, R. Kaji, T. Yokota, S. Takeda and 
T. Toda, "Pathogenic exon-trapping by SVA retrotransposon and rescue in 
Fukuyama muscular dystrophy." Nature, 2011  478(7367): 127-131. 
Taylor, M. S., J. Lacava, P. Mita, K. R. Molloy, C. R. Huang, D. Li, E. M. Adney, 
H. Jiang, K. H. Burns, B. T. Chait, M. P. Rout, J. D. Boeke and L. Dai, "Affinity 
Proteomics Reveals Human Host Factors Implicated in Discrete Stages of LINE-
1 Retrotransposition." Cell, 2013  155(5): 1034-1048. 
Tchenio, T., J. F. Casella and T. Heidmann, "Members of the SRY family 
regulate the human LINE retrotransposons." Nucleic Acids Res, 2000  28(2): 
411-415. 
Thayer, R. E., M. F. Singer and T. G. Fanning, "Undermethylation of specific 
LINE-1 sequences in human cells producing a LINE-1-encoded protein." Gene, 
1993  133(2): 273-277. 
Thompson, C. B., "New insights into V(D)J recombination and its role in the 
evolution of the immune system." Immunity, 1995  3(5): 531-539. 
Trelogan, S. A. and S. L. Martin, "Tightly regulated, developmentally specific 
expression of the first open reading frame from LINE-1 during mouse 
embryogenesis." Proc Natl Acad Sci U S A, 1995  92(5): 1520-1524. 
 67 
Tubio, J. M., Y. Li, Y. S. Ju, I. Martincorena, S. L. Cooke, M. Tojo, G. Gundem, 
C. P. Pipinikas, J. Zamora, K. Raine, A. Menzies, P. Roman-Garcia, A. Fullam, 
M. Gerstung, A. Shlien, P. S. Tarpey, E. Papaemmanuil, S. Knappskog, P. Van 
Loo, M. Ramakrishna, H. R. Davies, J. Marshall, D. C. Wedge, J. W. Teague, A. 
P. Butler, S. Nik-Zainal, L. Alexandrov, S. Behjati, L. R. Yates, N. Bolli, L. Mudie, 
C. Hardy, S. Martin, S. McLaren, S. O'Meara, E. Anderson, M. Maddison, S. 
Gamble, I. B. C. Group, I. B. C. Group, I. P. C. Group, C. Foster, A. Y. Warren, 
H. Whitaker, D. Brewer, R. Eeles, C. Cooper, D. Neal, A. G. Lynch, T. Visakorpi, 
W. B. Isaacs, L. van't Veer, C. Caldas, C. Desmedt, C. Sotiriou, S. Aparicio, J. A. 
Foekens, J. E. Eyfjord, S. R. Lakhani, G. Thomas, O. Myklebost, P. N. Span, A. 
L. Borresen-Dale, A. L. Richardson, M. Van de Vijver, A. Vincent-Salomon, G. G. 
Van den Eynden, A. M. Flanagan, P. A. Futreal, S. M. Janes, G. S. Bova, M. R. 
Stratton, U. McDermott and P. J. Campbell, "Mobile DNA in cancer. Extensive 
transduction of nonrepetitive DNA mediated by L1 retrotransposition in cancer 
genomes." Science, 2014  345(6196): 1251343. 
Ullu, E. and C. Tschudi, "Alu sequences are processed 7SL RNA genes." Nature, 
1984  312(5990): 171-172. 
Upton, K. R., D. J. Gerhardt, J. S. Jesuadian, S. R. Richardson, F. J. Sanchez-
Luque, G. O. Bodea, A. D. Ewing, C. Salvador-Palomeque, M. S. van der Knaap, 
P. M. Brennan, A. Vanderver and G. J. Faulkner, "Ubiquitous l1 mosaicism in 
hippocampal neurons." Cell, 2015  161(2): 228-239. 
Vagin, V. V., A. Sigova, C. Li, H. Seitz, V. Gvozdev and P. D. Zamore, "A distinct 
small RNA pathway silences selfish genetic elements in the germline." Science, 
2006  313(5785): 320-324. 
van den Hurk, J. A., I. C. Meij, M. C. Seleme, H. Kano, K. Nikopoulos, L. H. 
Hoefsloot, E. A. Sistermans, I. J. de Wijs, A. Mukhopadhyay, A. S. Plomp, P. T. 
de Jong, H. H. Kazazian and F. P. Cremers, "L1 retrotransposition can occur 
early in human embryonic development." Hum Mol Genet, 2007  16(13): 1587-
1592. 
van den Hurk, J. A., D. J. van de Pol, B. Wissinger, M. A. van Driel, L. H. 
Hoefsloot, I. J. de Wijs, L. I. van den Born, J. R. Heckenlively, H. G. Brunner, E. 
Zrenner, H. H. Ropers and F. P. Cremers, "Novel types of mutation in the 
choroideremia (CHM) gene: a full-length L1 insertion and an intronic mutation 
activating a cryptic exon." Hum Genet, 2003  113(3): 268-275. 
Vinckenbosch, N., I. Dupanloup and H. Kaessmann, "Evolutionary fate of 
retroposed gene copies in the human genome." Proc Natl Acad Sci U S A, 2006  
103(9): 3220-3225. 
Virgen, C. A., Z. Kratovac, P. D. Bieniasz and T. Hatziioannou, "Independent 
genesis of chimeric TRIM5-cyclophilin proteins in two primate species." 
Proceedings of the National Academy of Sciences of the United States of 
America, 2008  105(9): 3563-3568. 
Volkman, H. E. and D. B. Stetson, "The enemy within: endogenous retroelements 
and autoimmune disease." Nat Immunol, 2014  15(5): 415-422. 
 68 
Wallace, N., B. J. Wagstaff, P. L. Deininger and A. M. Roy-Engel, "LINE-1 ORF1 
protein enhances Alu SINE retrotransposition." Gene, 2008  419(1-2): 1-6. 
Walsh, C. P., J. R. Chaillet and T. H. Bestor, "Transcription of IAP endogenous 
retroviruses is constrained by cytosine methylation." Nat Genet, 1998  20(2): 
116-117. 
Wang, H., J. Xing, D. Grover, D. J. Hedges, K. Han, J. A. Walker and M. A. 
Batzer, "SVA elements: a hominid-specific retroposon family." J Mol Biol, 2005  
354(4): 994-1007. 
Watanabe, T., Y. Totoki, A. Toyoda, M. Kaneda, S. Kuramochi-Miyagawa, Y. 
Obata, H. Chiba, Y. Kohara, T. Kono, T. Nakano, M. A. Surani, Y. Sakaki and H. 
Sasaki, "Endogenous siRNAs from naturally formed dsRNAs regulate transcripts 
in mouse oocytes." Nature, 2008  453(7194): 539-543. 
Weber, M. J., "Mammalian Small Nucleolar RNAs Are Mobile Genetic Elements." 
PLoS Genet, 2006  2(12): e205. 
Wei, W., N. Gilbert, S. L. Ooi, J. F. Lawler, E. M. Ostertag, H. H. Kazazian, J. D. 
Boeke and J. V. Moran, "Human L1 retrotransposition: cis preference versus 
trans complementation." Mol Cell Biol, 2001  21(4): 1429-1439. 
Weichenrieder, O., K. Repanas and A. Perrakis, "Crystal structure of the 
targeting endonuclease of the human LINE-1 retrotransposon." Structure 
(Camb), 2004  12(6): 975-986. 
Wilson, S. J., B. L. J. Webb, L. M. J. Ylinen, E. Verschoor, J. L. Heeney and G. J. 
Towers, "Independent evolution of an antiviral TRIMCyp in rhesus macaques." 
Proceedings of the National Academy of Sciences of the United States of 
America, 2008  105(9): 3557-3562. 
Wissing, S., M. Munoz-Lopez, A. Macia, Z. Y. Yang, M. Montano, W. Collins, J. 
L. Garcia-Perez, J. V. Moran and W. C. Greene, "Reprogramming somatic cells 
into iPS cells activates LINE-1 retroelement mobility." Human Molecular 
Genetics, 2012  21(1): 208-218. 
Xing, J., H. Wang, V. P. Belancio, R. Cordaux, P. L. Deininger and M. A. Batzer, 
"Emergence of primate genes by retrotransposon-mediated sequence 
transduction." Proceedings of the National Academy of Sciences, 2006  103(47): 
17608-17613. 
Xiong, Y. and T. H. Eickbush, "Origin and evolution of retroelements based upon 
their reverse transcriptase sequences." EMBO J, 1990  9(10): 3353-3362. 
Yajima, I., S. Sato, T. Kimura, K. Yasumoto, S. Shibahara, C. R. Goding and H. 
Yamamoto, "An L1 element intronic insertion in the black-eyed white (Mitf[mi-bw]) 
gene: the loss of a single Mitf isoform responsible for the pigmentary defect and 
inner ear deafness." Hum Mol Genet, 1999  8(8): 1431-1441. 
Yan, N. and Z. J. Chen, "Intrinsic antiviral immunity." Nat Immunol, 2012  13(3): 
214-222. 
 69 
Yang, J., H. S. Malik and T. H. Eickbush, "Identification of the endonuclease 
domain encoded by R2 and other site-specific, non-long terminal repeat 
retrotransposable elements." Proc Natl Acad Sci U S A, 1999  96(14): 7847-
7852. 
Yang, N. and H. H. Kazazian, Jr., "L1 retrotransposition is suppressed by 
endogenously encoded small interfering RNAs in human cultured cells." Nat 
Struct Mol Biol, 2006  13(9): 763-771. 
Yang, N., L. Zhang, Y. Zhang and H. H. Kazazian, Jr., "An important role for 
RUNX3 in human L1 transcription and retrotransposition." Nucleic Acids Res, 
2003  31(16): 4929-4940. 
Yoder, J. A., C. P. Walsh and T. H. Bestor, "Cytosine methylation and the 
ecology of intragenomic parasites." Trends Genet, 1997  13(8): 335-340. 
Yohn, C. T., Z. Jiang, S. D. McGrath, K. E. Hayden, P. Khaitovich, M. E. 
Johnson, M. Y. Eichler, J. D. McPherson, S. Zhao, S. Paabo and E. E. Eichler, 
"Lineage-specific expansions of retroviral insertions within the genomes of 
African great apes but not humans and orangutans." PLoS biology, 2005  3(4): 
e110. 
Yu, F., N. Zingler, G. Schumann and W. H. Stratling, "Methyl-CpG-binding 
protein 2 represses LINE-1 expression and retrotransposition but not Alu 
transcription." Nucleic Acids Res, 2001  29(21): 4493-4501. 
Zhang, A., B. Dong, A. J. Doucet, J. B. Moldovan, J. V. Moran and R. H. 
Silverman, "RNase L restricts the mobility of engineered retrotransposons in 
cultured human cells." Nucleic Acids Res, 2014  42(6): 3803-3820. 
Zhang, Z., P. M. Harrison, Y. Liu and M. Gerstein, "Millions of years of evolution 
preserved: a comprehensive catalog of the processed pseudogenes in the 
human genome." Genome Res, 2003  13(12): 2541-2558. 
Zhao, K., J. Du, X. Han, J. L. Goodier, P. Li, X. Zhou, W. Wei, S. L. Evans, L. Li, 
W. Zhang, L. E. Cheung, G. Wang, H. H. Kazazian, Jr. and X. F. Yu, "Modulation 
of LINE-1 and Alu/SVA retrotransposition by Aicardi-Goutieres syndrome-related 
SAMHD1." Cell Rep, 2013  4(6): 1108-1115. 
Zheng, K., J. Xiol, M. Reuter, S. Eckardt, N. A. Leu, K. J. McLaughlin, A. Stark, 
R. Sachidanandam, R. S. Pillai and P. J. Wang, "Mouse MOV10L1 associates 
with Piwi proteins and is an essential component of the Piwi-interacting RNA 
(piRNA) pathway." Proceedings of the National Academy of Sciences, 2010  
107(26): 11841-11846. 
Zheng, Y. H., K. T. Jeang and K. Tokunaga, "Host restriction factors in retroviral 
infection: promises in virus-host interaction." Retrovirology, 2012  9: 112. 
 
 
 70 
Chapter 2 
 
Mutations in Human ORF1p Disrupt The Function of LINE-1 
Ribonucleoprotein Particles 
  It should be noted that some of the data images used in Figure 2.2 of this 
chapter were previously published in PLoS Genetics (Doucet et al. 2010) (see 
Figure 2.2 for details) and are presented here in strict accordance with PLoS  
journal policies and the  Creative Commons Attribution (CC BY) license 
(http://creativecommons.org/licenses/by/4.0/). I performed all the experiments 
pertaining to Figure 2.2. I designed and carried out all experiments pertaining to 
Figures 2.3 and 2.4. The data depicted in Figures 2.3 and 2.4 have not been 
published. 
 
Abstract 
 LINE-1 or L1 is the only active autonomous transposable element in the 
human genome. L1 mobilizes by the process of retrotransposition, which requires 
the activity of the two L1-encoded proteins (i.e., ORF1p and ORF2p). ORF1p is 
an ~40 kDa nucleic acid binding protein and ORF2p encodes an ~150 kDa 
protein with endonuclease and reverse transcriptase activities. During L1 
retrotransposition ORF1p and ORF2p bind to L1 RNA to form an L1 
ribonucleoprotein particle (RNP), which is a required L1 retrotransposition 
intermediate. To elucidate the function of L1 ORF1p, we have used a genetic cell 
culture-based retrotransposition assay to monitor the effect of mutations in 
ORF1p on L1 retrotransposition. We also have used biochemical assays to 
determine how ORF1p mutations affect the formation and function of L1 RNPs. 
We report that mutations in the ORF1p coiled-coil (CC), RNA recognition motif 
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(RRM), and/or carboxyl-terminal (CTD) domains are incompatible with L1 
retrotransposition. Biochemical analysis of these ORF1p mutants demonstrate 
that mutations that affect ORF1p RNA binding and/or mutations within the ORF1 
CC domain impair the formation of L1 RNPs. Functional analyses of ORF1p 
mutant RNPs using an enzymatic assay to detect ORF2p RT activity indicate that 
mutations in ORF1p may result in reverse transcription of L1 RNA beginning 
within the 3' end of the L1. In sum, these data suggest that ORF1p is necessary 
for the formation of functional L1 RNPs.  
 
Introduction 
 Long Interspersed Nuclear Element-1 (LINE-1, or L1) non-LTR 
retrotransposon sequences comprise ~17% of human DNA (Lander et al. 2001). 
L1 mobilizes throughout the genome by a process termed retrotransposition 
(Richardson et al. 2015). Although most genomic L1 sequences are inactive due 
to 5' truncations (Grimaldi et al. 1984, Lander et al. 2001) and various mutations, 
it is estimated that each cell contains at least 80-100 full length L1 sequences 
that are capable of retrotransposition (Sassaman et al. 1997, Brouha et al. 2003). 
Active L1 retrotransposition is known to cause genetic diseases (Hancks and 
Kazazian 2012) such as hemophilia A (Kazazian et al. 1988) and Duchenne 
muscular dystrophy (Narita et al. 1993). L1 retrotransposition also serves as an 
ongoing source of genetic sequence diversity that contributes to intra- and inter-
individual variation in the human population (Cordaux and Batzer 2009, Beck et 
al. 2010).  
 An active full-length L1 is ~6 kb in length and consists of a 5' UTR that 
functions to promote L1 transcription (Swergold 1990, Becker et al. 1993, 
Athanikar et al. 2004), two non-overlapping open reading frames (ORFs) 
separated by a 63 bp intergenic spacer, and a 3' UTR that ends in a variable 
length stretch of poly-adenosine residues (Scott et al. 1987, Dombroski et al. 
1991). The first L1 ORF (ORF1) encodes ORF1p, a ~40 kDa nucleic acid binding 
protein (Martin 1991, Holmes et al. 1992, Hohjoh and Singer 1996, Hohjoh and 
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Singer 1997) with nucleic acid chaperone activity (Martin and Bushman 2001). 
The second L1 ORF (ORF2) encodes ORF2p, an ~150 kDa protein, which 
contains endonuclease (EN) (Feng et al. 1996) and reverse transcriptase (RT) 
(Mathias et al. 1991, Dombroski et al. 1994) activities. Both L1-encoded proteins 
are required for L1 retrotransposition (Feng et al. 1996, Moran et al. 1996). 
 During the L1 retrotransposition process, a genomic L1 is transcribed in 
the nucleus and the resulting L1 mRNA is exported to the cytoplasm for 
translation. L1 translation occurs by an unconventional cap-dependent 
mechanism that ensures translation of both L1 ORFs (Leibold et al. 1990, 
McMillan and Singer 1993, Alisch et al. 2006, Dmitriev et al. 2007). Following 
translation of the L1 mRNA, ORF1p and ORF2p bind back to their encoding L1 
mRNA (a phenomenon known as cis-preference (Esnault et al. 2000, Wei et al. 
2001)) resulting in the formation of an L1 ribonucleoprotein particle (L1 RNP), 
which is an important retrotransposition intermediate (Kulpa and Moran 2005, 
Kulpa and Moran 2006). The L1 RNP then enters the nucleus (Kubo et al. 2006, 
Xie et al. 2013) where a new L1 copy is inserted into genomic DNA by the 
process of target site primed reverse transcription (TPRT) (Luan et al. 1993, 
Feng et al. 1996).  
 L1 retrotransposition requires functional ORF1p (Moran et al. 1996). 
Recent ORF1p structural studies have identified three distinct ORF1p functional 
domains (Januszyk et al. 2007, Khazina and Weichenrieder 2009, Khazina et al. 
2011, Callahan et al. 2012). The  amino-terminal region of ORF1p is composed 
of a coiled-coil (CC) domain that is thought to mediate the polymerization of 
ORF1p into trimers, the basic ORF1p functional unit (Martin et al. 2003, Khazina 
and Weichenrieder 2009, Khazina et al. 2011). Notably, the CC domain contains 
a putative leucine zipper motif that when mutated disrupts retrotransposition 
(Holmes et al. 1992, Hohjoh and Singer 1996, Hulme 2007, Khazina and 
Weichenrieder 2009, Doucet et al. 2010, Khazina et al. 2011). The central region 
of ORF1p contains an RNA recognition motif (RRM), which interacts with the 
ORF1p carboxyl terminus domain (CTD) to mediate RNA binding (Khazina and 
Weichenrieder 2009, Khazina et al. 2011). In addition to RNA binding, ORF1p 
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also exhibits putative nucleic acid chaperone activity, which can mediate the 
dissociation and/or annealing of double strand DNA in vitro (Martin and Bushman 
2001, Martin et al. 2005, Khazina and Weichenrieder 2009, Callahan et al. 2012). 
Genetic and biochemical experiments have demonstrated that mutations in the 
ORF1p RRM or CTD domains disrupt RNA binding activity and/or nucleic acid 
chaperone activity, and thus are incompatible with L1 retrotransposition (Martin 
et al. 2005, Hulme 2007, Khazina and Weichenrieder 2009, Doucet et al. 2010, 
Khazina et al. 2011).  
 Early studies demonstrated that L1 ORF1p binds to L1 RNA and forms 
cytoplasmic RNP complexes that represent important L1 retrotransposition 
intermediates (Martin 1991, Martin and Branciforte 1993, Hohjoh and Singer 
1996, Hohjoh and Singer 1997, Kulpa and Moran 2005). The subsequent 
development of an in vitro assay that monitors ORF2p RT activity (i.e., LINE-1 
Element Amplification Protocol or LEAP) in L1 RNPs provided the first 
biochemical evidence that ORF2p is also a constituent of L1 RNPs (Kulpa and 
Moran 2006). Notably, recent studies have employed epitope/RNA-tagging 
strategies coupled with biochemical and immunofluorescence microscopy 
methods to confirm that ORF1p, ORF2p, and L1 RNA constitute an L1 RNP 
(Doucet et al. 2010, Goodier et al. 2010, Taylor et al. 2013). Herein, we have 
expanded on these studies by analyzing how mutations in ORF1p impact the 
formation and function of L1 RNPs. We show that certain mutations in the 
ORF1p RRM and CTD perturb the normal biogenesis of L1 RNPs and are 
incompatible with retrotransposition. Analysis of ORF1p mutant RNPs suggest 
that mutations in ORF1p may affect L1 RNP function by modulating ORF2p RT 
activity.  
 
Results 
Mutations in ORF1p are incompatible with L1 retrotransposition 
 To analyze ORF1p function, we tested the effect of mutations in ORF1p 
on L1 retrotransposition using a cultured cell retrotransposition assay (Moran et 
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al. 1996, Wei et al. 2000). Briefly, HeLa cells were transfected with epitope-
tagged L1 constructs (Figure 2.1) that express a T7 gene10 epitope tag on the 
carboxyl terminus of ORF1p and also contain a neomycin retrotransposition 
indicator cassette (mneoI) within the L1 3' UTR (Figure 2.1) (Kulpa and Moran 
2005). The mneoI cassette contains an antisense copy of the neomycin 
phosphotransferase gene, which is interrupted by an intron in the same 
transcriptional orientation as L1. This arrangement ensures that the neomycin 
gene is expressed only when the L1 transcript is spliced, reverse transcribed, 
and inserted into genomic DNA (Freeman et al. 1994, Moran et al. 1996). The 
resulting neomycin-resistant foci then provide a visual, quantitative readout of 
retrotransposition activity (Moran et al. 1996, Wei et al. 2000). The following L1 
mutants were used to test the effects of point mutations in specific ORF1p 
domains (Figure 2.1): pDK103 (REKG235-238AAAA); pDK105 (RR261-262AA); 
pDK106 (RR261-262KK); pDK108 (R262K); pDK109 (R261K); pDK116 (YPAKLS282-
287AAAALA); pLZC (L93, 100, 107, 114V) (Hulme 2007); and pLZC/AA (L93, 100, 107, 114V 
+ RR261-262AA) (Hulme 2007).  In agreement with previous reports (Moran et al. 
1996, Kulpa and Moran 2005, Doucet et al. 2010), retrotransposition assays 
showed that pDK103, pDK105, pDK108, pDK106, and pDK116 were incapable 
of retrotransposition whereas, pDK108 retrotransposed at ~80% of wild type 
(pDK101) levels. The pLZC and pLZC/AA were previously demonstrated to 
abolish L1 retrotransposition activity (Hulme 2007, Doucet et al. 2010). Thus, the 
data suggest that the ORF1p CC, RRM, and CTD domains are required for L1 
retrotransposition. 
The Impact Of ORF1p Mutations On The Function Of L1 RNPs 
 We next tested the effect of ORF1p mutations on the assembly and 
function of L1 RNPs.  Briefly, HeLa cells were transfected with wild type and 
mutant L1 constructs (Figure 2.1) and then L1 RNPs were isolated from 
transfected cell lysates using ultracentrifugation over sucrose cushions (Kulpa 
and Moran 2005, Kulpa and Moran 2006). Following ultracentrifugation, cellular 
RNP pellets were collected and then assayed for the presence of T7-tagged 
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ORF1p and L1 RNA. The presence of T7-tagged ORF1p and L1 RNA in the RNP 
pellet  serves as an indication of L1 RNP formation. RNP fractions defined above 
also were assayed for L1 ORF2p reverse transcriptase activity using the LEAP 
assay (Kulpa and Moran 2006), which provides a readout for the presence of 
ORF2p in L1 RNPs and serves as an indication of L1 RNP function (i.e., the 
ability to reverse transcribe L1 RNA).  
 In agreement with previous reports (Kulpa and Moran 2005, Kulpa and 
Moran 2006), RNPs derived from HeLa cells transfected with the wild type 
pDK101 contained a substantial enrichment of L1 ORF1p compared to 
untransfected HeLa cells (Figure 2.2B), thus confirming the presence of L1 RNPs 
in the crude RNP pellet fraction. In pDK101 LEAP reactions, a diffuse band 
between ~220 and ~400 bp was visualized on agarose gels indicating the 
presence of ORF2p reverse transcriptase activity (Figure 2.2C). Notably, control 
experiments showed that LEAP activity was absent from RNPs derived from 
pDK135 transfected cells (Figure 2.2C) (pDK135 contains a mutation in the 
ORF2 reverse transcriptase domain rendering the element unable to 
retrotranspose) (Moran et al. 1996, Wei et al. 2001, Kulpa and Moran 2006). 
Sequencing of pDK101 LEAP products revealed that L1 reverse transcription 
initiated at variable sites within the L1 poly-adenosine sequence, which accounts 
for LEAP product size variation (data not shown, and (Kulpa and Moran 2006)). 
Control M-MLV RT PCR reactions confirmed the presence of L1 RNA in pDK101 
RNPs (Figure 2.2C).  
 RNA binding activity mutants (pDK103 (REKG235-238AAAA); pDK105 
(RR261-262AA); pDK116 (YPAKLS282-287AAAALA)):  In agreement with previous 
reports (Kulpa and Moran 2005, Kulpa and Moran 2006), RNPs derived from 
HeLa cells transfected with pDK105, pDK116, and pDK103 contained less 
ORF1p than did wild type pDK101 control RNPs (Figure 2.2B). Similarly, whole 
cell lysates harvested from cells transfected with pDK105, pDK116, and pDK103 
contained less ORF1p than lysates from pDK101 transfected cells (Figure 2.2B). 
Notably, the R261A mutation in pDK105 has been demonstrated to impair human 
ORF1p RNA binding activity in vitro (Khazina et al. 2011) and introduction of 
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(RR261-262AA) into the homologous region of mouse ORF1p  has been shown to 
reduce the RNA binding activity and the stability of mouse ORF1p in vitro (Martin 
et al. 2005). These data suggest that mutations in the ORF1p RRM and CTD 
interfere with the ability of ORF1p to localize to RNPs and/or affect ORF1p 
stability.  
 In LEAP reactions using pDK105 RNPs, LEAP activity was marked by a 
diffuse band and the appearance of distinct lower bands (below 300bp) on LEAP 
gels (Figure 2.2C). Notably, pDK116 and pDK103 LEAP products generally 
appeared more diffuse than wild type pDK101 LEAP activity. In addition, pDK116 
and pDK103 LEAP reactions often contained lower bands in LEAP gels similar to 
the lower bands observed in pDK105 LEAP gels (Figure 2.2C). Sequencing of 
pDK105 and pDK116 LEAP products indicated frequent initiation of L1 reverse 
transcription from within the 3' end of the L1 RNA (data not shown and (Kulpa 
and Moran 2006, Doucet et al. 2010)). Similar LEAP data also was reported for 
an L1 mutant that lacks the entire ORF1 sequence (Doucet et al. 2010). These 
data suggest that ORF2p can associate with L1 mRNA and carry out reverse 
transcription of L1 mRNA independently of ORF1p; and that ORF1p likely 
promotes the initiation of L1 reverse transcription from the L1 poly-adenosine tail 
(Kulpa and Moran 2006, Doucet et al. 2010). 
 Chaperone activity mutants (pDK106 (RR261-262KK); pDK109 (R261K)):  
Mutations in pDK106 and pDK109, which have previously been shown to affect 
ORF1p nucleic acid chaperone activity (Martin et al. 2005), did not affect the 
localization of ORF1p to RNPs (Figure 2.2B) and (Kulpa and Moran 2005). LEAP 
activity was similarly unaffected in pDK106 and pDK109 RNPs (Figure 2.2C). We 
did however notice the occasional appearance of lower molecular weight (less 
than ~300 bp) LEAP products in pDK106 and pDK109 LEAP reactions that were 
not observed in pDK101 LEAP reactions (Figure 2.2C). These data therefore 
suggest that although ORF1p may not be strictly required for L1 reverse 
transcriptase activity in RNPs, that certain ORF1p mutations affect the array of 
LEAP products observed in these assays. 
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 Leucine zipper mutants (pLZC (L93, 100, 107, 114V); pLZC/AA (L93, 100, 107, 114V 
+ RR261-262AA)): RNPs derived from pLZC (L93, 100, 107, 114V) mutant transfected 
cells contained less ORF1p than pDK101 control RNPs (Figure 2.2B). LEAP 
activity from pLZC RNPs appeared to be less compared to pDK101 controls 
upon visual inspection of LEAP gels (Figure 2.2C). Quantitative LEAP 
experiments confirmed that pLZC RNP LEAP activity is decreased compared to 
wild type controls (Hulme 2007, Doucet et al. 2010).  Notably, RNPs derived from 
mutant L1s that contain the L93, 100, 107, 114V mutations in ORF1p also contain less 
ORF2p than corresponding wild-type controls (Doucet et al. 2010). These data 
suggest that the LZC domain is required for the localization of ORF1p to L1 
RNPs and that the L93, 100, 107, 114V mutations could impair either the localization of 
ORF2p to L1 RNPs and/or ORF2p RT activity.  
 Because the L93, 100, 107, 114V mutation in ORF1 appeared to exert a 
negative effect on the localization of ORF2p to L1 RNPs and/or ORF2p RT 
activity, we hypothesized that ORF1p might interact directly with ORF2p. To test 
this, we introduced the RR261-262AA  mutation into the pLZC mutant construct to 
make an L1 mutant construct (pLZC/AA) that contains both the L93, 100, 107, 114V 
and the RR261-262AA  mutation. We did so reasoning that since the RR261-262AA 
mutation impaired the localization of ORF1p to L1 RNPs without affecting the 
localization of ORF2p to RNPs, that the introduction of the RR261-262AA mutation 
into pLZC might relieve any negative effect that the L93, 100, 107, 114V ORF1 
mutation could have on the localization of ORF2p to L1 RNPs and/or ORF2p RT 
activity. In L1 RNPs collected from pLZC/AA transfected cells, western blot 
experiments revealed a loss of ORF1p from pLZC/AA mutant RNPs compared to 
pDK101 wild type control RNPs (Figure 2.2B). LEAP activity also was decreased 
in pLZC/AA RNPs compared to pDK101 controls (Figure 2.2C), which has been 
verified by quantitative LEAP experiments using similar constructs (Hulme 2007, 
Doucet et al. 2010). Western blotting further revealed that pLZC/AA RNPs 
contained less ORF2p than corresponding wild-type controls (Doucet et al. 
2010). Notably, LEAP activity from pLZC/AA RNPs exhibited lower bands in 
agarose gels similar to those observed in pDK105 LEAP gels (Figure 2.2C). 
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Thus, pLZC/AA mutant RNPs display phenotypes similar to both the pLZC and 
the pDK105 mutant RNPs. In sum, these data suggest that the ORF1p putative 
leucine zipper domain is required for the proper localization of ORF1p and 
ORF2p to L1 RNPs. 
Engineering an ORF1p/ORF2p fusion protein to study the ORF1 LZC 
mutation 
 The above data suggest that mutations in ORF1p may negatively affect 
the localization of ORF1p and/or ORF2p to the L1 RNP. I further hypothesized 
that mutations in ORF1p also could affect ORF2p function (e.g., ORF2p reverse 
transcriptase activity). Because some of the ORF1p mutations (e.g., RR261-262AA,  
L93, 100, 107, 114V) affected the localization of ORF1p and/or ORF2p to L1 RNPs, an 
ORF1p-ORF2p fusion protein was constructed to facilitate an association 
between ORF1p and ORF2p so that I could test whether ORF1p mutations 
affected ORF2p function. The ORF1p-ORF2p fusion protein was constructed by 
substituting the ORF1 stop codon and the 63 bp intervening sequence between 
ORF1 and ORF2 with a single lysine residue, which effectively tethers ORF2p to 
the carboxyl terminus of ORF1p (Alisch et al. 2006). The ORF1p-ORF2p fusion 
protein construct (p1K2_TAP) was further modified to contain a TAP epitope tag 
on to the carboxyl terminus of ORF2 to facilitate the detection of the fusion 
protein using anti-TAP antibodies (Figure 2.3A). 
 First, to determine if the ORF1p-ORF2p fusion protein was expressed we 
transfected HeLa cells with p1K2_TAP and analyzed p1K2_TAP RNPs by 
western blot using anti-TAP antibodies. A prominent band of the expected size of 
an ORF1p-ORF2p fusion peptide (~190 kDa) was detected in p1K2_TAP RNPs 
using anti-TAP antibodies (Figure 2.3B: top panel). Notably, the ~190 kDa band 
was not present in RNPs derived from untransfected HeLa cells or from HeLa 
cells transfected with a wild-type L1 control (pAD2TE1) (Doucet et al. 2010), or 
an L1 that lacks the ORF1 sequence (pAD500) (Doucet et al. 2010) (Figure 2.3B: 
top panel). Several smaller molecular weight bands were detected in p1K2_TAP 
RNPs with the anti-TAP antibody (Figure 2.3B: top panel) suggesting that the 
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fusion could be processed into smaller peptides, or that the fusion had partially 
degraded during the sample preparation process (Figure 2.3B).  
 Next, we used an antibody specific to amino acids 31-49 of ORF1p to 
detect the amino terminal ORF1p end of the fusion peptide. Similar to blots 
probed with the anti-TAP antibody, we detected an ~190 kDa band in p1K2_TAP 
RNPs using the anti-ORF1p antibody (Figure 2.3B: bottom panel). The ~190 kDa 
band was noticeably absent from untransfected HeLa, pAD2TE1, and pAD500 
RNPs (Figure 2.3B: bottom panel). A band corresponding to free ORF1p (~40 
kDa) was detected in pAD2TE1 RNPs using the anti-ORF1p antibody (Figure 
2.3B: bottom panel). In contrast, free ORF1p was not detected in p1K2_TAP 
RNPs (Figure 2.3B: bottom panel). Thus, free ORF1p is not expressed from 
p1K2_TAP and the ORF1p-ORF2p fusion peptide is not processed to produce 
free ORF1p.  
 In additional control experiments we engineered a mutant fusion peptide in 
which the nucleotide sequence corresponding to the first 255 amino acids were 
deleted from ORF1p (p1K2(RF1)) (Figure 2.3C), which would be expected to 
yield an ~160 kDa fusion peptide. Indeed, an ~160 kDa band was detected in 
RNPs derived from HeLa cells transfected with p1K2(RF1) (Figure 2.3C). We 
also introduced a mutation into the ORF1p sequence that inserted a premature 
stop codon into ORF1 of p1K2_TAP (p1K2(S119X)), which is expected to result 
in early termination of the fusion protein (Moran et al. 1996, Wei et al. 2001, 
Alisch et al. 2006). Western blots demonstrated a substantial decrease in 
expression of the fusion peptide from p1K2(S119X) compared to p1K2_TAP 
(Figure 2.3C). Notably, free ORF2p was not detected in the p1K2(S119X) lane 
suggesting that ORF2p translation does not initiate from internal sequences 
within the ORF1p-ORF2p fusion protein RNA. Northern blotting experiments 
using a probe to the L1 5' UTR (5UTR99) demonstrated L1 RNA expression 
levels were similar between p1K2(S119X), p1K2_TAP and pAD2TE1 (Figure 
2.3D). Thus, the S119X mutation in ORF1 does not affect the accumulation of L1 
RNA, and confirms previous data suggesting that the S119X mutation does not 
affect expression of L1 RNA (Moran et al. 1996, Wei et al. 2001, Alisch et al. 
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2006). In sum, the above data suggest that an ORF1p-ORF2p fusion peptide is 
expressed from p1K2_TAP. 
The impact of the LZC mutation on the function of the ORF1p/ORF2p fusion 
protein 
 Next, we tested the effect of mutation in ORF1p on the function of the 
ORF1p-ORF2p fusion peptide. Although the ORF1p-ORF2p fusion protein does 
not retrotranspose in cis, it has been demonstrated to drive the retrotransposition 
of a retrotransposition reporter plasmid in a genetic trans-complementation assay 
(Figure 2.4A) (Wei et al. 2001, Alisch et al. 2006)). The genetic trans-
complementation assay monitors the ability of an L1 construct lacking the mneoI 
retrotransposition indicator cassette (i.e., a driver L1) to trans-mobilize a reporter 
mRNA consisting of the L1 5′ UTR, ORF1, and the spliced mneoI indicator 
cassette (i.e., ORF1mneoI) (Figure 2.4A). By taking advantage of the ORF1p-
ORF2p fusion protein, we addressed whether mutations in ORF1p affected the 
ability of the ORF1p-ORF2p fusion protein to trans-mobilize RNA derived from 
ORF1mneoI.  
 To test the effect of ORF1p mutations on the function of the ORF1p-
ORF2p fusion protein in trans-complementation assays, we made the following 
ORF1p-ORF2p fusion protein constructs (Figure 2.3A): (p1K2(AA); RR261-262AA), 
(p1K2(LZC); L93, 100, 107, 114V), (p1K2(LZC/AA); L93, 100, 107, 114V + RR261-262AA), 
(p1K2(S119X); S119X), (p1K2(RF1); ORF1Δ1-255). In control western blot 
experiments we observed similar expression levels of the fusion peptide and of 
the smaller bands from each of the fusion constructs (Figure 2.3E). Thus, the 
above mutations in ORF1 do not affect the expression of the ORF1p-ORF2p 
fusion peptide. 
 To determine the affect of ORF1p mutations when tethered to ORF2p to 
drive retrotransposition of a retrotransposition reporter construct in trans, the 
ORF1p-ORF2p fusion constructs described above were co-transfected with the 
ORF1mneoI reporter construct. Similar to a previous report (Alisch et al. 2006), 
the wild type p1K2_TAP efficiently trans-complemented the retrotransposition of 
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the ORF1mneoI reporter construct (Figure 2.4B). Notably, the trans-
complementation efficiency of p1K2(LZC) was ~65% of wild type control p1K2 
levels (Figure 2.4B). Thus, the LZC mutation in ORF1 does not significantly 
impair the ability of the fusion peptide to trans-complement the ORF1mneoI 
reporter construct. In contrast to p1K2(LZC), the trans-complementation 
efficiency of the p1K2(AA) and p1K2(LZC/AA) constructs were only ~38% and 
~19% respectively of control levels (Figure 2.4B). The trans-complementation 
efficiency of the mutant fusion construct p1K2(RF1) in which the first 255 amino 
acids were deleted from ORF1p also was significantly decreased (~50% of wild 
type p1K2 control levels). Notably, within the first 255 amino acids of ORF1p are 
several amino acids that have been demonstrated to be important for in vitro 
ORF1p RNA binding activity including R235, R210, R211, K133, K137, K140, 
and R141 (Martin et al. 2005, Khazina et al. 2011). Thus, mutations that affect 
ORF1p RNA binding activity negatively affect ORF1mneoI trans-
complementation. In additional control experiments, co-transfection of 
ORF1mneoI with an empty pCEP4 vector or the p1K2(S119X) mutant, which 
contains a missense mutation in ORF1 that results in early termination of 
translation (Moran et al. 1996, Wei et al. 2001, Alisch et al. 2006), expectedly did 
not result in the production of G418 resistant colonies (Figure 2.4B). Notably, the 
trans-complementation efficiency of pAD2TE1 was only ~12% of p1K2_TAP 
levels (Figure 2.4B), which could be explained by the considerable disparity in 
protein expression between p1K2_TAP and pAD2TE1 (Figure 2.3E). Thus, the 
data suggest that the LZC mutation (L93, 100, 107, 114V) in ORF1 by itself, is 
insufficient to impair the ability of the ORF1p-ORF2p fusion peptide to trans-
complement RNA derived from the ORF1pmneoI reporter construct.  
 
Discussion 
 The L1 RNP is a critical retrotransposition intermediate (Martin 1991, 
Martin and Branciforte 1993, Hohjoh and Singer 1996, Kulpa and Moran 2005, 
Kulpa and Moran 2006, Doucet et al. 2010). We have extended recent analyses 
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of L1 RNPs (Kulpa and Moran 2005, Kulpa and Moran 2006) by examining how 
mutation of ORF1p impacts the function and formation L1 RNPs. We report that 
certain mutations in ORF1p, which are incompatible with retrotransposition, can 
affect the formation and/or stability of L1 RNPs. We have categorized these 
mutations based on how they impact L1 RNPs (Figure 2.5).  
 ORF1p RNA binding mutants (pDK103, pDK105, pDK116): Mutations that 
affect the ability of ORF1p to bind RNA result in RNPs that lack ORF1p but 
contain ORF2p and L1 reverse transcriptase activity (Type I RNPS, Figure 2.5B). 
Mutant ORF1p failed to localize to RNPs isolated from cells transfected with 
pDK105, pDK103, and pDK116. pDK105 carries the RR261-262AA mutation 
which has been shown to significantly reduce the RNA binding capacity of mouse 
(Martin et al. 2005) and human ORF1p (Khazina et al. 2011). Moreover, this 
mutation has also been shown to reduce the stability of mouse ORF1p although 
it does not appear to affect overall structure of either mouse or human ORF1p 
(Martin et al. 2005, Khazina et al. 2011). The R235A mutation in pDK103 occurs 
in the RRM domain and has also been shown to reduce the RNA binding activity 
of human ORF1p in vitro (Khazina et al. 2011).  
 Although the effect on RNA binding activity of the YPKALS282-287AAALAA 
mutation has not been directly tested, several lines of evidence support that this 
mutation impairs the RNA binding activity. First, the YPKALS282-287AAALAA 
mutation severely compromises the ability of ORF1p to localize to RNPs; second, 
the constellation of pDK116 LEAP products bear similarity to pDK105 LEAP 
products (i.e., initiation of reverse transcription from within the 3' end of the L1 
mRNA) (Kulpa and Moran 2006, Doucet et al. 2010); and third, the YPKALS282-
287AAALAA mutation impairs L1 cytoplasmic foci formation (Doucet et al. 2010). 
Thus, ORF1p RNA binding activity is important for the formation and/or stability 
of L1 RNPs.  
 RNPs that were derived from ORF1p RNA binding mutants contain 
ORF2p (Doucet et al. 2010) and exhibit robust LEAP activity (Doucet et al. 2010) 
(Figure 2.2C). In agreement with previous data (Kulpa and Moran 2006, Doucet 
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et al. 2010, Kopera et al. 2011), this result suggests that L1 ORF2p can bind to 
L1 RNA and carry out L1 cDNA synthesis in the absence of ORF1p. Notably, L1 
elements that carry the RR261-262AA mutation or that entirely lack the ORF1 
sequence are able to retrotranspose (albeit at very low levels) in Chinese 
hamster ovary cells that are deficient in the non-homologous end joining DNA 
repair pathway (Kopera et al. 2011). Interestingly, sequencing of LEAP products 
from pDK105, pDK116 and an L1 that does not express ORF1p indicated that L1 
reverse transcription frequently initiated from within the L1 mRNA 3' end in RNPs 
devoid of ORF1p (Kulpa and Moran 2006, Doucet et al. 2010). Thus, in 
agreement with previous reports  (Kulpa and Moran 2006, Doucet et al. 2010) the 
data suggest that ORF1p may help facilitate the initiation of L1 reverse 
transcription from the L1 poly-adenosine tail.  
 ORF1 chaperone activity mutants (pDK106, pDK109): The second group 
of RNPs (Figure 2.5B; Type II RNPS) includes RNPs derived from L1s that 
carried the R261K mutation (i.e., pDK106 & pDK109). The R261K affects ORF1p 
nucleic acid chaperone activity in vitro  (Martin and Bushman 2001, Martin et al. 
2005) without affecting RNA binding activity and is incompatible with 
retrotransposition (Kulpa and Moran 2005, Martin et al. 2005, Martin et al. 2008, 
Khazina et al. 2011). We showed that pDK106 and pDK109 RNPs contained wild 
type levels of ORF1p and exhibited wild type LEAP activity. Notably, 
immunofluorescence experiments also demonstrated that L1 cytoplasmic foci 
formation is unaffected by the R261K mutation (Doucet et al. 2010). Thus, the 
R261K mutation does not affect formation of L1 RNPs, which suggests that this 
mutation affects some other aspect of L1 RNP function (e.g., nucleic acid 
chaperone activity). 
 ORF1 leucine zipper mutants (pLZC and pLZC/AA):  The third category of 
RNPs includes L1s with mutations in the putative LZC motif within the ORF1p CC 
domain (Figure 2.5B; type III RNPs). Compared to wild-type controls, LZC mutant 
RNPs contained less ORF1p and ORF2p (Figure 2.2B and (Hulme 2007, Doucet 
et al. 2010). Notably, LZC mutant RNPs also and exhibited a reduction in LEAP 
activity (Figure 2.2C and (Hulme 2007, Doucet et al. 2010). These results 
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suggested the possibilities that the LZC mutation in ORF1p affected the ability of 
ORF2p to localize to RNPs and/or to reverse transcribe L1 RNA. Notably, the 
ORF1p-ORF2p fusion peptide carrying the LZC defect was able to efficiently 
drive the retrotransposition of the ORF1mneoI reporter construct (Figure 2.4). 
The data therefore suggest that the LZC mutation in ORF1p does not impair 
ORF2p reverse transcriptase function because trans-complementation of RNA 
derived from the ORF1mneoI reporter is dependent on ORF2p reverse 
transcriptase activity (Wei et al. 2001, Alisch et al. 2006). Thus, the most 
parsimonious explanation of the data is that the ORF1p LZC mutation most likely 
impairs the localization of ORF1p and/or ORF2p to RNPs. These data suggest 
the possibility that a subtle interplay between the ORF1p and ORF2p proteins 
may exist, which if disturbed disrupts the formation of functional L1 RNPs. 
 A previous report presented genetic evidence suggesting that an 
engineered ORF1p-ORF2p fusion peptide could trans-mobilize ORF1mneoI 
(Alisch et al. 2006). In this study we have provided the first empirical evidence 
that a similar engineered ORF1p-ORF2p fusion peptide (p1K2_TAP) can be 
expressed in human cells and that it is capable of trans-mobilizing other cellular 
mRNAs (i.e., ORF1mneoI). We demonstrated that an ~190 kDa ORF1p-ORF2p 
fusion protein was expressed from p1K2_TAP in HeLa cell lysates (Figure 2.3B) 
and that it could actively promote the retrotransposition of RNA derived from the 
reporter plasmid ORF1mneoI (Figure 2.4B). Our data also suggested that free 
ORF1p is not expressed from p1K2_TAP and that the resulting ORF1p-ORF2p 
fusion peptide is not processed to liberate free ORF1p. Notably, we did not 
detect any evidence of an ORF1p-ORF2p fusion peptide from cells transfected 
with pAD2TE1 with either anti-ORF1p or anti-TAP antibodies (Figure 2.3B). 
Thus, these data are consistent with previous data suggesting that L1 translation 
does not produce an ORF1p-ORF2p fusion peptide (Leibold et al. 1990, McMillan 
and Singer 1993, Ergun et al. 2004, Alisch et al. 2006).  
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Methods 
Cell culture 
 HeLa cells were grown in high-glucose DMEM (Gibco) supplemented with 
10% FBS (Gibco), 100 U/mL penicillin-streptomycin (Invitrogen), and 0.29mg/mL 
L-glutamine (Gibco). Cell lines were maintained at 37°C with 7% CO2. 
Plasmid Constructs 
 The following plasmids are based on the previously described 
pJM101/L1.3 construct (Sassaman et al. 1997). The amino acid and nucleotide 
numbers indicate the mutation position based on L1.3 accession number L19088 
(Dombroski et al. 1993). The constructs were cloned into the pCEP4 expression 
vector (Invitrogen) and are equipped with the mneoI indicator cassette in the L1 
3’UTR unless otherwise indicated. Sub-cloning was used to introduce the TAP 
epitope tag sequences onto the 3’ end of ORF2. Because of this procedure, we 
deleted a portion of the L1 3’UTR (nucleotides 5818 to 5953). All plasmid DNA 
was prepared with a Midiprep Plasmid DNA Kit (QIAGEN). 
pDK101 is identical to pDK101, but contains the REKG235-238AAAA mutations in 
the ORF1p RRM domain (Moran et al. 1996, Kulpa and Moran 2005). 
pDK105 is identical to pDK101, but contains the RR261-262AA mutations in the 
ORF1p C-terminal domain (Moran et al. 1996, Wei et al. 2001, Kulpa and Moran 
2005) 
pDK106 is identical to pDK101, but contains the RR261-262KK mutations in the 
ORF1p C-terminal domain (Moran et al. 1996, Kulpa and Moran 2005). 
pDK108 is identical to pDK101, but contains the R262K mutation in the ORF1p C-
terminal domain (Moran et al. 1996, Kulpa and Moran 2005). 
pDK109 is identical to pDK101, but contains the R261K mutation in the ORF1p C-
terminal domain(Moran et al. 1996, Kulpa and Moran 2005). 
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pDK116 is identical to pDK101, but contains the YPAKLS282-287AAAALA 
substitution in the ORF1p C-terminal domain (Moran et al. 1996, Kulpa and 
Moran 2005).  
pDK135 is identical to pDK101, but contains the D702A mutation in the putative 
ORF2p RT active site (Moran et al. 1996, Wei et al. 2001, Kulpa and Moran 
2005). 
pDK136 is identical to pDK101, but contains the H230A mutation in the ORF2p 
EN domain (Moran et al. 1996, Wei et al. 2001, Kulpa and Moran 2005). 
pLZC: is identical to pDK101, but contains four leucine to valine mutations 
(L93,100,107,114V) in the ORF1p putative leucine zipper domain (Hulme 2007).  
pLZC/AA is identical to pDK105, but also contains four leucine to valine 
mutations (L93,100,107,114V; RR261-262AA) (Hulme 2007). 
pAD2TE1 is derived from pDK101 (L1.3) and contains both the T7 gene 10 
epitope tag on the carboxyl-terminus of ORF1p and a TAP tag on the carboxyl-
terminus of ORF2p (Doucet et al. 2010).  
pORF1mneoI consists of the L1 5' UTR, ORF1, and the spliced mneoI indicator 
cassette (Alisch et al. 2006). 
p1K2_TAP is derived from GP1AAA2 (Alisch et al. 2006) and contains a TAP tag 
on the carboxyl-terminus of ORF2p. John B. Moldovan (University of Michigan 
Medical School) constructed the plasmid. 
p1K2(RR-AA) is derived from p1K2_TAP, but contains the RR261-262AA mutations 
in the ORF1p C-terminal domain John B. Moldovan (University of Michigan 
Medical School) constructed the plasmid (Kulpa and Moran, 2005; Moran et al., 
1996; Wei et al., 2001). 
p1K2(LZC) is derived from p1K2_TAP, but contains four leucine to valine 
mutations (L93,100,107,114V) in the ORF1p putative leucine zipper domain John B. 
Moldovan (University of Michigan Medical School) constructed the plasmid.  
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p1K2(LZC/AA) is derived from p1K2_TAP, but contains a putative leucine zipper 
domain as well as a C-terminal domain mutant (L93,100,107,114V; RR261-262AA) in 
ORF1p. John B. Moldovan (University of Michigan Medical School) constructed 
the plasmid. 
p1K2(RF1) is derived from p1K2_TAP, except that the amino acids 1-255 have 
been deleted from ORF1p. John B. Moldovan (University of Michigan Medical 
School) constructed the plasmid. 
p1K2(S119X) is derived from p1K2_TAP, but contains a stop codon instead of a 
serine 119 of ORF1p (Moran et al. 1996). John B. Moldovan (University of 
Michigan Medical School) constructed the plasmid. 
pCEP/GFP, is a pCEP4-based plasmid that contains the humanized renilla green 
fluorescent protein (hrGFP) coding sequence from phrGFP-C (Stratagene) under 
the control of the pCEP4 CMV promoter (Alisch et al. 2006). 
The L1 retrotransposition assay 
 The cultured cell retrotransposition assay was conducted as described 
previously (Moran et al. 1996, Wei et al. 2000). Briefly, ~2x104 HeLa cells/well 
were plated in 6 well dishes. The next day, each well was transfected with 1 μg of 
plasmid DNA using 3 μL of FuGENE 6 transfection reagent (Roche). Three days 
post-transfection, cells were grown in the presence of G418 (400 μg/mL) to 
select for retrotransposition events. The media was changed daily. After ~12 
days of selection, the resultant cells were washed with 1X Phosphate-Buffered 
Saline (PBS), fixed, and stained with crystal violet to visualize colonies. In 
parallel, HeLa cells were plated in 6 well dishes and transfected with 0.5 μg of 
the same plasmids and pCEP4/GFP. Three days post-transfection cells were 
subjected to flow cytometry and the transfection efficiency was determined based 
on the number of GFP positive cells by FACS.  
Trans-complementation assay 
 The trans-complementation assay was performed as previously described 
(Wei et al. 2001). Briefly, HeLa cells were seeded in T-175 flasks (BD Falcon™) 
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at ~6×106 cells/flask and transfected the next day with 30 μg of plasmid DNA 
using 90 μL of FuGENE 6 transfection reagent (Roche). The next day, cells were 
co-transfected with equal amounts ORF1mneoI reporter plasmid and a driver L1 
that lacked the mneoI indicator cassette. Parallel co-transfection experiments of 
both plasmids plus pCEP/GFP were used to determine the transfection efficiency 
of each sample (see above). Seventy-two hours post-transfection, the HeLa cells 
were subjected to G418 selection (400 μg/mL). After 12-14 d of selection, the 
cells were fixed as described above, and the resultant G418-resistant colonies 
were counted to determine the trans-complementation efficiency 
Isolation of L1 RNPs and western blot analysis 
 Isolation of L1 RNPs has been described previously (Kulpa and Moran 
2005, Kulpa and Moran 2006). Briefly, HeLa cells were seeded in T-175 flasks 
(BD Falcon™) at ~6×106 cells/flask and transfected the next day with 30 μg of 
plasmid DNA using 90 μL of FuGENE 6 transfection reagent. Two days post-
transfection, hygromycin B (Gibco) (200 μg/mL) was added to the media to select 
for transfected cells. After one week of hygromycin selection, cells were 
harvested, lysed, and whole cell lysates were centrifuged at 1000 x g for 5 
minutes. The cleared whole cell lysates were then centrifuged through an 
8.5%/17% (w/v) sucrose cushion at 178,000 x g for 2 hours. The resultant pellet 
was resuspended with 100 μL dH2O + 1X Complete EDTA-free protease 
inhibitor cocktail (Roche). Bradford reagent (Bio-Rad) was used to determine 
protein concentration and the RNP sample was diluted to a final concentration of 
1.5 mg/mL. Proteins were detected by western blot using the following primary 
antibodies: mouse anti-T7-Tag (Novagen), rabbit anti-TAP (Open Biosystems), 
mouse anti-α-tubulin (Sigma), rabbit anti-S6 (Cell Signaling Technology). Goat 
anti-mouse, anti-rabbit and anti-rat HRP-conjugated secondary antibodies were 
purchased from GE/Amersham. Western blots were developed using either the 
pico or femto ECL substrate (Pierce) according to manufacturer’s protocols. 
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LEAP assay 
 The LEAP assay has been described previously(Kulpa and Moran 2006). 
Briefly, an aliquot (1 μL) of the RNP sample was added to 49 μL of LEAP assay 
master mix (50 mM Tris-HCL (pH=7.5), 50 mM KCl, 5 mM MgCl2, 10 mM DTT, 
0.4 μM 3’RACE adapter primer, 20U RNasin (Promega), 0.2 mM dNTPs, and 
0.05% (v/v) Tween 20) and was incubated at 37°C for 1 hour. LEAP cDNA 
products (1 μL) were amplified in a standard 50 μL PCR reaction containing 0.4 
μM of the 3’RACE outer primer and 0.4 μM of one of the following forward 
primers: L1 3’ end; Neo promoter sense; Neo8161S; LEAP-86; LEAP-46, using 
HotStart Pfu Turbo polymerase (Stratagene) according to the manufacturer’s 
protocol. The resultant products were visualized on 2% agarose gels. LEAP PCR 
products were isolated, cloned into the pCR-Blunt vector (Invitrogen), and 
sequenced to confirm their identity. 
RNA preparation and RT-PCR analysis 
 Total RNA was isolated using an RNeasy Kit (QIAGEN) coupled to an on-
column DNase treatment (QIAGEN). The isolated RNAs were resuspended in 
Ultrapure distilled water (GIBCO) and quantified using a Nanodrop 
spectrophotometer (Thermo Scientific). For the LEAP assay controls, RNA was 
isolated from 50 μL RNP sample (1.5 mg/mL). RT-PCR was performed on 0.5 μg 
total RNA using M-MLV reverse transcriptase (Promega) followed by PCR with 
primers specific to the transfected L1 constructs or GAPDH. HotStart Pfu Turbo 
polymerase (Stratagene) then was used to amplify the resultant cDNA according 
to the manufacturer’s instructions. The PCR protocol and the L1 and GAPDH 
oligonucleotide primers were previously described (Kulpa and Moran, 2006). 
Northern Blots 
 HeLa cells were seeded in T-175 flasks (BD Falcon™) at ~6×106 
cells/flask and transfected the next day with 30 μg of plasmid DNA using 90 μL of 
FuGENE 6 transfection reagent (Roche). Two days post-transfection, hygromycin 
B (Gibco) (200 μg/mL) was added to the media to select for transfected cells. 
After one week of hygromycin selection, cells were harvested, lysed, and RNA 
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was extracted with TRIzol® reagent (Ambion), and then poly(A)+ RNA was 
prepared from total RNA using an Oligotex mRNA kit (Qiagen). RNA samples 
were then subjected to glyoxal gel electrophoresis and northern blotting using the 
NorthernMax®-Gly Kit (Ambion) according to the manufactures protocol. 
Following electrophoresis, RNA was transferred to BrightStar® Nylon 
membranes (Invitrogen) and then cross-linked using UV light. For northern blot 
detection, membranes were prehybridized for ~4 hours at 68°C in NorthernMax® 
Prehybridization/Hybridization Buffer (Ambion), and then incubated with a strand 
specific RNA probe (final concentration of probe ~3×106 cpm ml-1) over night at 
68°C. 
 Strand-specific RNA probes were generated using the MAXIscript® T3 
system (Invitrogen). The 5UTR99 probe corresponds to bases 7-99 of the L1.3 5' 
UTR (Belancio et al. 2006) of the L1.3 sequence. RNA probe templates for T3 
reactions were generated by PCR using pJM101/L1.3Δneo as a PCR template 
with the following primers:  
5UTR99 (Forward): 5'-GGAGCCAAGATGGCCGAATAGGAACAGCT-3' 
5UTR99 (Reverse): 5'-AATTAACCCTCAAAGGGACCTCAGATGGAAATGCAG-
3'  
 The T3 promoter sequence (underlined) was added to the reverse primer 
of each primer pair. The pTRI-β-actin-125-Human Antisense Control Template 
(Applied Biosystems) was used in T3 reactions as a template to generate the β-
actin RNA probe. The northern blot experiment was conducted one time. 
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Figure 2.1: Schematic diagram of engineered human L1 constructs. 
The wild type human L1 construct, pDK101 expresses a human L1 (L1.3) 
(Sassaman et al. 1997) that contains a T7 gene10 epitope tag (blue flag) on the 
carboxyl-terminus of ORF1p. The pDK101 construct also contains an mneoI 
retrotransposition indicator cassette located within the L1 3' UTR.  A CMV 
promoter (black rectangle) augments L1 expression and an SV40 
polyadenylation signal (pA) is located downstream of the native L1 
polyadenylation signal. The mneoI cassette (red rectangle) is cloned into the L1 
3' UTR antisense to the L1 and contains a neomycin phosphotransferase gene 
that is disrupted by an intron flanked by splice donor (SD) and splice acceptor 
sites (SA) in the L1 sense orientation. The neomycin phosphotransferase gene 
can only be expressed when the L1 transcript is spliced, reverse transcribed, and 
inserted into genomic DNA (Moran et al. 1996, Wei et al. 2000). The approximate 
locations of the ORF1 coiled coil (CC), RNA recognition motif (RRM), and 
carboxyl-terminal (CTD) domains are indicated. The approximate locations of the 
ORF2p endonuclease (EN) domain  and the ORF2 reverse transcriptase (RT)  
domains are shown in the diagram. The approximate location of L1 mutations 
and the corresponding name of the mutant L1 plasmids are depicted on the 
diagram.  
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Figure 2.2: Mutations in ORF1p affect the formation of functional L1 RNPs. 
A) The effect of ORF1p mutations on L1 retrotransposition. The X-axis indicates 
the name of the L1 construct. The Y-axis indicates retrotransposition efficiency  
normalized to the wild type L1 control, pDK101 (black bars). Error bars represent 
standard deviations based on a single experiment with three technical replicates. 
Beneath the graph is a single well of a representative six-well tissue culture plate, 
displaying G418-resistant colonies from retrotransposition assays. (B) Mutations 
in ORF1p affect the localization of ORF1p to L1 RNPs. Western blots of HeLa 
cells transfected with the indicated L1 plasmids (top of blots). Anti-T7 antibodies 
were used to detect the T7-tagged ORF1p expressed from L1 plasmids. Top 
panel: Western blots from transfected HeLa cell crude RNP fractions (RNPs). 
Bottom panel: Western blots from transfected HeLa cell lysates. UTF = 
untransfected HeLa cells. Ribosomal protein S6 was used as a loading control. 
The red box indicates portion of gel image previously published (Doucet et al. 
2010). C)  LEAP assay results. Top panel: Approximately 20 μL of LEAP 
reactions from the indicated crude L1 RNP preps (top of gels) was loaded onto 
agarose gels. pDK135 contains mutations in the ORF2p RT domain that render 
the element unable to retrotranspose, NoRNP = LEAP reaction did not contain 
RNPs; NTC = PCR water control. Middle panel: M-MLV RT-PCR with L1 LEAP 
PCR primers serves as a positive control for the presence of L1 RNA in RNP 
preps. Blue arrow indicates L1 cDNA band. Bottom panel: GAPDH RT-PCR 
served as a loading control. Molecular size ladders are to the left of gels. The red 
box indicates portion of gel image previously published (Doucet et al. 2010). I 
conducted all experiments shown in Figure 2.2.  
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Figure 2.3: Characterization of an L1 ORF1p-ORF2p fusion peptide. 
A) Schematic of L1 ORF1p-ORF2p fusion construct (p1K2_TAP). p1K2_TAP 
was constructed by deleting the 63 bp spacer between ORF1 and ORF2 and 
mutating the ORF1 stop codon to a lysine (K) residue (green rectangle). The 
fusion construct is cloned into a pCEP4 mammalian expression vector and 
contains a TAP epitope tag (yellow flag) on the carboxyl-terminus of ORF2p to 
facilitate detection of the fusion peptide using anti-TAP antibodies. The 
expression of p1K2_TAP is augmented by the pCEP4 CMV promoter (black 
rectangle). The approximate locations of  mutations with corresponding name of 
the mutant fusion constructs are mapped onto the p1K2_TAP diagram. B) The 
ORF1p-ORF2p fusion peptide is expressed in HeLa cells. HeLa cells were 
transfected with the indicated construct and RNPs were analyzed for the 
presence of the ORF1p-ORF2p fusion peptide using anti-TAP (top panel) or anti-
ORF1p (bottom panel) antibodies. Green arrow indicates ORF1p-ORF2p fusion 
protein band; blue arrow indicates ORF2p-TAP protein band; red arrow indicates 
ORF1p-T7 protein band. Smaller bands in the p1K2_TAP lane of top panel may 
represent smaller TAP-tagged peptides (see main text) C) Deletion of the amino-
terminal amino acids (1-255) of ORF1p results in a proportional decrease in size 
of the 1K2 fusion peptide. RNPs from transfected HeLa cells transfected with the 
indicated 1K2 fusion constructs (top of blots) were analyzed using anti-TAP 
antibodies. Red arrow indicates the approximate location of the p1K2(RF1) 
fusion peptide (~160 kDa). Tubulin was used as a loading control. D) Northern 
blot results of 1K2 fusion RNA. Top panel: Northern blots using a probe to the L1 
5' UTR (5UTR99) was used to detect L1 RNA from poly-adenosine+ RNA 
extracted from HeLa cells transfected with the indicated constructs (above blots). 
Bottom panel: actin loading control northern blots. Blue arrow indicates L1 RNA. 
HeLa UTF = untransfected HeLa cells. E) Mutations in ORF1p do not affect the 
expression of the ORF1p-ORF2p fusion peptide. RNPs from transfected HeLa 
cells were analyzed with an anti-TAP antibody. Green arrow indicates ORF1p-
ORF2p fusion protein band; blue arrow indicates ORF2p-TAP protein band. 
Tubulin was used as a loading control. 
  
 96 
 
  
 97 
 
Figure 2.4: The effect of ORF1p mutations on 1K2 fusion trans-
complementation efficiency. 
(A) Schematic of the trans-complementation assay. HeLa cells are co-transfected 
with a driver L1 construct (i.e., p1K2_TAP) and the ORF1mneoI reporter 
construct, which carries a neomycin retrotransposition indicator cassette (mneoI). 
L1 driver constructs are not marked with mneoI indicator cassette. Successful 
trans-complementation of ORF1mneoI will confer G418 resistance to transfected 
cells. (B) Results of trans-complementation assay. The X-axis indicates the L1 
driver construct that was co-transfected with ORF1mneoI. The Y-axis on the 
graph indicates trans-complementation efficiency (black bars). Trans-
complementation efficiency values have been normalized to p1K2_TAP wild type 
controls (set to 100%). The number above each bar indicates the number of 
independent experiments (n) performed with each L1 driver construct. Error bars 
represent standard deviations. 
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Figure 2.5: Classification of ORF1p mutant L1 RNPs. 
 A) Wild type L1 RNPs (pDK101, pDK108): Robust localization of L1 ORF1p 
(blue circles), ORF2p (yellow circle), and RNA (black wavy line) to RNPs;  robust 
LEAP activity. B) TYPE I (RNA binding mutants: pDK103, pDK105, pDK116, 
pAD500): ORF1p fails to localize to L1  RNPs; RNPs contain wild type levels of 
ORF2p and exhibit wild type LEAP activity levels with an impairment in L1 RNA 
reverse transcription fidelity (i.e., L1 reverse transcription can initiate from within  
internal L1 sequences).  C) TYPE II (chaperone activity mutants: pDK106, 
pDK109): RNPs contain wild type levels of L1-encoded proteins and exhibit wild 
type LEAP activity. D) TYPE III (leucine zipper mutants: pLZC, pLZC/AA): Failure 
of ORF1p and ORF2p to localize to RNPs; decreased LEAP activity likely due to 
failure of ORF2p to localize to RNPs. Red-hatched box encloses L1 mutants that 
are not capable of retrotransposition.  
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Chapter 3 
 
The zinc-finger antiviral protein ZAP inhibits LINE and Alu 
retrotransposition 
 
 The research in this chapter was recently published as an article in PLOS 
Genetics (Moldovan and Moran 2015), and is presented here with only minor 
modifications to meet thesis formatting requirements. Use of the original article is 
in strict accordance with PLoS  journal policies and the  Creative Commons 
Attribution (CC BY) license (http://creativecommons.org/licenses/by/4.0/). I 
designed and carried out all experiments described in this chapter.  
 
Abstract 
 Long INterspersed Element-1 (LINE-1 or L1) is the only active 
autonomous retrotransposon in the human genome. To investigate the interplay 
between the L1 retrotransposition machinery and the host cell, we used co-
immunoprecipitation in conjunction with liquid chromatography and tandem mass 
spectrometry to identify cellular proteins that interact with the L1 first open 
reading frame-encoded protein, ORF1p. We identified 39 ORF1p-interacting 
candidate proteins including the zinc-finger antiviral protein (ZAP or ZC3HAV1). 
Here we show that the interaction between ZAP and ORF1p requires RNA and 
that ZAP overexpression in HeLa cells inhibits the retrotransposition of 
engineered human L1 and Alu elements, an engineered mouse L1, and an 
engineered zebrafish LINE-2 element. Consistently, siRNA-mediated depletion of 
endogenous ZAP in HeLa cells led to an ~2-fold increase in human L1 
retrotransposition. Fluorescence microscopy in cultured human cells 
demonstrated that ZAP co-localizes with L1 RNA, ORF1p, and stress granule 
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associated proteins in cytoplasmic foci. Finally, molecular genetic and 
biochemical analyses indicate that ZAP reduces the accumulation of full-length 
L1 RNA and the L1-encoded proteins, yielding mechanistic insight about how 
ZAP may inhibit L1 retrotransposition. Together, these data suggest that ZAP 
inhibits the retrotransposition of LINE and Alu elements. 
 
Introduction 
 Long INterspersed Element-1 (LINE-1, also known as L1) sequences 
comprise ~17% of human DNA and represent the only class of autonomously 
active retrotransposons in the genome (Lander et al. 2001). L1s mobilize (i.e., 
retrotranspose) throughout the genome via an RNA intermediate by a copy-and-
paste mechanism known as retrotransposition (reviewed in Beck et al. 2011). 
The overwhelming majority of human L1s are retrotransposition-deficient 
because they are 5' truncated, contain internal rearrangements (i.e., 
inversion/deletion events), or harbor point mutations that compromise the 
functions of the L1-encoded proteins (ORF1p and ORF2p) (Grimaldi et al. 1984, 
Lander et al. 2001). Despite these facts, it is estimated that the average diploid 
human genome contains ~80-100 L1 elements that are capable of 
retrotransposition (Sassaman et al. 1997, Brouha et al. 2003, Beck et al. 2010). It 
is estimated that a new L1 insertion occurs in approximately 1 out of 200 live 
human births (reviewed in Cordaux and Batzer 2009). On occasion, L1 
retrotransposition events can disrupt gene expression, leading to diseases such 
as hemophilia A (Kazazian et al. 1988), Duchenne muscular dystrophy (Holmes 
et al. 1994), and cancer (Miki et al. 1992, Shukla et al. 2013). Indeed, L1-
mediated retrotransposition events are responsible for at least 96 disease-
producing insertions in man (reviewed in Hancks and Kazazian 2012). 
 A full-length human L1 is ~6 kb in length and encodes a 5' UTR that 
harbors an internal RNA polymerase II promoter that directs transcription from at 
or near the first base of the element (Swergold 1990, Becker et al. 1993, 
Athanikar et al. 2004). The 5' UTR is followed by two open reading frames 
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(ORFs) that are separated by a short 63 bp inter-ORF spacer, and a 3' UTR that 
ends in a variable length poly adenosine (poly(A)) tract (Scott et al. 1987, 
Dombroski et al. 1991). The first L1 ORF encodes an ~40 kDa protein (ORF1p) 
that has nucleic acid binding (Martin 1991, Holmes et al. 1992, Hohjoh and 
Singer 1996, Hohjoh and Singer 1997, Khazina and Weichenrieder 2009) and 
nucleic acid chaperone activities (Martin and Bushman 2001, Khazina and 
Weichenrieder 2009). The second L1 ORF encodes a much larger ~150 kDa 
protein (ORF2p) (Ergun et al. 2004, Doucet et al. 2010, Goodier et al. 2010), 
which exhibits single-strand endonuclease (EN) (Feng et al. 1996) and reverse 
transcriptase (RT) (Mathias et al. 1991, Dombroski et al. 1994) activities. 
Experiments in cultured cells have revealed that activities associated with both 
ORF1p and ORF2p are required for efficient L1 retrotransposition (Feng et al. 
1996, Moran et al. 1996).  
 During a cycle of L1 retrotransposition, a full-length L1 is transcribed and 
the resultant bicistronic L1 mRNA is exported to the cytoplasm where it 
undergoes translation. Notably, L1 RNA is translated in a cap-dependent manner 
by an unconventional termination-reinitiation mechanism that facilitates 
translation of both L1 ORFs (Leibold et al. 1990, McMillan and Singer 1993, 
Alisch et al. 2006, Dmitriev et al. 2007). Following translation, ORF1p and 
ORF2p preferentially bind to their respective encoding L1 mRNA template (a 
phenomenon known as cis-preference (Esnault et al. 2000, Wei et al. 2001)) to 
form an L1 ribonucleoprotein particle (RNP) (Martin 1991, Hohjoh and Singer 
1996, Kulpa and Moran 2005, Kulpa and Moran 2006, Doucet et al. 2010). 
Components of the L1 RNP gain access to the nucleus by a process that does 
not strictly require cell division (Kubo et al. 2006), although L1 retrotransposition 
seems to be enhanced in dividing cells (Shi et al. 2007, Xie et al. 2013). Once 
the L1 RNP has entered the nucleus, the L1 RNA is reverse transcribed and 
inserted into genomic DNA by a process known as target-site primed reverse 
transcription (TPRT) (Luan et al. 1993, Feng et al. 1996, Cost et al. 2002). 
Briefly, the ORF2p endonuclease generates a single-strand endonucleolytic nick 
in genomic DNA at a thymidine rich consensus sequence (e.g., 5'-TTTT/A, 5'-
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TCTT/A, 5'-TTTA/A, etc.) (Feng et al. 1996, Cost and Boeke 1998, Morrish et al. 
2002). The resulting 3' hydroxyl group then is used by the ORF2p reverse 
transcriptase as a primer to initiate (-) strand L1 cDNA synthesis from the L1 
mRNA template (Feng et al. 1996, Cost and Boeke 1998). The completion of L1 
integration requires elucidation, but likely involves host proteins involved in DNA 
repair and/or replication (Morrish et al. 2002, Gilbert et al. 2005, Suzuki et al. 
2009, Taylor et al. 2013). Notably, the L1-encoded proteins also can work in 
trans to retrotranspose other cellular RNAs such as Short Interspersed Elements 
(SINEs) (e.g., Alu (Dewannieux et al. 2003) and SINE-R/VNTR/Alu (SVA) 
elements (Ostertag et al. 2003, Hancks et al. 2011, Raiz et al. 2012)). L1 also 
can mobilize uracil-rich small nuclear RNAs (e.g., U6 snRNA (Buzdin et al. 2002, 
Gilbert et al. 2005, Garcia-Perez et al. 2007), small nucleolar RNAs (e.g., U3 
snoRNA (Weber 2006)), and messenger RNAs, which results in the formation of 
processed pseudogenes (Esnault et al. 2000, Wei et al. 2001)). 
 Since L1 retrotransposition can be mutagenic, it stands to reason that the 
host cell employs multiple mechanisms to restrict L1 mobilization (reviewed in 
Levin and Moran 2011). For example, cytosine methylation of the L1 5' UTR 
suppresses L1 expression (Yoder et al. 1997, Bourc'his and Bestor 2004). In 
addition, piwi-interacting RNAs (piRNAs) suppress L1 expression in germ line 
cells (Aravin et al. 2007, reviewed in Levin and Moran 2011, and Siomi et al. 
2011). Finally, emerging studies have demonstrated that several cellular proteins 
restrict L1 retrotransposition. These proteins include several APOBEC3 family 
members ( reviewed in Schumann 2007, Richardson et al. 2014), TREX1 
(Stetson et al. 2008), MOV10 (Arjan-Odedra et al. 2012, Goodier et al. 2012, Li 
et al. 2013), hnRNPL (Peddigari et al. 2013), SAMHD1 (Zhao et al. 2013), RNase 
L (Zhang et al. 2014), and the melatonin receptor 1 (MT1) (deHaro et al. 2014).  
 To gain a more complete understanding of the interplay between the L1 
retrotransposition machinery and the host cell, we used liquid chromatography-
tandem mass spectrometry (LC-MS/MS) to identify proteins that co-
immunoprecipitate with L1 ORF1p in HeLa cells, reasoning that some of these 
proteins may affect L1 retrotransposition.  We next analyzed the effects of 
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ORF1p-interacting proteins on L1 retrotransposition by overexpressing a subset 
of them in a cultured cell retrotransposition assay (Moran et al. 1996, Wei et al. 
2000). Here, we report that the zinc-finger antiviral protein ZAP (Gao et al. 2002) 
interacts with L1 RNPs and inhibits L1 retrotransposition in cultured cells. ZAP 
also inhibits human Alu retrotransposition and the retrotransposition of mouse 
and zebrafish LINE elements. Molecular genetic and biochemical analyses 
suggest that ZAP inhibits retrotransposition by suppressing the accumulation of 
full-length L1 RNA and L1-encoded proteins in the cell. 
 
Results 
Identification of L1 ORF1p-interacting proteins 
 To identify proteins that interact with L1 ORF1p, we transfected HeLa cells 
with a human L1 construct, pJM101/L1.3FLAG, which expresses a version of 
ORF1p containing a FLAG epitope at its carboxyl-terminus (ORF1p-FLAG) 
(Figure 3.1A). The pJM101/L1.3FLAG construct exhibits robust retrotransposition 
activity in HeLa cells, albeit at a lower efficiency (~50%) than the untagged L1 
construct, pJM101/L1.3 (Figure 3.8A).  
Briefly, HeLa cells were transfected with pJM101/L1.3FLAG or 
pJM101/L1.3, a similar construct that lacks the FLAG epitope sequence (Figure 
3.1A). Whole cell lysates from transfected cells then were incubated with anti-
FLAG coated agarose beads to immunoprecipitate ORF1p-FLAG (see Methods). 
Immunoprecipitated fractions were analyzed by SDS-PAGE and proteins were 
visualized by silver staining (Figure 3.1B). The analysis of silver-stained gels 
revealed a prominent band of ~40 kDa (the theoretical molecular weight of 
ORF1p) in the pJM101/L1.3FLAG immunoprecipitation lane (Figure 3.1B; 
asterisk), which was not apparent in the pJM101/L1.3 lane. Western blot analysis 
with an antibody specific to L1.3 ORF1p (amino acids 31-49) confirmed the 
enrichment of ORF1p-FLAG in the pJM101/L1.3FLAG lane (Figures 3.1C and 
3.8B; bottom panel). We also observed a complex pattern of bands between ~25 
kDa and ~150 kDa that was present in the pJM101/L1.3FLAG lane that was not 
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evident in the pJM101/L1.3 lane (Figure 3.1B; black vertical bars). A similar 
pattern of protein bands was produced on silver-stained gels from 
pJM101/L1.3FLAG immunoprecipitation reactions using different wash and/or 
lysis conditions (Figures 3.8B and 3.8C, respectively). 
 To determine the identity of cellular proteins that associated with ORF1p-
FLAG, the bands from the lanes corresponding to the pJM101/L1.3FLAG and 
pJM101/L1.3 immunoprecipitation experiments were excised from SDS-PAGE 
gels and submitted for LC-MS/MS (see Methods). An LC-MS/MS-identified 
protein was selected as an ORF1p-interacting candidate if it met the following 
criteria: 1) the protein was unique to the pJM101/L1.3FLAG immunoprecipitation, 
and 2) the protein was identified by two or more unique peptide sequences 
(peptide error rate ≤ 0.05; protein probability ≥ 0.95) (Table 3.1 and Methods). 
Thirty-nine ORF1p-interacting protein candidates were identified that met these 
criteria (Table 3.1).   
To confirm the interactions between LC-MS/MS-identified proteins and 
ORF1p-FLAG, we evaluated 13 of the 39 ORF1p-FLAG interacting proteins for 
which there were commercially available antibodies and/or cDNA expression 
clones. Western blot analyses confirmed that these proteins associated with 
ORF1p-FLAG (Figure 3.1D). The 13 ORF1p-interacting proteins are involved in a 
variety of cellular processes including antiviral defense (ZAP (Gao et al. 2002) 
and MOV10 (Burdick et al. 2010)), nonsense-mediated decay (UPF1 (Leeds et 
al. 1991)), RNA splicing (hnRNPL (Hui et al. 2003) and DHX9 (Kernan et al. 
1991, Kuroda et al. 1991)), and transcription (PURA (Bergemann et al. 1992), 
CDK9 (Grana et al. 1994), and ILF3 (Kao et al. 1994)). Notably, gene ontology 
(Ashburner et al. 2000) and global analyses of RNA binding proteins in human 
cell lines (Baltz et al. 2012, Castello et al. 2012) revealed that the 13 validated 
ORF1p-FLAG interacting proteins are RNA binding proteins (RBPs). 
Consistently, immunoprecipitation experiments of ORF1p-FLAG conducted in the 
presence of RNaseA revealed that the association between ORF1p and each of 
the 13 ORF1p-interacting proteins was sensitive to RNase A treatment (Figure 
3.1D). Thus, the majority of ORF1p-interacting proteins associate with ORF1p by 
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binding to L1 RNA and/or other RNAs present within the L1 RNP (Mandal et al. 
2013).  
ORF1p-interacting proteins restrict L1 retrotransposition in HeLa cells 
 We next investigated whether overexpression of nine of the validated 
ORF1p-interacting proteins, as well as nine unvalidated ORF1p-interacting 
proteins, affects L1 retrotransposition (Moran et al. 1996, Wei et al. 2000). 
Briefly, HeLa cells were co-transfected with a cDNA plasmid expressing one of 
the ORF1p-FLAG interacting proteins and an engineered human L1 construct 
(pJJ101/L1.3; (Kopera et al. 2011)) marked with a blasticidin retrotransposition 
indicator cassette (mblastI) (Figures 3.2A and 3.2B; top panel). The mblastI 
cassette contains an antisense copy of the blasticidin deaminase gene, which is 
cloned into the L1 3' UTR. The blasticidin deaminase gene also is interrupted by 
an intron in the same transcriptional orientation as L1. This arrangement ensures 
that the blasticidin deaminase gene is expressed only when the L1 transcript is 
spliced, reverse transcribed, and inserted into genomic DNA. The resulting 
blasticidin-resistant foci then provide a visual, quantitative readout of 
retrotransposition activity (Moran et al. 1996, Morrish et al. 2002).  
 To monitor potentially toxic side effects of cDNA overexpression, HeLa 
cells also were co-transfected in a parallel assay with a cDNA expression vector 
and a control plasmid (pcDNA6/TR) that expresses the blasticidin deaminase 
gene (Figure 3.2B; bottom panel). Following blasticidin selection, the resulting 
foci provide a visual, quantitative readout of the effect of cDNA overexpression 
on colony formation (Figure 3.2B; bottom panel). This control is essential to 
determine if a cDNA affects L1 retrotransposition or cell viability and/or growth.   
 We co-transfected HeLa cells with each of the 18 ORF1p-FLAG 
interacting candidates and pJJ101/L1.3 (Figure 3.2C). An empty pCEP4 vector 
that was co-transfected with pJJ101/L1.3 served as a normalization control 
(Figures 3.2B and 3.2C). As a negative control, we demonstrated that a plasmid 
that expresses the humanized renilla green fluorescence protein (pCEP/GFP) did 
not affect pJJ101/L1.3 retrotransposition. As a positive control, we demonstrated 
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that a plasmid that expresses human APOBEC3A (pK_A3A) reduced 
pJJ101/L1.3 retrotransposition to ~18% of control levels (Figure 3.2C), which is in 
agreement with previous studies (Bogerd et al. 2006, Chen et al. 2006, 
Muckenfuss et al. 2006, Richardson et al. 2014). Four of the cDNA-expressing 
plasmids that we tested (ZAP-S (ZAP short isoform), hnRNPL, MOV10, and 
PURA) each reduced pJJ101/L1.3 retrotransposition to less than 50% of pCEP4 
control levels. Notably, ZAP-S (~30% of control), hnRNPL (~30% of control), 
MOV10 (~13% of control), and PURA (~10% of control) inhibited 
retrotransposition to levels similar to that of pK_A3A (~18% of control) (Figure 
3.2C). By comparison, the majority of the cDNA-expressing plasmids (14/18) did 
not significantly affect pJJ101/L1.3 retrotransposition levels (less than 50% 
inhibition when compared to pCEP4 control levels) (Figure 3.2C). Thus, the data 
suggest that ZAP-S, hnRNPL, MOV10, and PURA inhibit L1 retrotransposition in 
cultured cells. 
ZAP inhibits L1 retrotransposition 
  The above data (Figure 3.2C) imply that ZAP, hnRNPL, MOV10, and 
PURA may function as host factors that restrict L1 retrotransposition. Notably, 
hnRNPL (Peddigari et al. 2013), MOV10 (Arjan-Odedra et al. 2012, Goodier et al. 
2012), and PURA (Goodier et al. 2013) previously were shown to inhibit L1 
retrotransposition. However, the effect of ZAP on L1 retrotransposition has not 
been studied; thus, we sought to determine how ZAP inhibits L1 
retrotransposition.  
 ZAP is a poly (ADP-ribose) polymerase (PARP) family member (Kerns et 
al. 2008) initially characterized as an antiviral protein that inhibits murine 
leukemia virus (MLV) replication in cultured rat cells (Gao et al. 2002). Previous 
studies identified two human ZAP isoforms that resulted from alternative splicing 
(Kerns et al. 2008) (Figure 3.3A; top panel). The long ZAP isoform (ZAP-L) is 902 
amino acids in length and contains an amino-terminus CCCH zinc-finger domain 
and an inactive carboxyl-terminal PARP-like domain (Kerns et al. 2008). The 
short ZAP isoform (ZAP-S) is 699 amino acids in length and lacks the carboxyl-
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terminal PARP-like domain (Kerns et al. 2008). The HA-tagged human ZAP-L 
isoform restricted pJJ101/L1.3 retrotransposition to ~40% of control levels 
(Figure 3.3A; black bars) and the human ZAP-S isoform restricted pJJ101/L1.3 
retrotransposition to ~30% of control levels (Figures 3.2C and 3.3A; black bars). 
Notably, overexpression of ZAP-L or ZAP-S did not dramatically affect the ability 
of HeLa cells to form blasticidin-resistant colonies in pcDNA6/TR control assays 
(Figure 3.3A, white bars). Western blot control experiments confirmed the 
overexpression of ectopic ZAP-L and ZAP-S compared to untransfected controls 
~48 hours post-transfection (Figures 3.9A and 3.9B). Thus, ZAP inhibits L1 
retrotransposition in cultured cells and the ZAP-L PARP-like domain is not 
required for L1 restriction.  
Putative ZAP orthologs are present in several species (Kerns et al. 2008); 
thus, we tested whether a rat ZAP cDNA (rZAP) (Gao et al. 2002), that is 
orthologous to human ZAP-S (Gao et al. 2002, Kerns et al. 2008) could restrict 
pJJ101/L1.3 retrotransposition. Overexpression of rZAP efficiently reduced 
retrotransposition to ~40% of control levels (Figure 3.3A; black bars). Thus, the 
ability to restrict L1 retrotransposition is not limited to human ZAP.  
The ZAP zinc-finger domain is necessary and sufficient to inhibit L1 
retrotransposition 
 The ZAP zinc-finger domain binds to RNA and is required for antiviral 
activity (Guo et al. 2004, Chen et al. 2012). To analyze the role of the ZAP zinc-
finger domain in L1 restriction, we tested the effects of a truncated ZAP-S mutant 
that expresses the ZAP zinc-finger domain (ZAP-S/1-311; containing amino acids 
1-311) as well as a ZAP-S mutant that lacks the zinc-finger domain (ZAP-S/Δ72-
372; lacking amino acids 72-372) in pJJ101/L1.3 retrotransposition assays 
(Figure 3.3A; above graph). ZAP-S/1-311 restricted retrotransposition to ~10% of 
control levels (Figure 3.3A; black bars), whereas ZAP-S/Δ72-372 had little effect 
on retrotransposition (~80% of control levels) (Figure 3.3A; black bars). The 
overexpression of the wild type or mutant ZAP-S/Δ72-372 expression constructs 
did not adversely affect the ability of HeLa cells to form blasticidin-resistant 
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colonies in pcDNA6/TR control assays (Figure 3.3A; white bars). Notably, 
transfection with ZAP-S/1-311 resulted in an ~50% decrease in the ability of 
HeLa cells to form blasticidin-resistant colonies; however, this effect has been 
accounted for through normalization (Figure 3.2B) and thus is independent of the 
ability of ZAP-S/1-311 to restrict L1 retrotransposition. Indeed, similar off-target 
effects have been reported for A3A cDNA expressing plasmids in HeLa cell-
based L1 retrotransposition assays (Richardson et al. 2014). Western blot control 
experiments revealed that wild-type ZAP-S and the two mutant ZAP-S isoforms 
were expressed at similar levels ~48 hours post-transfection (Figures 3.9B and 
3.9C). Thus, the ZAP zinc-finger domain is necessary and sufficient to inhibit L1 
retrotransposition.  
ZAP restricts the retrotransposition of various non-LTR retrotransposons 
To determine if ZAP-S was able to restrict other non-long terminal repeat 
(non-LTR) retrotransposons, we tested whether ZAP-S expression affected 
human Alu retrotransposition. Unlike L1, Alu is a 7SL-derived non-autonomous 
retrotransposon that does not encode its own proteins (Ullu and Tschudi 1984). 
Instead, Alu elements must parasitize L1 ORF2p in trans to mediate their 
retrotransposition (Dewannieux et al. 2003). Briefly, HeLa cells were co-
transfected with a full-length L1 element (pJM101/L1.3Δneo), an Alu 
retrotransposition reporter plasmid (pAluneoTet), and a ZAP-S expression 
plasmid. Notably, ZAP-S potently reduced Alu retrotransposition to ~25% of 
control levels (Figure 3.3B). In contrast, the expression of the L1 restriction-
deficient ZAP-S/Δ72-372 mutant did not negatively affect Alu retrotransposition 
(Figure 3.3B). Thus, ZAP-S is able to restrict the mobility of the two most prolific 
retrotransposons present in the human genome. 
We next tested if human ZAP-S could restrict the retrotransposition of a 
natural mouse L1 (pGF21) (Goodier et al. 2001), a zebrafish LINE-2 (pZfL2-2) 
(Sugano et al. 2006), or a synthetic mouse L1 (pCEPsmL1) (Han and Boeke 
2004) that has been extensively mutagenized to alter 24% of the nucleic acid 
sequence without disrupting amino acid sequence. Human ZAP-S inhibited the 
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retrotransposition of human L1 (pJM101/L1.3; ~43% of control levels), natural 
mouse L1 (pGF21; ~24% of control levels), zebrafish L2 (pZfL2-2; ~19% of 
control levels), and synthetic mouse L1 (pCEPsmL1; ~70% of control levels) 
(Figure 3.3C). The restriction-defective ZAP-S mutant, ZAP-S/Δ72-372, did not 
significantly affect the retrotransposition activity of these retrotransposons (Figure 
3.3C). Notably, the milder inhibition of ZAP-S on pCEPsmL1 may be due to the 
elevated efficiency of pCEPsmL1 retrotransposition, the increased steady-state 
level of pCEPsmL1 mRNA and proteins, and/or the GC-rich nature of pCEPsmL1 
(Han and Boeke 2004). Thus, ZAP-mediated restriction of retrotransposition is 
not specific to human non-LTR retrotransposons. 
Depletion of endogenous ZAP enhances L1 retrotransposition 
 To test if endogenous ZAP restricts L1 retrotransposition, we used small 
interfering RNA (siRNA) to deplete endogenous ZAP from HeLa cells. Following 
siRNA treatment, cells were transfected with an L1 plasmid (pLRE3-mEGFPI) 
tagged with an EGFP indicator cassette (mEGFPI), which allows 
retrotransposition activity to be detected by EGFP fluorescence (Ostertag et al. 
2000). As a negative control, HeLa cells were transfected with the L1 
retrotransposition-defective plasmid pJM111-LRE3-mEGFPI, which carries two 
missense mutations that adversely affect ORF1p RNA binding (Moran et al. 
1996, Martin et al. 2005, Khazina and Weichenrieder 2009). Treatment of HeLa 
cells with an siRNA pool against ZAP resulted in an ~80% and ~90% reduction of 
ZAP-L and ZAP-S protein levels, respectively, when compared to HeLa cells 
treated with a non-targeting control siRNA pool (Figure 3.3D; top left panel). ZAP 
siRNA treatment led to an approximately two-fold increase in pLRE3-mEGFPI 
retrotransposition activity when compared to assays conducted in the presence 
of a control siRNA (Figures 3.3D; bottom panel and 3.9D). We further 
demonstrated that siRNA-mediated depletion of endogenous MOV10 (Figure 
3.3D; top right panel) from HeLa cells resulted in an approximately two-fold 
increase in pLRE3-mEGFPI retrotransposition (Figures 3.3D; bottom panel and 
3.9D), which is in agreement with previous studies (Arjan-Odedra et al. 2012, 
 115 
Goodier et al. 2012). These data suggest that endogenous ZAP may restrict L1 
retrotransposition. 
ZAP-S inhibits the accumulation of full-length LINE-1 mRNA  
 To investigate how ZAP restricts L1 retrotransposition, we analyzed the 
effect of ZAP-S expression on the accumulation of the L1 RNA. HeLa cells were 
co-transfected with pJM101/L1.3Δneo and either ZAP-S or ZAP-S/Δ72-372. 
Polyadenylated RNA from whole cell extracts then was analyzed by northern blot 
using RNA probes complementary to sequences within the L1.3 5' UTR 
(5UTR99) and ORF2 (ORF2_5804) (Figure 3.4A). Co-transfection with ZAP-S 
resulted in a reduction of full-length polyadenylated L1 RNA levels (~13% of 
pCEP4 control) compared to cells co-transfected with either the restriction-
defective ZAP-S/Δ72-372 (~47% compared to pCEP4 control) or an empty 
pCEP4 control vector (Figure 4B; black arrow in blot; black bars in graph). 
Interestingly, ZAP-S expression did not have a pronounced effect on the 
accumulation of smaller L1 RNA species, which may have resulted from cryptic 
splicing and/or premature polyadenylation (Figure 3.4B; top panel: blue and 
yellow arrows, bottom panel: blue and yellow bars) (Perepelitsa-Belancio and 
Deininger 2003, Belancio et al. 2006, Belancio et al. 2008). Finally, control 
experiments revealed that ectopic ZAP-S expression did not affect endogenous 
actin RNA levels (Figure 3.4B). Thus, ZAP-S expression reduces the 
accumulation of full-length L1 mRNA in cultured cells. 
ZAP-S inhibits the accumulation of ORF1p and ORF2p  
 We next examined the effect of ZAP-S expression on the accumulation of 
ORF1p and ORF2p. We co-transfected HeLa cells with either ZAP-S or ZAP-
S/Δ72-372 and the L1 plasmid, pJBM2TE1, which expresses an L1.3 element 
marked with a T7 gene10 epitope tag on the carboxyl-terminus of ORF1p and a 
TAP epitope-tag on the carboxyl-terminus of ORF2p (Figure 3.4C). Following co-
transfection, HeLa cells were treated with puromycin to select for cells 
expressing pJBM2TE1. Both whole cell lysates (WCL) and RNP fractions were 
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collected 5 days post-transfection and subjected to western blot analyses to 
monitor ORF1p and ORF2p expression levels.  
Expression of ZAP-S led to a decrease in the level of ORF1p and ORF2p 
in both WCL and RNP fractions, whereas the expression of the restriction-
defective ZAP-SΔ/72-372 mutant or an empty pcDNA3 vector did not 
dramatically affect ORF1p or ORF2p expression levels (Figure 3.4D). The 
reduction in ORF1p and ORF2p was most evident in the RNP fraction, likely 
because both ORF1p and ORF2p are enriched in RNPs (Hohjoh and Singer 
1996, Hohjoh and Singer 1997, Kulpa and Moran 2005, Kulpa and Moran 2006, 
Doucet et al. 2010). Control experiments revealed that ZAP-S expression did not 
affect the level of eIF3 protein (Figure 3.4D) and that ZAP-S and ZAP-S/Δ72-372 
are expressed at similar levels in whole cell lysates (Figure 3.4D: top WCL 
panel).  By comparison, ZAP-SΔ/72-372 is present at much lower levels in the 
RNP fraction compared to wild-type ZAP-S (Figure 3.4D; bottom RNP panel), 
suggesting that the zinc-finger domain is responsible for ZAP-S localization to the 
RNP fraction.  
 To determine if ZAP-S affects the expression of non-L1 proteins, we 
examined the effect of ZAP-S on EGFP expression. We co-transfected ZAP-S 
with an L1 plasmid (pLRE3-EF1-mEGFPΔIntron) (Wissing et al. 2011) that 
expresses the L1 element, LRE3 and an intact copy of the EGFP gene (Figure 
3.10A). In this case, LRE3 and EGFP are under the control of convergent 
promoters, which allows the simultaneous expression of LRE3 and EGFP from 
pLRE3-EF1-mEGFPΔIntron. Thus, EGFP expression is not dependent on 
retrotransposition. Forty-eight hours post-transfection, flow cytometry was used 
to isolate EGFP-positive cells (i.e., cells expressing pLRE3-EF1-mEGFPΔIntron) 
(Figure 3.10C). Western blotting demonstrated a marked reduction in ORF1p 
when compared to EGFP levels in cells that were co-transfected with ZAP-S 
(Figure 3.10B). By comparison, ORF1p and EGFP were present at comparable 
levels in cells that were co-transfected with either an empty pCEP4 vector or the 
restriction-deficient ZAP-SΔ/72-372 mutant (Figure 3.10B). Control experiments 
revealed that ZAP-S did not affect endogenous tubulin protein levels (Figure 
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3.10B). Thus, ZAP-S expression appears to preferentially restrict the expression 
of L1 ORF1p.  
ZAP co-localizes with ORF1p and L1 RNA in the cytoplasm 
 ORF1p, ORF2p, and L1 RNA form RNP complexes that appear as 
discrete cytoplasmic foci when visualized by fluorescence microscopy (Goodier 
et al. 2007, Doucet et al. 2010, Goodier et al. 2010). Notably, previous studies 
have shown that ZAP predominantly is localized in the cytoplasm (Liu et al. 2004) 
and that ZAP antiviral activity also is localized to the cytoplasm (Gao et al. 2002). 
To determine if ZAP co-localizes with ORF1p, we co-transfected HeLa cells with 
pJM101/L1.3Δneo and a plasmid that expresses a carboxyl-terminus turbo-GFP 
tagged ZAP-S protein (ZAP-S-tGFP). Control experiments showed that ZAP-S-
tGFP restricted pJJ101/L1.3 retrotransposition to ~55% of control levels (Figure 
3.11A). Confocal fluorescence microscopy revealed that ORF1p and ZAP-S-
tGFP co-localized in discrete cytoplasmic foci in ~68% of cells that co-expressed 
both ORF1p and ZAP-S-tGFP (Figure 3.5A). To test if transfected ORF1p co-
localizes with endogenous ZAP, we transfected HeLa cells with pAD2TE1, which 
expresses a human L1 (L1.3) containing a T7 gene10 epitope-tag on the 
carboxyl-terminus of ORF1p (Doucet et al. 2010). Confocal microscopy revealed 
that endogenous ZAP co-localized with ORF1p-T7 in cytoplasmic foci in ~91% of 
cells that contained ORF1p-T7 foci (Figure 3.5B). Next, to test if endogenous 
ORF1p co-localizes with transfected ZAP-S, we transfected PA-1 cells (a human 
embryonic carcinoma-derived cell line that expresses endogenous ORF1p 
(Zeuthen et al. 1980, Garcia-Perez et al. 2010)) with ZAP-S-tGFP. Confocal 
microscopy demonstrated that endogenous ORF1p co-localized with ZAP-S-
tGFP in ~89% of PA-1 cells that expressed ZAP-S-tGFP foci (Figure 3.5C). Thus, 
ORF1p and ZAP generally localize to the same region of the cytoplasm. 
To test if the ZAP-S zinc-finger domain is critical for the co-localization of 
ZAP-S with ORF1p, we co-transfected HeLa cells with pJM101/L1.3Δneo and a 
tGFP-tagged ZAP-S mutant that expresses the ZAP-S zinc-finger domain (ZAP-
S/Δ310-645-tGFP; lacking amino acids 310-645), or a ZAP-S mutant that lacks 
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the ZAP-S zinc-finger domain (ZAP-S/Δ72-372-tGFP; lacking amino acids 72-
372) (Figure 3.11A). In control experiments, ZAP-S/Δ310-645-tGFP restricted 
pJJ101/L1.3 retrotransposition to ~32% of control levels whereas ZAP-S/Δ72-
372-tGFP did not have a significant effect (~93% of control) on retrotransposition 
activity (Figure 3.11A). Confocal microscopy revealed that ORF1p and ZAP-
S/Δ310-645-tGFP co-localized in cytoplasmic foci in ~74% of cells that co-
expressed both ORF1p and ZAP-S/Δ310-645-tGFP (Figure 3.5D). In cells 
transfected with pJM101/L1.3Δneo and ZAP-S/Δ72-372-tGFP, ORF1p and ZAP-
S/Δ72-372-tGFP co-localized in only ~14% of cells that co-expressed both 
ORF1p and ZAP-S/Δ72-372-tGFP (Figure 3.5C). Thus, the ZAP-S zinc-finger 
domain is necessary and sufficient for the co-localization of ZAP-S and ORF1p in 
cytoplasmic foci. 
To determine if ZAP co-localizes with L1 RNA, we co-transfected HeLa 
cells with pJM101/L1.3 and either ZAP-S-tGFP, ZAP-S/Δ310-645-tGFP, or ZAP-
S/Δ72-372-tGFP. To visualize L1 RNA, transfected cells were probed with 
fluorescently labeled oligonucleotide probes complementary to sequences within 
the L1 5' UTR. As a control, cells were co-transfected with pJM101/L1.3 and an 
empty pCEP4 vector. In pCEP4 control experiments, fluorescence microscopy 
revealed that ORF1p co-localized with L1 RNA in cytoplasmic foci in ~88% of 
cells that contained ORF1p cytoplasmic Foci (Figure 3.6A and Figure 3.12A). In 
HeLa cells co-transfected with pJM101/L1.3 and ZAP-S-tGFP, L1 RNA co-
localized with ORF1p and ZAP-S-tGFP in cytoplasmic foci in ~23% of foci-
containing cells (Figure 3.6B and Figure 3.12A). Thus, ZAP and L1 RNA co-
localize in cytoplasmic foci.  
Fluorescence microscopy further revealed that in cells co-transfected with 
pJM101/L1.3 and ZAP-S/Δ310-645-tGFP that L1 RNA was detected in ORF1p 
and ZAP-S/Δ310-645-tGFP foci in only ~18% of foci-containing cells (Figure 3.6C 
and Figure 3.12A). In contrast, in cells co-transfected with pJM101/L1.3 and 
ZAP-S/Δ72-372-tGFP, L1 RNA co-localized with ORF1p in ~77% of cells that 
expressed ZAP/Δ72-372-tGFP and contained ORF1p cytoplasmic Foci (Figure 
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3.6D and Figure 3.12A). Thus, the data suggest that ZAP prevents the 
accumulation of L1 RNA in cytoplasmic foci.  
We next determined the effect of ZAP-S on ORF1p expression using 
confocal microscopy. HeLa cells were co-transfected with pJM101/L1.3Δneo and 
either ZAP-S-tGFP, ZAP-S/Δ310-645-tGFP, or ZAP-S/Δ72-372-tGFP. As a 
control, cells were co-transfected with pJM101/L1.3Δneo and an empty pCEP4 
vector. In pCEP4 control experiments, confocal microscopy revealed that ~10.8% 
of cells expressed ORF1p after ~48 hours (Figure 3.12B). In contrast, only ~2.8% 
of cells that were co-transfected with ZAP-S-tGFP expressed ORF1p and ~2.8% 
of cells that were co-transfected with ZAP-S/Δ310-645-tGFP expressed ORF1p 
(Figure 3.12B). Approximately 8.0% of cells that were co-transfected with ZAP-
S/Δ72-372-tGFP expressed ORF1p (Figure 3.12B). Thus, the data suggest that 
the ZAP-S zinc-finger domain is necessary and sufficient to inhibit the 
accumulation of ORF1p in HeLa cells.  
L1 cytoplasmic foci also co-localize with an array of RNA binding proteins, 
including markers of cytoplasmic stress granules (SGs) (Goodier et al. 2007, 
Doucet et al. 2010, Goodier et al. 2013). Notably, ZAP also localizes to 
cytoplasmic SGs (Leung et al. 2011). To determine whether ZAP-S/ORF1p foci 
co-localize with cytoplasmic SGs we transfected HeLa cells with 
pJM101/L1.3Δneo and ZAP-S-tGFP. Confocal microscopy revealed that ZAP-S-
tGFP/ORF1p co-localized with the endogenous SG associated protein eIF3 
(Figure 3.11B). Additionally, endogenous ZAP also co-localized with the SG 
marker, G3BP (Figure 3.11D). In contrast, ZAP-S-tGFP/ORF1p foci did not co-
localize with endogenous tubulin (Figure 3.11C), and endogenous ZAP did not 
co-localize with the processing body associated protein, DCP1α (Figure 3.11E). 
Thus, L1 ORF1p, ZAP, and SG associated proteins partition to the same 
cytoplasmic compartment. 
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Discussion 
 In this study, we identified 39 cellular proteins that interact with L1 ORF1p 
and validated 13 of these interactions in biochemical assays. Our data showed 
that the 13 validated ORF1p-interacting proteins associate with ORF1p via an 
RNA bridge (Figure 3.1D). Notably, 33 out of 39 of the ORF1p-interacting 
proteins also were detected in recent studies (Table S1; (Goodier et al. 2013, 
Peddigari et al. 2013, Taylor et al. 2013)). Importantly, we discovered that ZAP 
restricts human L1 and Alu retrotransposition. We also showed that hnRNPL, 
MOV10, and PURA inhibit L1 retrotransposition, which is in agreement with 
previous studies (Arjan-Odedra et al. 2012, Goodier et al. 2012, Goodier et al. 
2013, Li et al. 2013, Peddigari et al. 2013). Thus, our data both confirm and 
extend those previous analyses and will help guide future studies that endeavor 
to determine how L1 retrotransposition impacts the human genome. 
 ZAP inhibits the mobility of both human and non-human non-LTR 
retrotransposons. The overexpression of the human and rat orthologs of ZAP 
restricts human L1 retrotransposition (Figure 3.3A). Human ZAP-S 
overexpression restricts the retrotransposition of an engineered human SINE 
(Alu) (Figure 3.3B), an engineered mouse L1 (GF21), and an engineered 
zebrafish LINE-2 element (ZfL2-2) (Figure 3.3C). Although our studies primarily 
involved the overexpression of ZAP, we also demonstrated that the depletion of 
endogenous ZAP in HeLa cells led to an ~2-fold increase in L1 retrotransposition 
(Figure 3.3D). This observed increase in L1 retrotransposition activity is similar to 
increases in L1 activity that were observed upon depletion of MOV10 and 
hnRNPL proteins in other studies (Arjan-Odedra et al. 2012, Goodier et al. 2012, 
Peddigari et al. 2013). Thus, in principle, physiological levels of ZAP may be 
sufficient to influence retrotransposition in certain cell types.  
The ZAP CCCH zinc-finger domain is required to both bind and mediate 
the degradation of viral RNA (Guo et al. 2004, Guo et al. 2007).  Our data 
indicate that ZAP binding to L1 RNA is critical for L1 restriction. We 
demonstrated that ORF1p-FLAG and ZAP interact via an RNA bridge (Figure 
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3.1D). Moreover, we showed that overexpression of the ZAP zinc-finger domain 
more potently inhibits L1 retrotransposition than overexpression of wild type ZAP-
L or ZAP-S (Figure 3.3A), and that the ZAP-S zinc-finger domain is required to 
inhibit L1 retrotransposition (Figure 3.3A and Figure 3.11A). In addition to our 
genetic and biochemical data, fluorescence microscopy revealed that: 1) co-
transfected ZAP-S, L1 RNA, and ORF1p co-localize in the cytoplasm of HeLa 
cells; 2) the ZAP-S zinc-finger domain is necessary and sufficient for the co-
localization of ZAP-S, L1 RNA, and ORF1p; 3) endogenous ZAP co-localizes 
with transfected ORF1p in HeLa cells; and 4) endogenous ORF1p interacts with 
transfected ZAP-S in human PA-1 embryonic carcinoma cells (Figures  3.5A-
3.5E and Figures 3.6A-3.6D). Thus, the data suggest that ZAP interacts with L1 
RNA in order to mediate L1 restriction. 
Notably, the zebrafish ZfL2-2 retrotransposon lacks a homolog to ORF1 
and only encodes a single ORF that contains an apurinic/apyrimidinic 
endonuclease-like (EN) and a reverse transcriptase (RT) domain (Sugano et al. 
2006). The finding that ZAP-S efficiently restricts ZfL2-2 retrotransposition further 
indicates that ZAP-S likely restricts retrotransposition by interacting with LINE 
RNA. Although a ZAP consensus RNA target sequence/motif has not yet been 
identified, evidence suggests that ZAP recognizes long RNA stretches (>500 
nucleotides) and/or specific RNA tertiary structure (Guo et al. 2004, Chen et al. 
2012). The ability of ZAP to inhibit non-human LINE elements suggests that ZAP 
may not recognize a particular LINE linear consensus RNA sequence, but 
instead may recognize an unidentified structural feature common to certain LINE 
RNAs (Guo et al. 2004, Chen et al. 2012).  
Evidence suggests that ZAP prevents the accumulation of viral RNAs in 
the cytoplasm (Gao et al. 2002). ZAP-S overexpression significantly reduced the 
amount of polyadenylated, full-length L1 RNA (Figure 3.4B), which would be 
expected to inhibit retrotransposition by limiting the supply of L1 mRNA available 
for translation and as a template for TPRT. Notably, while ZAP-S selectively 
inhibited the accumulation of full-length L1 transcripts, it did not dramatically 
affect the accumulation of shorter, spliced and/or polyadenylated L1 RNAs 
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(Figure 3.4B) (Perepelitsa-Belancio and Deininger 2003, Belancio et al. 2006, 
Belancio et al. 2008, Belancio et al. 2010).  Thus, ZAP does not appear to affect 
L1 transcription per se, but instead likely affects the post-transcriptional 
processing of full-length L1 mRNA. In addition to biochemical data, fluorescence 
microscopy revealed that L1 RNA was depleted from L1 ORF1p cytoplasmic foci 
in the presence of ZAP (Figure 3.11A). The depletion of RNA from L1 
cytoplasmic foci was dependent on the ZAP-S zinc-finger domain. Based on 
these data it is likely that ZAP prevents the accumulation of cytoplasmic L1 
mRNA. 
Previous studies have shown that ZAP also suppresses the expression of 
viral proteins (Bick et al. 2003, Zhu et al. 2011, Zhu et al. 2012). Western blot 
experiments demonstrated that the overexpression of ZAP-S inhibited the 
accumulation of L1 ORF1p and L1 ORF2p in whole cell lysates and RNPs 
derived from transfected HeLa cells (Figure 3.4D and Figure 3.10B). In 
agreement with western blot experiments, confocal microscopy experiments 
showed that tGFP-tagged ZAP-S inhibited the expression of ORF1p in 
transfected HeLa cells and that the ZAP-S zinc-finger domain is critical for the 
inhibition of ORF1p expression (Figure 3.12B). ZAP-S expression also inhibited 
Alu retrotransposition (Figure 3.3B), which depends on ORF2p to be supplied in 
trans by L1 (Dewannieux et al. 2003). In contrast to these data, ZAP-S 
overexpression did not significantly affect the expression and/or accumulation of 
EGFP or other endogenous proteins (e.g., eiF3 and tubulin) (Figure 3.4D and 
Figure 3.10B). Thus, ZAP may preferentially limit the accumulation of ORF1p and 
ORF2p by interacting with L1 mRNA.  
In sum, our data suggest that ZAP restricts L1 retrotransposition by 
preventing the accumulation of cytoplasmic L1 RNA. Notably, a recent study 
suggests that ZAP may interfere with translation of viral RNA, and that translation 
inhibition may precede viral RNA destruction (Zhu et al. 2012). Although a 
reduction in L1 RNA could explain the observed decrease in L1 protein 
expression, it also is conceivable that the interaction between ZAP and L1 RNA 
could interfere with L1 translation (Figure 3.7). 
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It remains unclear how ZAP might destabilize full-length L1 RNA to restrict 
retrotransposition.  Evidence suggests that ZAP recruits exosome components 
(Guo et al. 2007) along with other proteins involved in RNA degradation (Chen et 
al. 2008, Zhu et al. 2011) to destroy viral RNA. Interestingly, 
immunofluorescence microscopy experiments revealed that ORF1p and ZAP co-
localize with components of cytoplasmic SGs (Figures 3.10B and 3.10D), which 
contain numerous RNA binding proteins involved in cytosolic RNA metabolism 
(reviewed in Buchan and Parker 2009). Indeed, ZAP previously has been shown 
to localize to SGs (Leung et al. 2011) and SGs have been suggested to play a 
role in regulating L1 retrotransposition (Goodier et al. 2007) and viral 
pathogenesis (Reineke and Lloyd 2013). The co-localization of ORF1p and ZAP 
with SGs also suggests that ZAP may possibly inhibit L1 translation, as SG 
assembly is stimulated by translational arrest (reviewed in Buchan and Parker 
2009). Thus, we propose that ZAP interacts directly with L1 RNA in the 
cytoplasm, which likely results in the recruitment in SG components and/or other 
cellular factors involved in RNA metabolism to destabilize L1 RNA and/or block 
translation (Figure 3.7). 
 ZAP exhibits antiviral activity against a variety of viruses such as MLV 
(Gao et al. 2002), alphaviruses (Bick et al. 2003), filoviruses (Muller et al. 2007), 
HIV-1 (Zhu et al. 2011), and hepatitis-B virus (Mao et al. 2013). Interestingly, 
many putative L1 restriction factors also are involved in antiviral defense (i.e., a 
subset of APOBEC3 proteins, TREX1, MOV10, SAMHD1, and RNaseL). L1 
elements have been active in mammalian genomes for ~160 million years 
(Burton et al. 1986, Smit et al. 1995, Yang et al. 2014). Thus, it is tempting to 
speculate that some host factors, such as ZAP, may have first evolved to combat 
endogenous retrotransposons and subsequently were co-opted as viral 
restriction factors (Sawyer et al. 2004, Sawyer et al. 2005, Sawyer and Malik 
2006, Kerns et al. 2008). Indeed, identifying host factors that modulate L1 
retrotransposition may prove to be an effective strategy to identify host antiviral 
factors.  
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Methods 
Cell Culture 
 HeLa-JVM cells were grown in high-glucose DMEM (Gibco) supplemented 
with 10% FBS (Gibco), 100 U/mL penicillin-streptomycin (Invitrogen), and 0.29 
mg/mL L-glutamine (Gibco) (Moran et al. 1996). HeLa-HA (Hulme et al. 2007) 
and PA-1 (Zeuthen et al. 1980) cells were grown in MEM (Gibco) with 10% FBS, 
100 U/mL penicillin-streptomycin, 0.29 mg/mL L-glutamine, and 0.1 mM 
nonessential amino acids (Gibco). Cell lines were maintained at 37°C with 7% 
CO2 in humidified incubators (Thermo Scientific). 
Plasmids 
 Oligonucleotide sequences and cloning strategies used in this study are 
available upon request. All human L1 plasmids contain the indicated fragments of 
L1.3 (accession no. L19088) (Sassaman et al. 1997) DNA cloned into pCEP4 
(Invitrogen) unless otherwise indicated. A CMV promoter augments expression of 
all L1 and cDNA expressing plasmids unless noted otherwise. L1 plasmids also 
contain an SV40 polyadenylation signal that is located downstream of the native 
L1 polyadenylation signal. All plasmid DNA was prepared with a Midiprep 
Plasmid DNA Kit (Qiagen). 
 The following cDNA expression plasmids were obtained from OriGene: 
CDK9 (SC119344); DDX21 (SC108813); GNB2L1 (SC116322); hnRNPDL 
(SC107613); MOV10 (SC126015); MATR3 (SC113375); ZAP-S (ZC3HAV1 
transcript variant 2) (SC101064); ZAP-S-tGFP (GFP-tagged ZC3HAV1 transcript 
variant 2) (RG208070); hnRNPA2B1 (SC313092); IGF2BP3 (SC111161); PURA 
(SC127792); UPF1 (SC118343). 
 The following cDNA expression plasmids were obtained from Open 
Biosystems: hnRNPL (6174088); LARP2 (5164712); LARP4 (5219803); 
SYNCRIP (5495201). 
 The following cDNA expression plasmids were obtained from Addgene: 
rZAP (pcDNA4-TO-Myc-rZAP; Addgene plasmid#: 17381, kindly provided by Dr. 
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Stephen Goff) (Gao et al., 2002) and ZAP-L (pcDNA4 huZAP(L); Addgene 
plasmid#: 45907, kindly provided by Dr. Harmit Malik) (Kerns et al. 2008). 
pJM101/L1.3: is a pCEP4-based plasmid that expresses a human L1 (L1.3) 
equipped with an mneoI retrotransposition indicator cassette. L1 expression is 
augmented by a CMV promoter located upstream of the L1 5' UTR and an SV40 
polyadenylation signal that is located downstream of the native L1 
polyadenylation signal (Dombroski et al. 1993, Freeman et al. 1994, Moran et al. 
1996, Sassaman et al. 1997) 
pJM101/L1.3FLAG: was derived from pJM101/L1.3 and contains a single FLAG 
epitope on the carboxyl-terminus of ORF1p. Dr. Huira Kopera (University of 
Michigan Medical School) constructed the plasmid. 
pAluneoTet: expresses an Alu element cloned from intron 5 of the human NF1 
gene (Wallace et al. 1991) that is marked with the neoTet reporter gene. The 
reporter (Esnault et al. 2002) was subcloned upstream of the Alu poly adenosine 
tract (Dewannieux et al. 2003). 
pCEP/GFP: is a pCEP4 based plasmid that expresses the humanized renilla 
green fluorescent protein (hrGFP) coding sequence from phrGFP-C 
(Stratagene), which is located downstream of the pCEP4 CMV promoter (Alisch 
et al. 2006). 
pJJ101/L1.3: is a pCEP4 based plasmid that contains an active human L1 (L1.3) 
equipped with an mblastI retrotransposition indicator cassette (Kopera et al. 
2011). 
pJJ105/L1.3: is similar to pJJ101/L1.3, but contains a D702A missense mutation 
in the RT active site of L1.3 ORF2 (Kopera et al. 2011). 
pJM101/L1.3Δneo: is a pCEP4 based plasmid that contains an active human L1 
(L1.3) (Wei et al. 2001). 
pLRE3-EF1-mEGFPΔIntron: is a pBSKS-II+ based plasmid that expresses an 
active human L1 (LRE3) that is tagged with an EGFP cassette (mEGFPI) 
containing an antisense, intronless copy of the EGFP gene. A UbC promoter 
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drives EGFP expression. An EF1α promoter drives L1 expression (Wissing et al. 
2011). 
pAD2TE1: is similar to pJM101/L1.3 except that it was modified to contain a T7 
gene10 epitope-tag on the carboxyl-terminus of ORF1p and a TAP epitope-tag 
on the carboxyl-terminus of ORF2p. The 3′-UTR contains the mneoI 
retrotransposition indicator cassette (Doucet et al. 2010). 
pJBM2TE1: is similar to pAD2TE1 except that the pCEP4 backbone was 
modified to contain the puromycin resistance (PURO) gene in place of the 
hygromycin resistance gene.  
pLRE3-mEGFPI: is a pCEP4 based plasmid that contains an active human L1 
(LRE3) equipped with an mEGFPI retrotransposition indicator cassette (Ostertag 
et al. 2000, Garcia-Perez et al. 2010). The pCEP4 backbone was modified to 
contain a puromycin resistance (PURO) gene in place of the hygromycin 
resistance gene. The CMV promoter also was deleted from the vector; thus, L1 
expression is driven only by the native 5′ UTR (Ostertag et al. 2000). 
pJM111-LRE3-mEGFPI: is identical to pLRE3-mEGFPI except that it contains 
two missense mutations in ORF1 (RR261-262AA), which render the L1 
retrotransposition-defective (Moran et al. 1996). Mr. William Giblin (University of 
Michigan Medical School) constructed the plasmid (Zhang et al. 2014). 
pGF21: contains an 8.8 kb fragment which includes a full length mouse GF21 L1 
element that contains the mneoI indicator cassette (Goodier et al. 2001). 
pZfL2-2: is a pCEP4 based plasmid that contains the ZfL2-2 ORF (ZL15, 
accession no. AB211150) cloned upstream of the mneoI indicator cassette 
(Sugano et al. 2006). 
pCEP4smL1: contains a codon optimized full-length mouse element (derived 
from L1spa) containing the mneoI indicator cassette (Han and Boeke 2004).  
ZAP-S/1-311: encodes the ZAP-S amino acid sequence from 1-311 and the 
following sequence of non-templated amino acids 
(IIIYTGFLFCCGFFFFFFFLEGVSLCCPGWS).  
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ZAP-S/Δ72-372: was derived by deleting the SfoI-XhoI fragment from ZC3HAV1 
transcript variant 2 (OriGene, SC101064), and expresses a ZAP-S mutant 
protein that lacks amino acid sequence from 72-372. 
ZAP-S/Δ310-645-tGFP: expresses a ZAP-S mutant protein that lacks amino acid 
sequence from 310-645 and contains a carboxyl terminus tGFP epitope tag. 
ZAP-S/Δ72-372-tGFP: expresses a ZAP-S mutant protein that lacks amino acid 
sequence from 72-372 and contains a carboxyl terminus tGFP epitope tag. 
LARP5: was derived by cloning LARP5 cDNA (Open Biosystems, 40118844) into 
pcDNA3 (Invitrogen). 
LARP1: was constructed by cloning the LARP1 cDNA (Open Biosystems, 
3138935) into pcDNA3 (Invitrogen).  
pK_A3A: expresses HA-tagged APOBEC3A and was a generous gift from Dr. 
Brian Cullen (Bogerd et al. 2006). 
pDCP1α-GFP: expresses  a GFP-tagged version of DCP1α and was a generous 
gift from Dr. Gregory Hannon (Liu et al. 2005). 
pG3BP-GFP: expresses a GFP-tagged version of G3BP and was a generous gift 
from Dr. Jamal Tazi (Tourriere et al. 2003). 
pcDNA6/TR: expresses the blasticidin resistance gene and was obtained from 
Invitrogen. 
Immunoprecipitation of L1 ORF1p 
 HeLa-JVM cells were seeded in T-175 flasks (BD Falcon) at ~6-8×106 
cells/flask and transfected the next day with 20 μg of plasmid DNA using 60 μL of 
FuGENE HD (Promega). Approximately 48 hours post-transfection, hygromycin 
B (Gibco) (200 μg/mL) was added to the medium to select for transfected cells. 
After approximately one week of hygromycin selection, cells were washed 3 
times with ice cold PBS and collected with a rubber policeman into 50 mL conical 
tubes (BD Falcon). Cells were then pelleted at 1,000×g and frozen at -80°C. To 
produce whole cell lysates (WCL), frozen cell pellets were rapidly thawed and 
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then lysed in ~3 mL (1 mL lysis buffer per 100 mg of cell pellet) of lysis buffer (20 
mM Tris-HCl (pH 7.5), 150 mM NaCl, 10% glycerol, 1 mM EDTA, 0.1% IGEPAL 
CA-630 (Sigma), 1X complete EDTA-free protease inhibitor cocktail (Roche)) on 
ice for 30 minutes. WCLs were then centrifuged at 15,000×g for 15 minutes at 
4°C. Supernatants were transferred to a clean tube and protein concentration 
was determined using the Bradford reagent assay (BioRad). For the IP, ~1 mL of 
the supernatant (~3 mg total protein) was pre-cleared with ~15 μL (packed gel 
volume) of mouse IgG-agarose beads (Sigma) for 4 hours at 4°C. Pre-cleared 
supernatants were then mixed with ~15 μL (packed gel volume) of EZview Red 
ANTI-FLAG M2 Affinity Gel (Sigma) and incubated overnight with rotation at 4°C. 
The beads then were rinsed 3x with 0.5 mL of lysis buffer, and then washed 3 
times with 0.5 mL of lysis buffer for 10 minutes per wash on ice with gentle 
agitation. Protein complexes were eluted from the beads by adding ~70 μL of 2X 
NuPAGE LDS Sample Buffer (Novex), supplemented with NuPAGE Sample 
Reducing Agent (Novex), directly to the washed beads and incubating for 10 
minutes at 70°C. Following incubation, the beads were pelleted and the sample 
was transferred to a fresh tube. For SDS-PAGE analysis, 20 μL of the IP were 
loaded onto a 4-15% gradient midi-gel (BioRad) and run under reducing 
conditions. Gels were silver stained using the SilverQuest Silver Staining Kit 
(Novex) to visualize proteins.  
Protein Identification by LC-MS/MS 
 The Proteomics Facility at the Fred Hutchinson Cancer Research Center 
(Seattle, WA) conducted protein identification experiments. Excised silver-stained 
gel slices were destained and subjected to in-gel proteolytic digestion with trypsin 
as described (Shevchenko et al. 1996). Following gel-slice digestion, the 
digestion products were desalted using C18-micro ZipTips (Millipore) and were 
dried by vacuum centrifugation. The resultant peptide samples were 
resuspended in 7 μL of 0.1% formic acid and 5 μL were analyzed by liquid 
chromatography coupled to tandem mass spectrometry (LC-MS/MS). LC-MS/MS 
analysis was performed using an LTQ Orbitrap XL mass spectrometer (Thermo 
Scientific). The LC system, configured in a vented format (Licklider et al. 2002), 
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consisted of a fused-silica nanospray needle (PicoTip emitter, 50 µm ID) (New 
Objective) packed in-house with Magic C18 AQ 100A reverse-phase medium (25 
cm) (Michrom Bioresources Inc.) and a trap (IntegraFrit Capillary, 100 µm ID) 
(New Objective) containing Magic C18 AQ 200A reverse-phase medium (2 cm) 
(Michrom Bioresources Inc.). The peptide samples were loaded onto the column 
and chromatographic separation was performed using a two mobile-phase 
solvent system consisting of 0.1% formic acid in water (A) and 0.1% acetic acid 
in acetonitrile (B) over 60 min from 5% B to 40% B at a flow rate of 400 
nL/minutes. The mass spectrometer operated in a data-dependent MS/MS mode 
over the m/z range of 400-1800. For each cycle, the five most abundant ions 
from each MS scan were selected for MS/MS analysis using 35% normalized 
collision energy. Selected ions were dynamically excluded for 45 seconds.   
 For data analysis, raw MS/MS data were submitted to the Computational 
Proteomics Analysis System (CPAS), a web-based system built on the LabKey 
Server v11.2 (Rauch et al. 2005) and searched using the X!Tandem search 
engine (Craig and Beavis 2004) against the International Protein Index (IPI) 
human protein database (v3.75), which included additional common 
contaminants such as BSA and trypsin. Search results were compared between 
the pJM101/L1.3FLAG lane and the pJM101/L1.3 lane to generate a list of 
candidate L1 ORF1p associated proteins unique to the pJM101/L1.3FLAG 
immunoprecipitation. The search output files were analyzed and validated by 
ProteinProphet (Nesvizhskii et al. 2003). Peptide hits were filtered with 
PeptideProphet (Keller et al. 2002) error rate ≤ 0.05, and proteins with probability 
scores of ≥ 0.95 were accepted. Suspected contaminants (e.g. keratin) were 
filtered from the final L1 RNP candidate list. 
L1 Retrotransposition Assays 
 The cultured cell retrotransposition assay was carried out essentially as 
described (Moran et al. 1996, Wei et al. 2000). For retrotransposition assays with 
L1 constructs tagged with mblastI, HeLa-JVM cells were seeded at ~1-2×104 
cells/well in a 6-well plate (BD Falcon). Within 24 hours, each well was 
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transfected with 1 μg of plasmid DNA (0.5 μg L1 plasmid + 0.5 μg cDNA plasmid 
or pCEP4) using 3 μL of FuGENE 6 transfection reagent (Promega). Four days 
post-transfection, blasticidin (EMD Millipore) containing medium (10 μg/mL) was 
added to cells to select for retrotransposition events. Medium was changed every 
two days. After ~8 days of selection, cells were washed with PBS, fixed, and then 
stained with crystal violet to visualize colonies. To control for transfection 
efficiency and off-target effects of cDNA plasmids, in parallel with 
retrotransposition assays, HeLa-JVM cells were plated in 6-well plates at 500-
1,000 cells/well and transfected with 0.5 μg pcDNA6/TR (Invitrogen) plasmid + 
0.5 μg cDNA plasmid using 3 μL of FuGENE 6 transfection reagent (Promega). 
The pcDNA6/TR control assays were treated with blasticidin in the same manner 
as for retrotransposition assays.  
 For retrotransposition assays with L1 constructs tagged with mneoI, HeLa-
JVM cells were transfected as described above. Two days after transfection, 
cells were treated with medium supplemented with G418 (Gibco) (500 μg/mL) for 
~10-12 days. As a control, HeLa cells were plated at ~2×104 cells/well in a 6-well 
plate and transfected with 0.5 μg pcDNA3 (Invitrogen) plasmid + 0.5 μg cDNA 
plasmid using 3 μL of FuGENE 6 transfection reagent (Promega). The pcDNA3 
control assays were treated with G418 in the same manner as for 
retrotransposition assays. 
Alu Retrotransposition Assays 
 For Alu retrotransposition assays (Dewannieux et al. 2003), ~4×105 HeLa-
HA cells were plated per well of a 6-well plate (BD Falcon) and transfected with 
0.67 μg of pJM101/L1.3Δneo + 0.67 μg of pAluneoTet + 0.67 μg of cDNA plasmid 
using 6 μL FuGENE HD (Promega). Three days post-transfection, cells were 
grown in the presence of G418 (500μg/mL) to select for Alu retrotransposition 
events. As a control, HeLa-HA cells were plated at ~4×105 cells/well in a 6-well 
plate and transfected with 0.67 μg of pcDNA3 (Invitrogen) + 0.67 μg of pAluneoTet 
+ 0.67 μg of cDNA plasmid using 6 μL of FuGENE HD (Promega). The pcDNA3 
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control assays were treated with G418 in the same manner as for Alu 
retrotransposition assays. 
siRNA knockdown and pLRE3-mEGFPI retrotransposition assays 
 In experiments to study the effect of endogenous proteins on L1 
retrotransposition, HeLa cells (~8×105 cells) were plated in 60 mm tissue culture 
dishes (BD Falcon). The next day, the cells were transfected with 50 nM of a 
control siRNA pool (D-001810-10, ON-TARGETplus Non-targeting Pool, Thermo 
Scientific) or siRNA against ZAP (L-017449-01-0005, ON-TARGETplus Human 
ZC3HAV1 (56829) siRNA - SMARTpool, Thermo Scientific) or MOV10 (L-
014162-00-0005, ON-TARGETplus Human MOV10 (4343) siRNA - SMARTpool, 
Thermo Scientific) using the DharmaFECT 1 transfection reagent (Thermo 
Scientific). Twenty-four hours after siRNA treatment, cells were transfected with 
pLRE3-mEGFPI or pJM111-LRE3-mEGFPI (5 µg), using 15 µL of FuGENE HD 
transfection reagent (Roche). After 48 hours, cells were trypsinized and an 
aliquot of the cells (~2×106 cells) was used to monitor endogenous protein levels 
(72 hours after siRNA treatment) by western blot analysis (see below for list of 
primary antibodies). Blots were analyzed using an Odyssey CLx (LI-COR) with 
the following secondary antibodies: IRDye 800CW Donkey anti-Rabbit IgG 
(1:10,000) (LI-COR) and IRDye 680RD Donkey anti-Mouse IgG (1:10,000) (LI-
COR). Knockdown efficiencies were calculated using LI-COR Image Studio 
Software (v3.1.4) and are the average of three independent experiments. 
Endogenous tubulin was used as the normalization control. The remaining cells 
were re-plated at ~2×105 cells/well of a 6-well plate and cultured in medium 
supplemented with puromycin (5 µg/ml, Gibco/Life Technologies) to select for 
cells transfected with pLRE3-mEGFPI. After 4 days of puromycin selection, the 
percentage of GFP positive cells was determined by flow cytometry using an 
Accuri C6 flow cytometer (BD Biosciences).  
RNP Isolation 
 RNPs were isolated as previously described (Kulpa and Moran 2005). 
Briefly, HeLa-JVM cells were seeded onto 60 mm tissue culture dishes (BD 
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Falcon) and 24 hours later cells were co-transfected with 2.5 μg of pJBM2TE1 
and 2.5 μg of the indicated cDNA plasmid using 15 μL of FuGENE HD 
(Promega). Approximately two days after transfection, puromycin (5 μg/mL) was 
added to culture medium to select for cells transfected with pJBM2TE1. After ~3 
days of puromycin selection (5 days after transfection), cells were lysed in RNP 
lysis buffer (150 mM NaCl, 5 mM MgCl2, 20 mM Tris-HCl (pH 7.5), 10% glycerol, 
1mM DTT, 0.1% NP-40, and 1x complete EDTA-free protease inhibitor cocktail 
(Roche)). Following lysis, whole cell lysates were centrifuged at 12,000xg for 10 
minutes at 4°C, and then the cleared lysate was layered onto a sucrose cushion 
(8.5% and 17% sucrose) and subjected to ultracentrifugation at 4°C for 2 hours 
at 178,000xg. The supernatant was discarded and the resulting pellet was 
resuspended in water supplemented with 1x complete EDTA-free protease 
inhibitor cocktail (Roche). Approximately 20 μg (total protein) of the RNP sample 
or ~30 μg (total protein) of the cleared whole cell lysate (supernatant post 
12,000xg centrifugation) were then analyzed by western blot. Blots were 
analyzed using an Odyssey® CLx (LI-COR) with the following secondary 
antibodies: IRDye 800CW Donkey anti-Rabbit IgG (1:10,000) (LI-COR) and 
IRDye 680RD Donkey anti-Mouse IgG (1:10,000) (LI-COR).    
 To simultaneously analyze the effects of ZAP-S on ORF1p and EGFP 
protein expression, HeLa-JVM cells were seeded onto 10 cm dishes (~2.7×106 
cells/dish) (BD Falcon) and transfected with 10 μg of plasmid DNA (5.0 μg 
pLRE3-EF1A-mEGFPΔIntron + 5.0 μg cDNA plasmid or pCEP4) using 30 μL of 
FuGENE HD. After 48 hours, cells were harvested with trypsin and then 
subjected to flow cytometry to isolate GFP expressing cells. Approximately 1.2-
1.7×106 GFP positive cells were collected for each transfection condition using a 
MoFlo Astrios cell sorter (Beckman Coulter). The GFP gate was set using 
untransfected HeLa-JVM cells. The sorted cells were lysed as described in the IP 
procedure and lysates were then subjected to western blotting using standard 
procedures. For all other protein expression analyses, HeLa-JVM cells were 
seeded at ~4×105 cells/well in 6-well plates and transfected with 2 μg of plasmid 
DNA with 6 μL of FuGENE HD. Cells were collected 48 hours after transfection 
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using a rubber policeman and lysates were prepared as described above. 
Western blots were visualized using either the SuperSignal West Femto 
Chemiluminescent Substrate (Pierce) or SuperSignal West Pico 
Chemiluminescent Substrate (Pierce) and Hyperfilm ECL (GE Healthcare). 
Northern Blots 
 HeLa-JVM cells were seeded in T-175 flasks (BD Falcon) and transfected 
with 20 μg of plasmid DNA (10 μg pJM101/L.13Δneo + 10 μg cDNA plasmid) 
using 60 μL FuGENE HD. Two days after transfection, cell pellets were collected 
and frozen at -80°C. Frozen cell pellets were then thawed and total RNA was 
extracted with TRIzol reagent (Ambion), and then poly(A)+ RNA was prepared 
from total RNA using an Oligotex mRNA kit (Qiagen). Each sample (~1.5 μg of 
poly(A)+ RNA) was subjected to glyoxal gel electrophoresis and northern blotting 
using the NorthernMax-Gly Kit (Ambion) according to the manufacturer’s 
protocol. Following electrophoresis, RNA was transferred to BrightStar Nylon 
membranes (Invitrogen) and then cross-linked using UV light. For northern blot 
detection, membranes were prehybridized for ~4 hours at 68°C in NorthernMax 
Prehybridization/Hybridization Buffer (Ambion), and then incubated with a strand 
specific RNA probe (final concentration of probe ~3×106 cpm ml-1) overnight at 
68°C. For band quantification, northern blot films were analyzed using ImageJ 
software (Schneider et al. 2012).  
 Strand-specific RNA probes were generated using the MAXIscript T3 
system (Invitrogen). The 5UTR99 (Belancio et al. 2006) probe corresponds to 
bases 7-99 of the L1.3 5' UTR and the ORF2_5804 probe corresponds to 
nucleotides 5560-5804 of the L1.3 sequence. RNA probe templates for T3 
reactions were generated by PCR using pJM101/L1.3Δneo as a PCR template 
with the following primer pairs:  
(5UTR99: 5'-GGAGCCAAGATGGCCGAATAGGAACAGCT-3' and 5'-
AATTAACCCTCAAAGGGACCTCAGATGGAAATGCAG-3');  
(ORF2_5804: 5'- GACACATGCACACGTATGTTTATT-3' and 5'- 
AATTAACCCTCACTAAAGGGTGAGTGAGAATATGCGGTGTTT-3').  
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The T3 promoter sequence (underlined) was added to the reverse primer of each 
primer pair. The pTRI-β-actin-125-Human Antisense Control Template (Applied 
Biosystems) was used in T3 reactions as a template to generate the β-actin RNA 
probe. Each northern blot experiment was independently repeated three times 
with similar results. 
Immunofluorescence Microscopy 
 Immunofluorescence microscopy was performed essentially as described 
(Doucet et al. 2010) with modifications. Briefly, cells were plated on round glass 
cover slips (Fisher) in a 12-well plate or into 4-well chambered glass slides 
(Fisher) and transfected ~24 hours later with 0.5 μg of plasmid DNA using 1.5 μL 
of FuGENE 6 transfection reagent. To visualize proteins, approximately 48 hours 
post-transfection cells were washed with 1x PBS, fixed with 4% 
paraformaldehyde for 10 minutes and then treated with ice-cold methanol for 1 
minute. Next, cells were incubated for 30 minutes at 37°C in 1x PBS + 3% BSA. 
Cells then were incubated with primary antibodies in 1x PBS + 3% BSA for 1 
hour at 37°C. Cells were washed three times with 1x PBS (10 minutes per wash) 
and then incubated with appropriate, fluorescently-labeled secondary antibodies 
diluted in 1x PBS for 30 minutes at 37°C. The following secondary antibodies 
were used for indirect immunofluorescence: Alexa Fluor 488 conjugated Goat 
anti-Mouse and Goat anti-Rabbit (Invitrogen) (1:1000), Alexa Fluor 546 
conjugated Goat anti-Mouse and Goat anti-Rabbit IgG (Invitrogen) (1:1000), and 
Cy5 conjugated Donkey anti-Rabbit IgG (H+L) (Jackson ImmunoResearch) 
(1:100). To obtain images, a cover slip and/or slide was visually scanned and 
representative images were captured using a Leica SP5X confocal microscope 
(63x/1.4 objective; section thickness 1 μm).  
Combined RNA FISH (Fluorescence in situ Hybridization) and 
immunofluorescence 
 Cells were plated on round glass cover slips (Fisher) in a 12-well plate and 
transfected ~24 hours later with 0.5 μg of plasmid DNA using 1.5 μL of FuGENE 
6 transfection reagent. Approximately 48 hours after transfection, cells were fixed 
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with 4% paraformaldehyde for 10 minutes and then permeabilized with 0.2% 
Triton X-100 in 1x PBS for 7 minutes. Following permeabilization, coverslips 
were incubated for 5 minutes in FISH (fluorescence in situ hybridization) wash 
buffer (2x SSC, 10% formamide) for 5 minutes. To visualize L1 RNA, coverslips 
were then incubated with 300 nM FISH probes (sequences below) in FISH 
hybridization buffer (2x SSC, 10% formamide, 1% dextran sulphate) for ~4 hours 
at 37°C. Following hybridization, cells were incubated for 30 minutes in FISH 
wash buffer at 37°C and then incubated with FISH wash buffer + 3% BSA for an 
additional 30 minutes at 37°C. To visualize L1 ORF1p by immunofluorescence, 
coverslips then were incubated with αORF1p antibodies (1:2000) in 1x PBS + 3% 
BSA for 1 hour at 37°C. Cells were washed three times with 1x PBS (10 minutes 
per wash). Cells were  incubated with Alexa Fluor 546 conjugated Goat anti-
Rabbit IgG (Invitrogen) (1:1000) in 1x PBS + DAPI (50 ng/mL) for 30 minutes at 
37°C. Coverslips were mounted on slides with VECTASHIELD mounting media 
(Vector Laboratories). Combined RNA FISH/immunofluorescence samples were 
imaged with a Zeiss Axioplan2 microscope (63x objective; Axiovision 4.8 
software). RNA FISH/immunofluorescence images (Figures 3.6A-3.6D) were 
globally processed using the Photoshop CS6 (version 13.0 x64) Levels tool to 
adjust input levels.  The L1 RNA was labeled using 21 Quasar670-labelled anti-
sense oligonucleotide probes complimentary to sequences within the L1.3 5' 
UTR (probes were designed and produced by Biosearch Technologies, 
Petaluma, CA). The sequences of the 21 L1 probes are as follows: 5'-
aaatcaccgtcttctgcgtc-3', 5'-ggtacctcagatggaaatgc-3', 5'-cactccctagtgagatgaac-3', 
5'-ccctttctttgactcagaaa-3', 5'-aatattcgggtgggagtgac-3', 5'-cttaagccggtctgaaaagc-
3', 5'-caggtgtgggatatagtctc-3', 5'-tgctagcaatcagcgagatt-3', 5'-ttgcagtttgatctcagact-
3', 5'-tttgtttacctaagcaagcc-3', 5'-cagaggtggagcctacagag-3', 5'-ctgtctttttgtttgtctgt-3', 
5'-cacttaagtctgcagaggtt-3', 5'-ctctcttcaaagctgtcaga-3', 5'-ttgaggaggcagtctgtctg-3', 
5'-ctgcaggtctgttggaatac-3', 5'-ttctaacagacaggaccctc-3', 5'-cctttctggttgttagtttt-3', 5'-
gatgggttttcggtgtagat-3', 5'-gtctttgatgatggtgatgt-3', 5'-tttgtggttttatctacttt-3'. 
Primary Antibodies  
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 Polyclonal antibodies against peptide sequences 31-49 of L1.3 ORF1p 
(αORF1p) were raised in rabbits and affinity-purified (Open Biosystems). αCDK9 
(2316), αUPF1 (9435), and αGFP (2955) were obtained from Cell Signaling 
Technology. αhnRNPL (NBP1-67852), αILF3 (EPR3627), αLARP1 (NBP1-
19128), αMATR3 (NB100-1761), αNCL (NB100-1920SS), and αDHX9 (NB110-
40579) were obtained from Novus Biologicals. αFAM120A (ab83909), αPURA 
(ab79936), and αHA tag (ab9110) were obtained from Abcam. αMOV10 
(SAB1100141), αZAP (Anti-ZC3HAV1 (HPA047818)), and αTubulin (T9026) 
were obtained from Sigma. αZC3HAV1 (16820-1-AP) was obtained from 
Proteintech. αeIF3 (p110) (sc-28858) was obtained from Santa Cruz 
Biotechnology. αT7-Tag mouse monoclonal (69522-3) was obtained from 
Novagen. αTAP rabbit polyclonal (CAB1001) was obtained from Thermo 
Scientific. 
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Figure 3.1: The identification of host proteins immunoprecipitated with L1 
ORF1p-FLAG.  
(A) Schematic of L1 constructs:  pJM101/L1.3 expresses a human L1 (L1.3) 
(Sassaman et al. 1997) containing an mneoI retrotransposition indicator cassette 
within the L1 3' UTR.  The pJM101/L1.3FLAG construct is identical to 
pJM101/L1.3, but contains a single FLAG epitope on the carboxyl-terminus of 
ORF1p. Both constructs were cloned into a pCEP4 mammalian expression 
vector. A CMV promoter augments L1 expression and an SV40 polyadenylation 
signal (pA) is located downstream of the native L1 polyadenylation signal. (B) 
Results of immunoprecipitation experiments: Whole cell lysates from HeLa cells 
transfected with either pJM101/L1.3 or pJM101/L1.3FLAG were subjected to 
immunoprecipitation using an anti-FLAG antibody. The proteins then were 
separated by SDS-PAGE, visualized by silver staining, and subjected to LC-
MS/MS. An ~40 kDa band corresponding to the theoretical molecular weight of 
ORF1p is visible in the pJM101/L1.3FLAG lane (*). Black bars indicate the 
approximate molecular weights of the ORF1p-FLAG interacting proteins. 
Molecular weight standards (kDa) are shown on the left hand side of the gel. (C) 
Validation of the ORF1p-FLAG immunoprecipitation: Western blot experiments 
using an antibody specific to amino acids 31-49 of L1.3 ORF1p verified the 
enrichment of ORF1p-FLAG in pJM101/L1.3FLAG, but not pJM101/L1.3 
immunoprecipitation reactions. Cells transfected with the pCEP4 vector served 
as a negative control. (D) Validation of putative ORF1p-FLAG interacting 
proteins: Western blot images of the pJM101/L1.3FLAG and pJM101/L1.3 
immunoprecipitation (IP) reactions. The pCEP4 lanes denote whole cell lysates 
derived from HeLa cells transfected with an empty pCEP4 vector (~1.0% input). 
Primary antibodies used to probe western blots are indicated to the left of the 
images. Immunoprecipitation reactions were conducted in either the absence 
(left) or presence (right) of RNaseA (10 μg/mL). The putative cellular functions of 
the ORF1p-FLAG interacting proteins are indicated on the right hand side of the 
blots.  
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Figure 3.1: The identification of host proteins immunoprecipitated with L1 
ORF1p-FLAG.  
 139 
Figure 3.2: Several of the ORF1p-FLAG interacting proteins inhibit L1 
retrotransposition.  
(A) Schematic of the cultured-cell retrotransposition assay: HeLa cells were 
transfected with an engineered human L1.3 construct (pJJ101/L1.3) marked with 
a blasticidin indicator cassette (mblastI). The pJJ101/L1.3 construct was cloned 
into a pCEP4 mammalian expression vector. A CMV promoter augments L1 
expression and an SV40 polyadenylation signal (pA) is located downstream of 
the native L1 polyadenylation signal. The mblastI cassette is cloned into the L1 3' 
UTR antisense to the L1 and contains a blasticidin deaminase gene that is 
disrupted by an intron in the L1 sense orientation. The blasticidin deaminase 
gene can only be expressed when the L1 transcript is spliced, reverse 
transcribed, and inserted into genomic DNA (Moran et al. 1996, Wei et al. 2000). 
(B) Schematic of the pJJ101/L1.3 retrotransposition screen: To analyze the effect 
of the ORF1p-FLAG interacting proteins on L1 retrotransposition, HeLa cells 
were co-transfected with equal amounts of pJJ101/L1.3 and a cDNA plasmid 
expressing one of the candidate ORF1p-FLAG interacting proteins or a pCEP4 
empty vector. To control for potential off-target effects, HeLa cells also were co-
transfected with a control plasmid (pcDNA6/TR) that expresses the blasticidin 
deaminase gene and a cDNA plasmid expressing one of the candidate proteins 
or a pCEP4 empty vector. Both assays were subjected to the same blasticidin 
selection regimen. The resultant number of blasticidin-resistant colonies in 
pcDNA6/TR control assays provides a visual, quantitative readout of the effect of 
cDNA overexpression on the ability of cells to grow in the presence of blasticidin.   
(C) Results of pJJ101/L1.3 retrotransposition screen: HeLa cells were co-
transfected with pJJ101/L1.3 and each of the indicated cDNA expressing 
plasmids. L1 retrotransposition was assayed in 6-well tissue culture plates. The 
X-axis indicates the cDNA that was co-transfected with pJJ101/L1.3. The 
bracketed number next to each cDNA indicates the number of independent 
experiments. The Y-axis indicates L1 retrotransposition activity after accounting 
for cDNA toxicity (see Figure 3.2B). Retrotransposition activity (black bars) is 
normalized to the pCEP4 empty vector control. Error bars represent the standard 
deviation for each set of experiments. The red dotted line indicates a 50% 
inhibition of retrotransposition activity. 
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Figure 3.2: Several of the ORF1p-FLAG interacting proteins inhibit L1 
retrotransposition.   
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Figure 3.3: ZAP-S inhibits LINE and Alu retrotransposition.  
(A) ZAP inhibits L1 retrotransposition: Top panel: Schematics of ZAP constructs. 
Depicted are the relative positions of the zinc-finger domains (light gray 
rectangles), cysteine-histidine (CCCH) zinc-fingers (vertical black bars), and 
PARP-like domain (dark gray rectangles) of the ZAP-L and ZAP-S expression 
constructs. ZAP-L contains a carboxyl-terminal HA tag (blue rectangle labeled 
HA). The ZAP-S/1-311 construct contains an additional 31 amino acids at the 
carboxyl terminus. The ZAP-S/ 72-3  harbors a deletion that removes the 
CCCH zinc fingers (See Methods). Middle panel: Results of the retrotransposition 
assays. The X-axis indicates the cDNA co-transfected with pJJ101/L1.3 or 
pcDNA6/TR. The Y-axis indicates pJJ101/L1.3 retrotransposition activity (black 
bars), or pcDNA6/TR colony formation activity (white bars). All values have been 
normalized to the pCEP4 empty vector control (100%). The numbers above the 
bar graphs indicate the number of independent experiments performed with each 
cDNA expression construct. Error bars represent standard deviations. Bottom 
panel:  A single well of a representative six-well tissue culture plate, displaying 
blasticidin-resistant colonies from the pJJ101/L1.3 retrotransposition assay (top, 
black rectangle) and the pcDNA6/TR control assay (bottom, white rectangle). (B) 
ZAP inhibits Alu retrotransposition: The X-axis indicates the cDNA co-transfected 
with pJM101/L1.3Δneo and pAluneoTet. The Y-axis indicates the 
retrotransposition efficiency. All values are normalized to the pCEP4 empty 
vector control (100%). Control assays using a plasmid that expresses the 
neomycin phosphotransferase gene (pcDNA3) were conducted similarly to 
pcDNA6/TR control assays as outlined in Figure 3.2B. Representative images of 
G418-resistant HeLa foci from the Alu retrotransposition assay are shown below 
the bar graph. The results are the average of three independent experiments. 
Error bars indicate standard deviations. (C) ZAP inhibits the retrotransposition of 
mouse and zebrafish LINE elements. The X-axis indicates the cDNA that was co-
transfected with human L1 (pJM101/L1.3 (black bars)), mouse L1 (pGF21 (dark 
grey bars)), zebrafish L2 (pZfL2-2 (light grey bars)), or synthetic mouse L1 
(pCEPsmL1 (white bars)). The Y-axis indicates the retrotransposition efficiency. 
Representative images of G418-resistant HeLa cell foci are shown below the bar 
graph. Control assays using a plasmid that expresses the neomycin 
phosphotransferase gene (pcDNA3) were conducted similarly to pcDNA6/TR 
control assays outlined in Figure 3.2B. All values are normalized to the pCEP4 
empty vector control (100%). Error bars indicate standard deviations. (D) The 
depletion of ZAP enhances L1 retrotransposition: Top panels: Western blots of 
whole cell lysates derived from mock HeLa cell transfections or HeLa cells 
transfected with indicated siRNAs. Blue arrows point to the approximate location 
of ZAP-L and ZAP-S. Bottom panel: The bar graph depicts pLRE-mEGFP1 
retrotransposition activity following siRNA treatment. The X-axis indicates the 
siRNA. The Y-axis indicates the pLRE-mEGFP1 retrotransposition efficiency 
normalized to the control siRNA (set to 1). Retrotransposition efficiency values 
are reported as the mean from four independent experiments. Error bars indicate 
the standard deviations. Asterisks indicate statistically significant differences from 
the control siRNA experiments (two-tailed t test/p<0.05).   
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Figure 3.3: ZAP-S inhibits LINE and Alu retrotransposition.  
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Figure 3.4: The effect of ZAP-S on L1 RNA and L1 protein expression.  
(A) Schematic of pJM101/L1.3Δneo: Bold black lines indicate the approximate 
location of probes (5UTR99 and ORF2_5804) used in the northern blot 
experiments. pJM101/L1.3Δneo is expressed from a pCEP4 vector. A CMV 
promoter augments L1 expression and an SV40 polyadenylation signal (pA) is 
located downstream of the native L1 polyadenylation signal. (B) Results of 
northern blots: Top panel: HeLa cells were co-transfected with pJM101/L1.3Δneo 
and either the indicated ZAP-S expression plasmids or an empty pCEP4 vector. 
Northern blot images depict the effect of ZAP-S overexpression on 
polyadenylated L1 RNA levels. The constructs transfected into HeLa cells are 
indicated above each lane. UTF indicates untransfected HeLa cells and serves 
as a negative control. Probes (5UTR99 and ORF2_5804) are indicated in the top 
left corner of the respective blots. The black arrow indicates the position of the 
full-length L1 RNA. The blue and yellow arrows indicate shorter L1 RNA species. 
The experiment was repeated three times with similar results. Actin served as a 
loading control. RNA size standards (~kb) are shown at the right of the blot 
image. Bottom panel: Quantification of northern blot bands. The X-axis indicates 
the cDNA expression construct that was co-transfected with pJM101/L1.3Δneo. 
The Y-axis indicates relative band intensity normalized to pCEP4 controls 
(100%). Black bars represent the full-length L1 band.  Blue and yellow bars 
represent the smaller L1 RNA bands, corresponding to the colored arrows, 
respectively, in the top panel. The results are the average of three independent 
experiments. Error bars represent standard deviations. (C) Schematic of 
pJBM2TE1: The construct contains a T7 epitope tag on the carboxyl-terminus of 
ORF1p and a TAP tag on the carboxyl-terminus of ORF2p.  An mneoI 
retrotransposition indicator cassette is present in the 3’ UTR. pJMB2TE1 is 
expressed from a pCEP4 backbone, which has been modified to contain a 
puromycin selectable marker. A CMV promoter augments L1 expression and an 
SV40 polyadenylation signal (pA) is located downstream of the native L1 
polyadenylation signal. (D) ZAP-S decreases the accumulation of the L1-
encoded proteins:  HeLa cells were co-transfected with pJBM2TE1 and the 
plasmids indicated above each lane. UTF indicates untransfected HeLa cells and 
serves as a negative control. Depicted are western blots using whole cell lysates 
(WCL, top panel) or RNP fractions (RNP, bottom panel). Blue arrows indicate the 
positions of ORF2p, ORF1p, ZAP-S, and ZAP-S/ 72-3 . The eIF3 protein is 
used as a loading control. Representative images are shown. The experiments 
were repeated three times with similar results. 
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Figure 3.4: The effect of ZAP-S on L1 RNA and L1 protein expression.  
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Figure 3.5: The co-localization of ORF1p and ZAP in cytoplasmic foci.  
(A) Co-localization of transfected ORF1p and ZAP-S in HeLa cells: ORF1p (red) 
expressed from pJM101/L1.3Δneo co-localizes with ZAP-S-tGFP (green). The 
experiment was repeated five times with similar results. (B) Co-localization of 
transfected ORF1p with endogenous ZAP in cytoplasmic foci in HeLa cells: 
ORF1p-T7 (green) expressed from pAD2TE1 co-localizes with endogenous ZAP 
(red). The experiment was repeated five times with similar results. (C) Co-
localization of transfected ZAP-S-tGFP with endogenous ORF1p in cytoplasmic 
foci in PA-1 cells: ZAP-S-tGFP (green) co-localizes with endogenous ORF1p 
(red). PA-1 experiments were repeated twice with similar results. (D-E) The ZAP-
S zinc-finger domain is necessary for co-localization with ORF1p in HeLa cells: 
ORF1p (red) expressed from pJM101/L1.3Δneo co-localizes with ZAP-S/Δ310-
645-tGFP (green) (panel D). ORF1p (red) expressed from pJM101/L1.3Δneo 
forms cytoplasmic foci that do not contain ZAP-S/Δ72-372-tGFP (green) (panel 
E). The right-most image of each panel represents a merged image. The cell 
type is indicated at the top left (yellow), the protein name is listed on the bottom 
left, and the name of the primary antibody used (italicized) is annotated at the 
bottom right. Nuclei were stained with DAPI (blue) and the scale bar represents 
25 μM.  
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Figure 3.6: The co-localization of ZAP with L1 RNA and ORF1p in HeLa 
cells.  
(A) Co-localization of transfected L1 RNA and ORF1p: ORF1p (red) expressed 
from pJM101/L1.3 co-localizes with L1 RNA (magenta). (B) Co-localization of 
transfected L1 RNA and ORF1p with transfected ZAP-S-tGFP in cytoplasmic 
foci: ORF1p (red) and L1 RNA (magenta) expressed from pJM101/L1.3 co-
localize with ZAP-S-tGFP (green). (C-D) The ZAP-S zinc-finger domain is 
necessary for co-localization with ORF1p: ORF1p (red) and L1 RNA (magenta) 
expressed from pJM101/L1.3 co-localize with ZAP-S/Δ310-645-tGFP (green) 
(panel C). ZAP-S/Δ72-372-tGFP (green) diffusely distributes throughout the 
cytoplasm, while ORF1p (red) expressed from pJM101/L1.3 forms cytoplasmic 
foci with L1 RNA (magenta) (panel D). The right-most image of each panel 
represents a merged image. The name of the protein or RNA is indicated at the 
bottom left, and the name of the primary antibody used (italicized) is annotated at 
the bottom right of each image. Nuclei were stained with DAPI (blue) and the 
scale bar represents 25 μM. Experiments were repeated three times with similar 
results. 
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Figure 3.6: The co-localization of ZAP with L1 RNA and ORF1p in HeLa 
cells.  
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Figure 3.7: A working model for how ZAP restricts L1 retrotransposition.  
Once a genomic L1 (black rectangle located on the green chromosome) is 
transcribed, the resultant bicistronic L1 mRNA is exported to the cytoplasm for 
translation. L1 ORF1p (blue circles) and ORF2p (yellow circle) bind back to L1 
mRNA to form an L1 RNP. The L1 RNP gains access to the nucleus where a 
new L1 copy is inserted into genomic DNA by the process of TPRT (black 
rectangle located on the blue chromosome). In ZAP-mediated restriction, ZAP 
(red hexagon) interacts with L1 mRNA in the cytoplasm (1), which we propose 
leads to the destabilization of L1 RNA (2) and/or a block in translation (?) through 
the recruitment of other cellular factors (e.g., SG associated proteins, RNA decay 
proteins) involved in RNA metabolism. 
 
  
 150 
Figure 3.8:  Supporting data for Figure 3.1.  
(A) The FLAG epitope on ORF1p is compatible with retrotransposition: 
Constructs were tested in a transient HeLa cell retrotransposition assay (Moran 
et al. 1996, Wei et al. 2000). The X-axis indicates the L1 plasmid.  The Y-axis 
indicates the retrotransposition efficiency. Retrotransposition assays were 
normalized to pJM101/L1.3 (100%). The pJM105/L1.3 plasmid serves as a 
negative control and harbors a point mutation in the ORF2p RT domain that 
renders the element inactive (Moran et al. 1996). Representative results from a 
single experiment are depicted below the graph. The assay was repeated two 
times with similar results. (B) Immunoprecipitation reactions conducted using 
various wash conditions:  Top panel: HeLa cells were transfected with pCEP4, 
pJM101/L1.3, or pJM101/L1.3FLAG and were subjected to lysis using two 
different salt concentrations (500 mM NaCl (left gel) or 150 mM NaCl (right gel)). 
Shown are the images of silver stained gels from immunoprecipitation reactions. 
The black rectangles indicate the cropped image depicted in Figure 3.1B. 
Molecular weight standards (~kDa) are shown on the left side of the gel. Bottom 
panel: Image of full western blot used in Figure 3.1C. The black rectangle 
indicates the cropped lanes depicted in Figure 3.1C. Molecular weight standards 
(~kDa) are shown on the left side of the gel.  (C) Immunoprecipitation reactions 
under different lysis buffer conditions: Silver stained gels of IP fractions from 
untransfected HeLa (HeLa UTF) or HeLa cells transfected with 
pJM101/L1.3FLAG. Lysis buffer contained either 0.1% CHAPS (left gel) or 1.0% 
Triton X-100 (right gel). Black arrows correspond to the approximate location of 
ORF1p-FLAG; black bars indicate the approximate location of proteins enriched 
in the pJM101/L1.3FLAG lane. Molecular weight standards (kDa) are shown on 
the left side of the gels. 
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Figure 3.8:  Supporting data for Figure 1.  
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Figure 3.9:  Supporting data for Figure 3.3.  
(A-C) Transfected ZAP is expressed in HeLa cells:  Western blots of whole cell 
lysates demonstrate the expression of ZAP-L (panel A) and ZAP-S and ZAP-
S/72-372 (panels B and C) 48 hours post-transfection. UTF indicates 
untransfected HeLa cells. The antibodies are indicated at the right side of the 
blots. Blue arrows indicate the approximate locations of the ZAP proteins. 
Tubulin serves as a loading control. Molecular weight standards (kDa) are shown 
on the left side of the blots. (D) The depletion of endogenous ZAP enhances L1 
retrotransposition: Flow cytometry was used to determine the percentage of 
EGFP-positive, live-gated cells for each siRNA transfection condition (noted 
above the plots). The X-axis depicts the scattering at 533 nm; the Y-axis depicts 
the scattering at 585 nm. The EGFP-positive gate was set using the 
retrotransposition-deficient negative control, pJM111-LRE3-mEGFPI (Moran et 
al. 1996, Zhang et al. 2014). 
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Figure 3.9:  Supporting data for Figure 3.3.  
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Figure 3.10:  Supporting data for Figure 3.4  ZAP-S preferentially 
suppresses the expression of ORF1p.  
(A) A schematic of the pLRE3-EF1-mEGFPΔIntron: pLRE3-EF1-mEGFPΔIntron 
expresses a human L1 (LRE3) that is tagged with an mEGFPI expression 
cassette that lacks an intron. The human elongation factor-1 alpha (EF1α) 
promoter (arrow) augments L1 transcription. The ubiquitin C (UbC) promoter 
(upside down arrow) drives EGFP transcription. (B) ZAP-S inhibits ORF1p 
expression: Western blots were conducted using whole cell lysates derived from 
cells co-transfected with pLRE3-EF1-mEGFPΔIntron and the ZAP-S expression 
plasmid or pCEP4 indicated above each lane. UTF indicates whole cell lysates 
from untransfected HeLa cell. Antibodies are indicated on the right side of each 
blot. Tubulin is used as a loading control. Western blot images depict a 
representative experiment that was repeated three times with similar results. 
Notably, upon extended exposure times ORF1p was able to be visualized in the 
ZAP-S lane. (C) ZAP-S does not inhibit EFGP expression and/or accumulation: 
HeLa cells were co-transfected with pLRE3-EF1-mEGFPΔIntron and the 
indicated expression plasmids (noted above the plots). Flow cytometry was used 
to determine the percentage of EGFP-positive, live-gated cells for each condition. 
UTF indicates untransfected HeLa cells. The EGFP-positive gate was set using 
the UTF sample as a negative control. The X-axis depicts the percentage of 
EGFP positive cells. The Y-axis indicates the side scattering profile (SSC). 
Approximately 1.2 - 1.7 x 106 GFP positive cells were collected and analyzed for 
each transfection condition. 
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Figure 3.10:  Supporting data for Figure 3.4  ZAP-S preferentially 
suppresses the expression of ORF1p.  
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Figure 3.11: Supporting data for Figure 3.5. 
(A) ZAP-S-tGFP inhibits retrotransposition in HeLa cells: Top panel: Schematics 
of tGFP-tagged ZAP constructs. Depicted are the relative positions of the zinc-
finger domains (light gray rectangles), cysteine-histidine (CCCH) zinc-fingers 
(vertical black bars), and tGFP tag (green rectangles) ZAP-S expression 
constructs. Bottom panel: Results of pJJ101/L1.3 retrotransposition assays. The 
X-axis indicates the cDNA co-transfected with pJJ101/L1.3 or pcDNA6/TR. The 
Y-axis indicates pJJ101/L1.3 retrotransposition activity (black bars). All values 
have been normalized to the pCEP4 empty vector control (100%). The numbers 
above the bar graphs indicate the number of biological replicates performed with 
each cDNA expression construct. Error bars represent standard deviations. (B-E) 
ORF1p and ZAP co-localize with stress granules in HeLa cells: HeLa cells were 
co-transfected with pJM101/L1.3Δneo and ZAP-S-tGFP; proteins were visualized 
by direct immunofluorescence. ORF1p co-localizes with ectopic ZAP-S-tGFP and 
eIF3 in cytoplasmic foci (panel B). ORF1p co-localizes with ectopic ZAP-S-tGFP 
(panels A and B), but not with tubulin (panel C). GFP-tagged G3BP co-localizes 
with endogenous ZAP in cytoplasmic foci (panel D). GFP-tagged DCP1  forms  
cytoplasmic punctate structures, which do not appear to co-localize with 
endogenous ZAP (panel E). The right-most image in each panel represents a 
merged image. The cell type is indicated at the top left (yellow), the protein name 
is listed on the bottom left, and the name of the primary antibody used (italicized) 
is annotated at the bottom right. Nuclei were stained with DAPI (blue) and the 
scale bar represents 25 μM.  
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Figure 3.12: Supporting data for Figure 3.6.  
(A) Fluorescence microscopy was used to determine the percentage of cells that 
contained L1 RNA in cytoplasmic ORF1p foci. The X-axis indicates the plasmid 
that was co-transfected with pJM101/L1.3. The Y-axis of the graph depicts the 
percentage of cells where L1 RNA was detected in cytoplasmic ORF1p foci. 
Experiments were repeated three times. A total of ~60 visual fields (~1600 cells) 
were examined amongst all three experiments and ~33-41 ORF1p foci containing 
cells were evaluated for each experimental condition. Error bars represent 
standard deviations. (B) Confocal microscopy was used to determine the number 
of ORF1p-expressing cells ~48 hours post transfection. The X-axis indicates the 
plasmid that was co-transfected with pJM101/L1.3Δneo. The Y-axis of the graph 
depicts the percentage of cells that express ORF1p. Experiments were repeated 
twice. Each experiment contained two biological replicates and ~1100-1500 cells 
were enumerated amongst all experiments for each condition. Error bars indicate 
standard deviations.  
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Table 3.1: L1 ORF1p-interacting protein candidates identified by LC-MS/MS. 
ORF1p-interacting proteins were selected based on the criteria that the protein 
was unique to the pJM101/L1.3FLAG IP and was identified by two or more 
unique peptides (peptide error ≤ 0.05; protein probability ≥ 0.95). Column 1 = 
protein name. Column 2 = protein mass. Column 3 = total number of identified 
peptides. Column 4 = number of unique peptides. Column 5 = the percentage of 
amino acid coverage for each of the respective proteins. Columns 6-8 = whether 
the proteins were identified in the indicated studies (Goodier et al. 2013, 
Peddigari et al. 2013, Taylor et al. 2013). Green highlighting indicates ORF1p-
interacting candidates that were verified by western blot (Figure 3.1D). "Y" in 
columns 6-8 indicate that the protein was identified as a significant L1-interacting 
protein by statistical and/or direct biochemical methods; “n.s.” in column 7 
indicates that the protein was identified in the study, but that it did not reach the 
significance threshold set by the authors.   
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